Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Ruize Qu; Yi Zhang; Yanpeng Ma; Xin Zhou; Lulu Sun; Changtao Jiang; Zhipeng Zhang; Wei Fu

doi:10.1002/advs.202205563

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Qu, Ruize; Zhang, Yi; Ma, Yanpeng; Zhou, Xin; Sun, Lulu; Jiang, Changtao; Zhang, Zhipeng; Fu, Wei 2023-08-01 00:00:00 IntroductionColorectal cancer (CRC) is the third most common and fatal cancer with 71 160 estimated new cases and 24 080 new deaths in the USA in 2023.[1] CRC has heterogeneous genomic, epigenomic, and transcriptomic transformations and undergoes complex processes that lead to tumorigenesis.[2] Genetic predisposition is an important factor in CRC progression accounting for 12–35% of all cases. According to this, CRC can be classified as Lynch syndrome, familial adenomatous polyposis, or Peutz‐Jeghers syndrome.[3] Additionally, emerging evidence indicates that internal and external environmental factors are involved in the development of CRC.[4] The heritability of CRC remains unclear in most patients, while sporadic CRC cases are mostly abided by the “adenoma–carcinoma sequence”; CRC evolves from colorectal polypoid adenomas and progresses into malignant tumors over several years, thus, suggesting the occurrence of complicated mutation procedures[5] and illustrating the non‐negligible importance of environmental factors in its development and progression.[6]The microenvironment of the human body is composed of a highly integrated microbiota, including bacteria, fungi, viruses, archaea, and parasites. Notably, the microbiota mainly consists of bacteria, particularly, Firmicutes, Bacteroidetes, and Actinobacteria.[7] The colorectum has the largest population of bacteria, ≈3 × 1013 cells,[8] and crosstalk between microorganisms and the colorectal epithelium is a key factor influencing basic physiological activities, including energy harvest, metabolic regulation, homeostatic preservation, and immune reactions.[9] Dysbiosis‐related inflammation and carcinogen formation are two of the primary reasons for microbiota‐related carcinogenesis.[10] Alterations of gut microbiota have been observed in precancerous adenomas during early cancer stages.[11] Moreover, microorganisms, especially bacteria, are pivotal in the evolution of several diseases including CRC.[12] Ratios of these microorganisms vary based on the anatomical site and between eastern and western countries,[13] and these differences may be associated with disease development.[14]Metabolites produced by gut microbiota, including bile acids (BAs) and short‐chain fatty acids (SCFAs), are essential components involved in the crosstalk between microorganisms and the host and play either protective or harmful roles in the development of CRC.[15] The effects of these metabolites on inflammation and cancer development and progression warrant further investigation.[16] Studies on the interaction between gut microbiota and CRC have been conducted and hence should be systematically summarized. Moreover, other gut microbiota components, such as viruses and fungi, the recently discovered probiotics from gut microbiota that related to CRC, the intratumoral microbiota in CRC, the pattern of gut microbiota in early‐onset CRC patients, and the metabolites produced by the microbiota have also been reviewed, but to a lesser extent. In this review, we summarize and discuss the latest reports on the relationship between gut microbiota and metabolites in CRC and the prospects of treating CRC through the targeting of these metabolites.Association between Gut Microbiota and CRCLandscape of CRC MicrobiotaThe gut microbiota of healthy individuals is less diverse than that of patients with CRC, which show a global compositional shift.[17] Specific bacteria, including Fusobacterium nucleatum, Escherichia coli, Bacteroides fragilis, and Streptococcus gallolyticus, were linked to CRC in various association and mechanistic studies.[18] Despite geographical variations in gut microbiota, a microbial core of seven enriched bacteria (B. fragilis, F. nucleatum, Porphyromonas asaccharolytica, Parvimonas micra, Prevotella intermedia, Alistipes finegoldii, and Thermanaerovibrio acidaminovorans) has been confirmed in CRC through meta‐analysis of 526 fecal samples from shotgun metagenome datasets.[19] Therefore, microbiota can be used as CRC biomarkers through the detection and quantification of the alterations in the relative abundances of these bacteria.Gut microbiota composition varies between anatomical locations.[20] As was previously reported, operational taxonomic unit level of gut microbiota composition changed in distal but not proximal CRC cases, while mucosal bacterial biofilms affects tumor formation in proximal CRC cases but not distal ones, suggesting different roles of gut microbiota in different anatomical subsites of CRC.[21] One reason could be that bacteria showed more accumulation in the distal colon when there are changes in the local environment including surgery and infection;[22] it was also found that bacterial oncogenes were more abundant in the stools of distal CRC patients compared to proximal CRC patients.[23] However, a greater abundance of F. nucleatum was found in proximal CRC cases, whose metabolism can induce carcinogens and inflammation in the tumor microenvironment and increase mutation rate.[24] These phenomena suggest that the subsite location of CRC tumor may be associated with site‐specific bacteria, and some bacteria play differential roles in proximal and distal CRCs, which should be further examined in the future.Other than bacteria, the gut microbiota also includes viruses and fungi whose roles in the development of CRC have been studied. One study indicated substantial changes in the abundance of enteroviruses and 22 other viral taxa (including cytomegalovirus) in patients with CRC,[25] but other studies have reported conflicting data.[26] Meanwhile, another study highlighted the changes in phage characteristics in CRC and indicated that the cancer‐related virome is primarily formed by temperate bacteriophages.[27] Despite limited studies, an enhanced abundance of Malassezia has been identified in patients with CRC.[28] These studies suggest that transkingdom microbial interactions may be essential in CRC oncogenesis.Interaction between Gut Microbiota and CRCSubsequent studies have shown that the gut microbiota which includes E. coli, Enterococcus, Bacteroides, and Clostridium can contribute to CRC by enhancing abnormal crypt foci induced by 1,2‐dimethylhydrazine.[29] Interestingly, mice transplanted with gut microbiota from patients with CRC had more intestinal polyps than those receiving microbiota from healthy controls.[30] Comparative metagenomic or metataxonomic approaches have indisputably proven that patients with CRC have an imbalanced taxonomic structure in comparison to healthy individuals, with an upregulation and downregulation in the abundance of pro‐oncogenic (e.g., Bacteroides, Escherichia, Fusobacterium, and Porphyromonas) and potentially protective (e.g., Roseburia) bacteria, respectively.[31] These data highlight the essential role of the microbial communities on carcinogenesis.Undeniably, the formation of the human gut microbiota is continuously progressing, but the functional components of this microbiota are not well understood. This could be attributed to the complex composition of the gut microbiota and the impact of the external environment on the microbes.These factors result in unpredictable crosstalk between the host and microbes.[32] Host–microbial interactions in CRC were first identified in 1975, when it was shown that the incidence of colon tumors caused by dimethylhydrazine, a carcinogen, was significantly lower in germ‐free rats than in rats with an intestinal microbiome.[4] Notably, the influence of the gut microbiota on the development of CRC includes communication with the host immune system through pattern recognition receptor signaling, inflammasomes, and cytokines; the production of inflammation, which is a special type of immune reaction; and the secretion of metabolites, including BAs and SCFAs.[33] Mechanistically, inflammatory and immune reactions caused by the interplay between the CRC‐promoting bacteria and the host are among the most common mechanisms in CRC development[34] (Figure 1). These bacterial species stimulate chemokine production by CRC cells including chemokine (C‐C motif) ligand 5 and chemokine (C‐X‐C motif) ligands 9 and 17, thereby activating immune responses which can lead to accumulation of T cells (e.g., cytotoxic T lymphocytes, T helper type 1 (Th1), and interleukin (IL)‐17‐producing Th cells) in tumor tissues[35] and the modulation of inflammatory responses in the colon. The latter occurs through cytokine secretion, specifically of IL‐17A, IL‐22, and IL‐23A, which promote tissue inflammation.[30] Moreover, pattern recognition receptors are involved in the crosstalk between the immune system and the microbiota as they can recognize microbial antigens and activate a number of signaling pathways, including the nucleotide‐binding oligomerization domain‐like receptor,[36] retinoic acid‐inducible gene I‐like receptor,[37] toll‐like receptor,[38] and absent in melanoma 2‐like receptor[39] pathways, to activate an immune response. Furthermore, production of metabolites that induce CRC development is another essential mechanism. However, the detailed mechanism of host–microbial interaction in CRC is still unknown, and further confirmatory research is needed before it can be leveraged for beneficial therapeutic effects.1FigureThe role of the gut microbiota in CRC progression through immune, inflammatory, and metabolic reactions. Several bacterial species in the gut could induce the host to produce chemokines including chemokine (C‐C motif) ligand 5 (CCL5), chemokine (C‐X‐C motif) ligands 9 (CXCL9), and CXCL17. Tumor cells accumulate T cells that promote inflammation and leads to progression of CRC. Microbial antigens produced by the gut microbiota could activate signaling through various receptors including nucleotide‐binding oligomerization‐like receptor (NLR), retinoic acid‐inducible gene I‐like receptor (RLR), toll‐like receptor (TLR), and absent in melanoma 2‐like receptor (AIMR), that stimulate the immune response.Herein, we discuss the major bacterial species of the microbiota and summarize the protective or harmful roles they may play in CRC formation, development, and/or metastasis (Table 1).1TableMechanisms of action of CRC‐associated gut bacterial speciesOrganismGram stainingEffect in CRCExpression pattern in CRCMechanismRole in tumor formation, development, and metastasisInteraction with other gut microbiotaFusobacterium nucleatumNegativePromoteEnhancedProliferation of CRC cellsDNA damage and carcinogenesis through oxidative stressMutation in the Apc tumor suppressor geneIncrease of tumor‐promoting cytokines through NF‐κB activationSecretion of FadA adhesion protein that activating Wnt/β‐catenin signalingInhibit T cell activation and NK cell‐meditated killing of tumor cellsImmune surveillance suppressionPromote CRC cell to acquire stem cell‐like featuresFormationDevelopmentMetastasis–Escherichia coliNegativePromoteEnhancedInflammatory reactionsDNA damageSecretion of virulence factors to activate COX‐2, etc.Promote cell‐cycle arrestInduce apoptosis of CRC cellsDisrupt the gut vascular barrierFormationMetastasisPromoting procarcinogenic bacteria including Bacteroides fragilisBacteroides fragilisNegativePromoteEnhancedHigher in proximal colonInteraction with IL‐17Activation of NF‐κBAccumulation of regulatory T cells to enhance inflammatory responseIncreasing paracellular permeabilityActivation of β‐catenin signaling pathwayProliferation of CRC cellsDNA damage through polyamine metabolismInducing bacterial dysbiosis by promoting procarcinogenic bacteriaDisturbance of the host immune apparatus and gut barrierPromotion of mucin degradationDevelopmentPromoting procarcinogenic bacteria including Escherichia coliStreptococcus gallolyticusPositivePromoteEnhancedActivation of NF‐κB and IL‐8Inflammatory reactionProliferation of CRC cells through β‐catenin signaling but not inflammationFormation–Clostridium butyricumPositiveInhibitDecreasedProduction of SCFAs including butyrate and acetateDecrease of secondary BAs secretionInhibiting proliferation of CRC cellsInducing apoptosis in CRC cellsInhibition of Wnt/β‐catenin signaling pathwayModulation of gut microbiotaActivation of GPRs including GPR43 and GPR109ADevelopmentModulating gut microbiotaStreptococcus thermophilusPositiveInhibitDecreasedBanning the invasion of Escherichia coliProduction of β‐Galactosidase to enhance abundance of probioticsActivation of oxidative phosphorylationInhibition of Hippo signaling pathwayDevelopmentBanning the invasion of Escherichia coliEnhance abundance of probiotics including Bifidobacterium and LactobacillusLacticaseibacillus paracaseiPositiveInhibitDecreasedInhibiting proliferation of CRC cellsInducing apoptosis of CRC cellsProducing LpEVs as intercellular communication moleculesLactobacillus paracasei DTA81 diminish liver oxidative stress and decrease proliferating cell nuclear antigenDevelopment–Ruminococcus gnavusPositiveInhibitDecreasedDegrade lysoglycerophospholipidPromote tumor immune surveillance function of CD8+T cellFormationDevelopmentCommensal growing with Blautia productaCRC: colorectal cancer; NF‐κB: nuclear factor‐kappa B; NK: natural killer; COX‐2: cyclooxygenase 2; IL‐: interleukin; GPR: G‐protein coupled receptor; LpEVs: Lacticaseibacillus paracasei‐derived extracellular vesicles.CRC‐Promoting Bacterial SpeciesEnrichment of tumor‐promoting bacterial species is an important mechanism employed by gut microbiota during CRC development. Along with polyketide synthase positive (pks+) E. coli, enterotoxigenic B. fragilis, and S. gallolyticus, F. nucleatum isolates are major protumorigenic bacteria. F. nucleatum is a gram‐negative oral commensal anaerobe implicated in a wide spectrum of disorders, such as cardiovascular diseases, rheumatoid arthritis, inflammatory bowel disease, and CRC.[40] Patients with these disorders show higher levels of F. nucleatum compared to healthy individuals;[41] importantly, a progressive trend for an increased abundance of F. nucleatum in CRC, from highly dysplastic adenomas through to late cancer stages, has been observed.[5] F. nucleatum can activate the formation and development of CRC through proliferation of cancer cells but not noncancerous cell lines.[42] Infection of CRC cells with F. nucleatum increases tumor cell proliferation, invasive activity, and ability to form xenograft tumors in Apcmin/+ mice.[43] The abundance of F. nucleatum in CRC was associated with an increase of tumor‐promoting cytokines, including IL‐17A and tumor necrosis factor‐α (TNF‐α), through the sensitization of the nuclear factor‐kappa B (NF‐κB) signaling pathway.[44] Additionally, F. nucleatum has been shown to promote CRC metastasis by upregulating long noncoding RNA Keratin7‐antisense (KRT7‐AS) and Keratin7 (KRT7) through activation of NF‐κB.[45] F. nucleatum also causes CRC cells to acquire stem cell‐like features through manipulating lipid droplet‐mediated Numb degradation.[46] The FadA adhesion protein secreted by F. nucleatum binds to E‐cadherin, and enhances the level of inflammatory and cancer genes, through activating the Wnt/β‐catenin signaling in intestinal epithelial cells.[42,47]E. coli is a gram‐negative anaerobic bacterium mainly found in the intestines. Though generally not pathogenic, some virulent strains of E. coli which colonize the human gut are nosogenic and can lead to diseases via multiple mechanisms.[48] Greater abundance of E. coli was observed in mucosal samples from patients with CRC.[49] Colibactin, a genotoxic polyketide‐peptide produced by polyketide synthase positive (pks+) E. coli,[50] causes double‐stranded DNA damage through the activation of the DNA damage signaling and cell‐cycle arrest pathways[51] and induction of tumor formation.[52] E. coli also secretes other virulence factors, such as cycle‐inhibiting factor, cytotoxic necrotizing factor and cyclooxygenase 2 (COX‐2), and cytolethal distending toxin, which can induce cell‐cycle arrest, DNA damage, and apoptosis.[53] Moreover, E. coli was also found to promote CRC metastasis through disrupting the gut vascular barrier, and induce the formation of a premetastatic niche.[54]B. fragilis toxin (BFT), a secreted metalloproteinase enterotoxin, is linked to early carcinogenesis. BFT is associated with the occurrence of adenomas and serrated polyps in the human colon,[11a] promotion of Th17‐mediated colitis in a mouse model,[55] and distal CRC in Apcmin+/− mice through interaction with IL‐17 and subsequent activation of the NF‐κB signaling pathway.[56] In addition, colonization by BFT+ B. fragilis can promote accumulation of regulatory T cells, thereby inducing IL‐17‐mediated procarcinogenic inflammatory responses.[57] In colon epithelial cells, BFT promotes the cleavage of E‐cadherin, increasing paracellular permeability and activating the β‐catenin signaling pathway leading to enhanced cell proliferation.[58] Moreover, BFT activates DNA damage through polyamine catabolism in CRC cells.[59] Interestingly, BFT+ B. fragilis can also induce bacterial dysbiosis locally by promoting the growth of other procarcinogenic bacteria, disturbing the host immune apparatus[57] and the gut barrier,[58] and inducing mucin degradation.[60]S. gallolyticus infection‐related endocarditis and bacteremia can enhance the risk of CRC,[61] and exposure to S. gallolyticus antigens is closely correlated with increased CRC incidence.[62] In xenograft and azoxymethane/dextran sodium sulfate (AOM/DSS) mouse models exposed to S. gallolyticus, the tumor burden increased, and the dysplasia grade worsened.[63] Nevertheless, the underlying mechanisms involved in S. gallolyticus‐mediated CRC progression may be associated with high levels of NF‐κB and IL‐8 mRNA, inflammatory reactions, and β‐catenin,[63a] although further investigations are warranted.A meta‐analysis has revealed seven bacteria commonly enriched in CRC,[19] including P. asaccharolytica, P. micra, P. intermedia, A. finegoldii, and T. acidaminovorans. These bacterial species may have harmful roles in cancer promotion, yet their roles in CRC progression have not been adequately studied to date.CRC‐Protecting Bacterial SpeciesIn addition to these core bacteria, several CRC‐depleted bacteria have been named and were negatively linked to mutualistic networks of enriched bacteria.[19] The depleted bacteria included probiotic bacteria, such as Clostridium butyricum and Streptococcus thermophilus, which are potentially beneficial in CRC prevention through production of substances, such as butyrate, and antagonistic action against the pathobionts.[64] Ruminococcus gnavus and Blautia producta are commensal bacteria that were found to degrade lysoglycerophospholipid in the microenvironment of the intestinal tissue and promote tumor immune surveillance function of CD8+T cells, thus inhibiting the occurrence and development of colon cancer.[65] Research on CRC‐protecting microbiota is still limited, despite its high translational potential in prevention and treatment of CRC.Clostridium ButyricumC. butyricum, a gram‐positive anaerobic bacterium that produces butyrate, exists in various natural environments, including soil, milk products, and some vegetables. C. butyricum is also one of the common human gut microbiota species that is found in ≈10% to 20% of adults and is one of the original colonizers found in human infants.[66] As a symbiont in the human digestive system, C. butyricum ferments fibrous foods in the gut to aid digestion, thus, producing SCFAs, including butyrate and acetate,[67] which are protective in CRC. In addition, C. butyricum inhibits proliferation and induces apoptosis in CRC cells, through interacting with the Wnt/β‐catenin signaling pathway and modulating the composition of the gut microbiota. This decreases the secretion of secondary BAs closely related to cancer development, enhances the secretion of SCFAs, and activates G‐protein coupled receptors (GPRs) including GPR43 and GPR109A that suppress tumor progression.[68]Streptococcus ThermophilusS. thermophilus is a gram‐positive fermentative anaerobic bacterium which can be isolated from fermented milk products, such as yogurt. It protects the gut epithelium through preventing invasive E. coli, thereby relieving acute diarrhea in infants, and small‐intestinal methotrexate‐induced mucositis in rat models.[69] Gavage of S. thermophilus inhibited tumor formation in both Apcmin/+ and azoxymethane‐injected mice. Moreover, production of β‐galactosidase by S. thermophilus enhances the abundance of probiotics, such as Bifidobacterium and Lactobacillus. Furthermore, the galactose produced by S. thermophilus was shown to modulate oxidative phosphorylation and the Hippo signaling pathway, which lead to tumor‐suppressive effects.[70]Lacticaseibacillus ParacaseiL. paracasei is a gram‐positive bacterium with probiotic properties in CRC. It enhances apoptosis and inhibits proliferation of tumor cells by regulating the Bcl‐2 family proteins, producing reactive oxygen species (ROS) and cell wall protein, enhancing calreticulin translocation, and modifying the cell cycle.[71] L. paracasei‐derived extracellular vesicles act as intercellular communication molecules. They are taken up by CRC cells, where they inhibit the proliferation, migration, invasion, and promote apoptosis.[72] Additionally, L. paracasei DTA81 prevents the development of CRC at an early stage by diminishing liver oxidative stress (OS) and decreasing the secretion of proliferating cell nuclear antigen.[73]Other Microbiota TypesViromeAlterations have been reported in the fecal virome (phages included) in patients with CRC.[25,27] The bacterial composition of the gut microbiota could be changed through phage regulation including pathogenic bacteria development and subsequent biofilm formation. An increase in the abundance of several phages was found in the feces of patients with CRC. Through analysis of 317 metagenomic samples gathered from China (Hong Kong), Austria, and Japan, enrichment of five bacteriophages was identified, namely, Peptacetobacter hiranonis Phage, F. nucleatum animalis 7_1 Phage, F. nucleatum polymorphum Phage, F. nucleatum animalis 4_8 Phage, and P. micra Phage.[74] SpSL1 is the phage that being more abundant in early‐stage CRC, and infects Streptococcus species.[25] HK544, Punalikevirus, Lambdalikevirus, and Mulikevirus can reduce the abundance of E. coli in patients with CRC and lead to dysbiosis.[25] However, the causal relationship between the phage and bacteria remains unclear, and further studies on the underlying mechanisms are essential to identify potential therapeutic targets.FungiFungi are major components of the gut microbiota whose dysbiosis affects human health through induction of inflammatory and immune reactions.[75] Fungal diversity is diminished in patients with CRC in comparison to healthy individuals, which is more evident in the early stage the disease.[76] Dysbiosis in patients with CRC and colon polyps could be attributed to the downregulation of beneficial yeasts and upregulation of pathological fungi, including Trichosporon and Malassezia genera. Immune reaction is currently considered to be the major paths employed by fungi during CRC development. For instance, Candida albicans can activate the interaction between macrophages and innate lymphoid cells, increase expression of IL‐22, and promote CRC.[77] Dysbiosis of gut fungi also affects the function of CARD9, thereby decreasing the activation of inflammasomes and maturation of IL‐18 and enhancing expansion of myeloid‐derived suppressor cells. Consequently, this increases susceptibility to CRC.[75] Owing to the limited studies and sample sizes, the spectrum of fungi in CRC remains unclear, although fungal dysbiosis has important roles in tumor development.Intratumoral Microbiota in CRCThe advent of metagenomic sequencing highlights the tumor microbiota as an integral part of the microenvironment affecting tumor progression. Moreover, the abundance of Fusobacterium increased in liver metastatic CRCs but not primary liver cancers,[78] and intratumoral E. coli damaged the gut vascular barrier and promoted metastasis,[54] indicating the importance of tumor microbiota. The intratumoral microbiota is heterogeneous and progressively changes as CRC progresses from adenoma to carcinoma.[79] The mechanisms underlying these changes are unclear. One study evaluating CRC and adenoma samples found an enrichment of Fusobacterium, Bacteroides, Parvimonas, and Prevotella without a reduction in other bacteria.[79] Yet another study, which examined 294 matched tumor and tumor‐adjacent biopsies, reported an increase in the abundance of Fusobacterium, Streptococcus, and Proteobacteria in tumors, whereas Firmicutes abundance decreased.[80] Interestingly, the intratumoral microbiota also changes based on the anatomical subsite; ascending and descending colon cancer samples showed significant microbial alterations.[81] Importantly, the microbiota in a single tumor is evenly distributed and not limited to some regions.[82]F. nucleatum is among the most common bacterial species in patients with CRC and can be detected in their biopsies. Its DNA is generally found in tumor cells.[83] Moreover, increased levels of mucosa‐associated and internalized E. coli were observed in tumors, and higher bacterial levels were observed in patients with stage III/IV cancer than in those with stage I cancer, suggesting a possible association between bacterial abundance and poor prognosis.[54] Data on intratumoral microbiota in CRC are currently limited, but a list of available literature sources has been summarized in Table 2. Future research on the microbial community of tumors may further reveal the host–bacterial interactions in CRC.2TableSummary of recent studies on intratumoral microbiota in CRCGut microbiotaAuthorYearDisease typeSample typeSample sizeIncreaseDecreaseBurns 2015CRCSurgery tissue88CandidatusPortieraProvidenciaFusobacteriumBacteroidesRikenellaceaeLachnospiraceaeRuminococcaceaeFlemer2017CRCColorectal polypSurgery tissueBiopsies tissue136Bacteroidetes Cluster2Firmicutes Cluster2PathogenPrevotellaBacteroidetes Cluster1Firmicutes Cluster1Bullman2017CRCFresh‐frozen tissue88Fusobacterium nucleatumFusobacterium necrophorumBacteroides fragilisBacteroides thetaiotaomicronNoneShah2018CRCBiopsies tissue294FusobacteriumStreptococcusParvimonasFaecalibacteriumRuminococcaceaeNielsen2019CRCColorectal adenomaFFPE tissue299PrevotellaNoneLee2021CRC (MSI‐H)Surgery tissue153Fusobacterium nucleatumNoneKordahi2021Colorectal polypsBiopsies tissue240TAP: BacteroidetesSSP: ProteobacteriaFirmicutesLiu2021CRCColorectal adenomaBiopsies tissue436FusobacteriumBacteroidesParvimonasPrevotellaNoneCRC: colorectal cancer; MSI‐H: microsatellite instability high; TAP: tubular adenomatous polyps; SSP: sessile serrated polyps; FFPE: formalin‐fixed and paraffin‐embedded.Gut Microbiota Metabolites and Their Effects on CRCMetabolites are essential components in the interaction (crosstalk) between the gut microbiota and the human body.[6] Microorganisms in the colon produce metabolites after the uptake of certain substances,[84] which then act as signaling elements and substrates in metabolic reactions[85] and are closely related to cancer development, including CRC.[86] The composition of gut microbiota metabolites includes volatile small molecules, lipids, proteins and peptides, sugars, secondary bile products or terpenes, biogenic amines, oligosaccharides, glycolipids, organic acids, and amino acids.[53] Various metabolites possess different properties depending on the regulation pathways involved; some have health‐promoting and antineoplastic abilities, while others have proinflammatory and carcinogenic properties.[87] Additionally, these metabolites are potentially beneficial in clinical and translational research, particularly, in the detection of cancers such as CRC and prediction of treatment effects.[88] Moreover, they may be more easily applicable than microbial taxa because they affect microbial functions and host–microbiota metabolic crosstalk.[85] In the following sections, we summarized some major gut microbiota metabolites and their promoting (Figure 2) and inhibiting (Figure 3) effects on CRC (Table 3).2FigurePromoting effects of gut microbiota metabolites on CRC. Metabolites including several bile acids (e.g., DCA and LCA), and trimethylamine n‐oxide (TMAO) promote CRC development by increasing cancer cell proliferation, increasing DNA damage, enhancing tumor invasion and metastasis, reducing cell–cell adhesion, and promoting genomic instability.3FigureProtective roles of gut microbiota metabolites against CRC. Metabolites including bile acids such as ursodeoxycholic acid (UDCA), SCFAs such as butyrate, and amino acids play a protective role by assembling the tight junction, inhibiting inflammation, promoting cancer cell apoptosis, and protecting colon epithelial barriers, to inhibit growth of CRC.3TableGut microbiota‐associated metabolites in CRC and their mechanisms of actionClass of metabolitesMetaboliteProducersPotential mechanismBAsDCAClostridium hiranonis,Clostridium hylemonae,Clostridium sordelli,Clostridium scindensInflammation, angiogenic formation, DNA damage, and DNA repair inhibitionLCAClostridium hiranonis, Clostridium hylemonae,Clostridium sordelli,Clostridium scindensApoptosis, cell proliferation, oxidative DNA damage, inflammatory reactionsUDCAParabacteroides distasonisAntiapoptotic, anti‐inflammatory, and antioxidant effectSCFAsAcetateBacteroides. Hydrogenotrophica, M ethanobrevibacter smithii, R uminococcus gnavus–ButyrateRoseburia intestinalis, Butyrivibriocrossotus, Faecalibacterium cf. prausnitziiImmunity, inflammation, differentiation, apoptosis, phagocytosis, and efferocytosisFormateF. nucleatumAhR signaling, cancer stemness, inflammationTMAOTMAOEnterobacteriaceaeInflammation, altering protein folding, oxidative stress, and DNA damageTryptophanIndoleEscherichia coli, Bacteroides thetaiotaomicron, Bacteroides ovatus, C. limosumSuppress inflammation, fix abdominal wall structures, AHR ligendsIAABacteroides ovatus, Bacteroides fragilis, Escherichia coliSuppress inflammation, fix abdominal wall structures, AHR ligendsSerineS‐adenosylmethionineSaccharomyces cerevisiae, Pichia pastoris, Candida utilis, and Escherichia coliUpregulates cell adhesion gene expression and promotes cell migration and metastasisVirulence factorsFadAFusobacterium nucleatummediates adhesion and invasion of epithelial and endothelial cellsFap2Fusobacterium nucleatumImmunity, binds to Gal‐GalNAcBAs: bile acids; DCA: deoxycholic acid; LCA: lithocholic acid; UDCA: ursodeoxycholic acid; SCFAs: short‐chain fatty acids; TMAO: trimethylamine n‐oxide; IAA: indoleacetic acid.Bile AcidsBA metabolism is associated with gut microbiota and exerts both beneficial and harmful effects on the host.[89] Primary BAs, including cholic acid (CA) and chenodeoxycholic acid (CDCA), are produced using cholesterol in the liver, conjugated to glycine or taurine, and excreted into the duodenum to facilitate fat digestion. They are biotransformed and activate the gut microbiota by reshaping the gut microbiota composition.[10b] On the one hand, BAs can alter membrane lipid composition, and increased BA concentrations can solubilize membranes and dissociate integral membrane proteins.[90] On the other hand, BAs could also shape the composition of the gut microbiota by indirect effects through BA receptors, especially the farnesoid X receptor (FXR). In healthy participants, the FXR agonist obeticholic acid (OCA) inhibited the synthesis of endogenous BAs and significantly increased the abundances of S. thermophilus, Lactobacillus casei, and Bifidobacterium breve, suggesting that FXR activation alters the small intestinal microbiota in response to changes in endogenous BA concentrations.[91] Subsequently, the BAs were reabsorbed in the distal ileum for enterohepatic circulation. BAs that enter the colon undergo complex biotransformation through interaction with gut microbiota, and are converted to secondary BAs,[87] which are linked to tumor progression. Notably, accumulating evidence has demonstrated an association between BA metabolism and CRC.[92] For example, CA and CDCA were found to regulate NF‐κB and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathways to promote CRC.[93] In addition, in N‐methyl‐N′nitro‐N‐nitrosoguanidine‐treated mice infusion of CA and CDCA caused a higher incidence of neoplasia in normal versus germ‐free mice, which highlights the key role of microbiota conversion of BAs in CRC progression.[94]Bile salt hydrolases catalyze the hydrolysis of the conjugated primary BAs and have been purified from bacteria of the gut microbiota, including B. fragilis, Bacteroides vulgatus, Clostridium perfringens, Listeria monocytogenes, Lactobacillus, and Bifidobacterium.[87] Dehydroxylation is also essential for secondary BA formation, and is catalyzed by intestinal bacterial enzymes.[95]Both primary and secondary BAs are involved in the regulation of lipid activity and glucose metabolism, which is enabled by BA‐responsive receptors, including FXR, pregnane X receptor (PXR), constitutive androstane receptor, vitamin D receptor (VDR), and G protein‐coupled bile acid receptor 1 (TGR5).[96] BA could activate these receptors and play an essential role not only in regulating lipid absorption and energy homeostasis, but also in initiating various pathologies, including CRC.[97] The related BA‐responsive receptors and associated signaling pathways of the major BAs in CRC are summarized in Table 4.4TableMajor bile acids in CRC and their related bile acid‐responsive receptors and associated signaling pathwaysBAsBA‐responsive receptorsAssociated signaling pathwaysCANot specifiedNF‐κB signaling, MAPK signalingCDCATGR5NF‐κB signaling, JAK2/STAT3 signalingDCAFXR, PXRNF‐κB signaling, EGFR/MAPK signaling, Wnt/β‐catenin signaling, ERK signalingLCAVDRNF‐κB signaling, Wnt/β‐catenin signalingUDCATGR5YAP signaling, EGFR/ERK signalingCA: cholic acid; CDCA: chenodeoxycholic acid; DCA: deoxycholic acid; LCA: lithocholic acid; UDCA: ursodeoxycholic acid; FXR: farnesoid X receptor; PXR: pregnane X receptor; VDR: vitamin D receptor; TGR5: G protein‐coupled bile acid receptor 1; NF‐κB: nuclear factor‐kappa B; MAPK: mitogen‐activated protein kinase; JAK2: Janus kinase 2; STAT3: signal transducer and activator of transcription 3; EGFR: epidermal growth factor receptor; ERK: extracellular regulated kinase; YAP: yes‐associated protein.Deoxycholic Acid (DCA)DCA, one of the main secondary BAs produced by Clostridium, is a tumor promoter in CRC.[98] Clinical studies found a relationship between serum DCA levels and colonic mucosal proliferation,[99] and more importantly, an increase in DCA levels in the sera and feces from patients with CRC.[89] The role of DCA in CRC progression is attributed its regulatory effects on cellular signaling cascades and its membrane perturbing effects. DCA has detergent properties that can result in membrane perturbations, leading to prostaglandin and ROS production from arachidonic acid via the activation of COX‐2 and lipooxygenase. This results in inflammation, angiogenic formation, DNA damage, and DNA repair inhibition, which could be reversed through apoptotic promoting effect of PXR through DCA resistance.[100] Additionally, the epidermal growth factor receptor and β‐catenin signaling pathway are activated in response to reduced expression of FXR,[101] and β‐catenin stabilized COX‐2 mRNA to form a positive feedback loop.[102] DCA was also found to specifically reduced adhesion of HET‐1A cells to vitronectin and reduced cell–surface expression of integrin‐αν via effects on endocytic recycling processes.[103] Moreover, DCA regulates p53 through proteasome‐mediated degradation by stimulating the extracellular signal‐related kinase (ERK) signaling pathway, thereby enhancing tumor promotion in CRC.[104]Lithocholic Acid (LCA)LCA, mainly produced by Clostridium, is a secondary BA that acts as an endogenous CRC promoter, similar to DCA.[99] It produces ROS in the gastrointestinal tract, leading to destruction of the epithelial layer through decreased apoptosis, enhanced cell proliferation, oxidative DNA damage, inflammatory reactions, and NF‐κB signaling pathway activation.[89] Additionally, LCA modulates the muscarinic 3 receptor and Wnt/β‐catenin signaling in colonic epithelial cells, promoting cancer stemness that play a role in the development of CRC.[105] Loss of the human leukocyte antigen was observed in colon adenocarcinoma cells after LCA treatment, and this may be an immune surveillance escape mechanism.[106] Furthermore, LCA treatment induced increased the expression of matrix metalloproteinase (MMP) genes, including MMP‐1, MMP‐2, and MMP‐7, and stimulated urokinase plasminogen activator receptor, which induced tumor invasion and metastasis and promoted a malignant epithelial phenotype.[107] IL‐8 expression was also enhanced when stimulated with LCA, thus, activating the ERK1/2/mitogen‐activated protein kinase (MAPK) signaling pathway, suppressing the activity of STAT3, and stimulating CRC angiogenesis.[108] However, LCA was also determined to be CRC‐protective in a context‐dependent manner with the VDR. LCA was found to bind and activate VDR, inducing expression of CYP3A in vivo, which functions to detoxify BAs in the liver and intestine, thereby providing protection against CRC.[109]Ursodeoxycholic Acid (UDCA)UDCA is a secondary BA and the 7β‐hydroxy isomer of CDCA produced by Parabacteroides distasonis, and used in clinical settings due to its therapeutic effects in cholesterol gallstone diseases and other digestive diseases, including biliary cirrhosis, sclerosing cholangitis, and recurrent pancreatitis.[98] However, the effect of UDCA on CRC remains debatable.UDCA exerts its therapeutic effects by upregulating the hydrophilicity of the biliary pool and downregulating the potency of harmful secondary BAs, including DCA and LCA which can lower inflammatory reactions on the colonic mucosa, through modulation of epidermal growth factor receptor/ERK signaling pathways.[110] UDCA can also inhibit the activation of COX‐2 by DCA, thereby controlling inflammatory reactions.[100a] In addition, UDCA was found to protect against malignant progression of CRC through TGR5–yes‐associated protein (YAP) axis.[111]By contrast, other studies have claimed that UDCA can be converted into toxic LCA by microorganisms and lead to CRC development and progression. The authors argued that Clostridium can convert UDCA to LCA and impact the 7α‐dehydroxylation of CA and CDCA.[112] Moreover, the protective effects of UDCA against colorectal adenomatous polyps were investigated, and UDCA had no significant overall effect on cancer risk reduction.[112] Further studies on UDCA are warranted to determine its effect and underlying mechanisms in CRC.SCFAsSCFAs are metabolites found in the digestive system, which are produced from microbial fermentation of fiber by anaerobic gut microbiota, including Firmicutes (Clostridium and Lactobacillus), Bacteroides (Bifidobacterium), Actinobacteria (Propionibacterium), Proteobacteria, and Verrucomicrobia.[113] SCFAs are easily absorbed and can supply energy to colon cells.[114] Butyrate, propionate, and acetate are the three main SCFAs in the intestines; butyrate is primarily produced by Firmicutes,[115] propionate by Firmicutes, Bacteroides, Acetobacterium, and Clostridium aceticum, and acetate by Propionibacterium species.[116] Importantly, SCFAs are a key component of glycolysis that play important roles in host and cell homeostasis,[117] act as protective molecules in CRC development, and change as the gut microbiota changes during tumor progression;[11b] therefore, SCFAs are closely associated with CRC development.ButyrateButyrate is produced by anaerobic bacteria (such as Roseburia intestinalis, Butyrivibriocrossotus, Faecalibacterium cf. prausnitzii) in the colon,[118] provides energy for colorectal epithelial cells,[119] and inhibits inflammation and tumor formation.[120] Expression of a butyrate transporter protein, which could maximize the transport and metabolism of butyrate induced by rapid beta‐oxidation to generate cellular fuel,[121] was reduced in tumors of patients with CRC.[122] Notably, epithelial barrier dysfunction is a major contributing factor to the development and progression of CRC because it triggers inflammation by activating macrophages that produce inflammatory cytokines.[123] Butyrate can help to maintain epithelial tight junctions through activation of adenosine monophosphate‐activated protein kinase[124] and protect the function of the colon epithelial barrier through induction of mucin 2 secretion,[125] which may occur in a GPR43‐dependent manner.[126] Moreover, butyrate can affect the internal nervous system and regulate neuronal excitability; thus, colon motility and extracorporeal contraction reactions are increased, which prevents CRC development.[127]Butyrate also accumulates and functions as a histone deacetylase (HDAC) inhibitor to accelerate histone acetylation and participate in the apoptosis and proliferation of CRC cells.[128] Additionally, butyrate impedes the angiogenesis, metastasis, and survival of CRC cells through the neuropilin‐1/vascular endothelial growth factor pathway by inhibiting Sp1 transactivation;[129] it can reduce cell proliferation, clone formation, and migration by promoting secretion of endocan through the ERK2/MAPK pathway;[130] butyrate inducing apoptosis in CRC cells by inhibiting the Wnt/β‐catenin signaling[131] and facilitates anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity.[132] In summary, butyrate acts as a vital gut microbiome metabolite and protects against the progression of CRC.Other SCFAsAcetate and propionate are SCFAs fermented from soluble fibers, which have protective effects against CRC. As the final product of fermentation, acetate can be condensed to butyrate in the human colon by bacteria, such as Roseburia spp., F. prausnitzii, and Coprococcus sp. through the action of butyryl‐CoA:acetate CoA‐transferase,[133] thereby contributing to the syntrophy of the gut microbiome and inhibiting CRC progression. Propionate is an HDAC inhibitor which inhibits malignant transformation and induces the apoptosis of precancerous colonic cells, despite its poor effectiveness (in comparison to butyrate) and reduced abundance in CRC.[134] Finally, formate secreted by F. nucleatum, can drives CRC tumor invasion by triggering Aryl hydrocarbon receptor signaling, while increasing cancer stemness.[135] Formate can be considered a gut‐derived oncometabolite relevant for CRC progression.Trimethylamine n‐oxide (TMAO)TMAO is a small organic compound, mainly produced by Enterobacteriaceae, whose concentration in blood increases after ingestion of dietary l‐carnitine and phosphatidylcholine. TMAO is a marker of cardiovascular risk associated with CRC. A prospective cohort study of 835 CRC cases and 835 matched controls found a positive correlation between plasma TMAO levels and CRC risk for the first time. The study showed that subjects with high plasma TMAO levels had a 3.4‐fold higher risk of CRC than subjects with low plasma TMAO levels.[136] In 2017, a study found that serum TMAO levels in patients with CRC was significantly higher than in healthy control subjects. In addition, the study reported that patients with higher serum TMAO levels have lower survival rates than those with lower serum TMAO levels, thus, serum TMAO is a possible prognostic marker for CRC.[137] Although these studies suggest a direct or indirect role for TMAO in CRC, others have shown no correlation between serum TMAO levels and CRC risk. A study conducted on 677 CRC patients and 677 healthy controls reported no significant correlation between serum TMAO levels and the incidence of CRC.[138] Since TMAO levels vary by ethnicity, diet, and region, larger clinical trials are needed to validate the TMAO–CRC correlation, and whether elevated TMAO levels are a cause or a consequence of cancer. Recent studies have postulated a possible association between TMAO levels and CRC, but there is no valid mechanistic approach to its role in carcinogenesis. As studied previously, TMAO may interact in several processes that could impact CRC, such as inflammation, protein folding, oxidative stress, and DNA damage.[139] Excess TMAO leads to sustained and uncontrolled ROS production, which causes inflammation. Inflammation can damage DNA, cause mutations or induce genomic instability, and ultimately leading to the development of CRC.[139]Amino AcidsWhen compared to healthy controls, 17 metabolites were significantly altered in CRC patients.[140] Among them, 10 metabolites are amino acids, specifically l‐alanine, glycine, l‐proline, l‐aspartate, l‐valine, l‐leucine, l‐serine, l‐phenylalanine, l‐α‐aminobutyric acid, and norvaline. Furthermore, differences in the pathways associated with branched‐chain amino acid (BCAA) metabolism in the stages leading to CRC were also observed. Compared to healthy control, the first 4 enriched pathways in CRC are 1) amyl‐tRNA biosynthesis, 2) valine, leucine, and isoleucine biosynthesis, 3) phenylalanine metabolism, and 4) phenylalanine, tyrosine, and tryptophan biosynthesis, suggesting that amino acids metabolic pathways other than individual amino acids in the colorectum are altered in the early the stages leading to CRC.[140]The metabolism of amino acids provides the host with biologically active metabolites through gut microbiota. The amino acid tryptophan is catabolized to a series of indole derivatives (e.g., indole‐3‐acetic acid, indole‐3‐sulfate, indole‐3‐propionic acid, and indole‐3‐aldehyde), which are ligand receptors for aromatic hydrocarbons, such as the Aryl hydrocarbon receptor. Activation of innate lymphocytes and aromatic hydrocarbons in gut‐resident T cells increases IL‐22 production, which helps to prevent colonic inflammation (colitis) and inflammatory bowel disease, which can lead to precancerous lesions.[141] In addition, in vivo, tryptophan metabolites not only suppress inflammation, but also fix abdominal wall structures and in association with beneficial bacteria in the gut, may slow the progression of CRC.[142] Tryptophan metabolism plays an important role in inhibiting the growth of CRC, although the underlying mechanism remains nebulous.Serine metabolism plays a crucial role in the proliferation and survival of tumor cells. Phosphoglycerate dehydrogenase (PHGDH), a key enzyme in serine biosynthesis, can undergo monoubiquitination and increase activity in CRC cells, thereby increasing levels of serine, glycine, and S‐adenosylmethionine (SAM), which in turn upregulates cell adhesion gene expression and promotes cell migration and CRC metastasis.[143]Other MetabolitesIn addition to the above, metabolites originating from dietary phytochemicals also play important roles in CRC. Most of the dietary phytochemicals are transformed into other metabolites by the gut microbiota in the colon through hydrogenation, dehydroxylation, and demethylation.[144] These metabolites have altered bioactivity, and some phenolic metabolites, such as the stilbene resveratrol and dehydroxylated phenolic acids, have anti‐inflammatory properties, thus, reducing the secretion of inflammatory cytokines, such as TNF‐α, COX‐2, and NF‐κB.[145] Moreover, a few phenolic compounds produced by the gut microbiota have antimicrobial effects and alter the composition of gut microbiota by suppressing pathogens such as C. perfringens, and promoting probiotics such as Lactobacilli spp.,[146] thereby producing knock‐on effects on gut microbiota metabolism.[16a] Besides, some virulence factors, such as Fusobacterium adhesin A (FadA) and fibroblast activation protein 2 (Fap2), are induced by gut microbiota and contribute to carcinogenesis. FadA, secreted by F. nucleatum, is a highly conserved virulence factor in C. perfringens that mediates adhesion and invasion of epithelial and endothelial cells.[47] The binding of FadA to E‐cadherin activates the β‐catenin signaling pathway, which in turn increases NF‐κB, Wnt7b, and the cyclin D1 and Myc oncogenes.[42] Fap2 is a galactose‐sensitive hemagglutinin and adhesin that may play a role in the virulence of C. perfringens.[147] The binding of Fap2 to the T‐cell immune receptor with immunoglobulin G inhibits the activity of natural killer cells against tumor cells, leading to the development of CRC.[148] Abed et al. showed that fusobacterial Fap2 could act as a lectin, binding to d‐galactose‐β‐(1–3)‐N‐acetyl‐d‐galactosamine, which is overexpressed in CRC.[149] Investigations on fecal metabolites associated with mouse models of colon tumorigenesis with varying mutational loads revealed that Lactobacillus reuteri and its metabolite, reuterin, are downregulated in mouse and human CRC. Reuterin may alter the redox balance and reduce proliferation and survival of colon cancer cells or induce selective protein oxidation and inhibit ribosomal biogenesis and protein translation to protect against CRC.[150]Several gut microbiota‐derived metabolites contribute to CRC development and progression. Thus, a better understanding of the gut microbiota pathways involved in the biosynthesis of CRC‐related metabolites would greatly aid in intestinal health management, especially CRC prevention. It is important to identify the causal role between gut microbiota‐derived metabolites and CRC.Role of Diet on the Gut Microbiota–Host InteractionsAs discussed above, the gut microbiota may influence the pathophysiology of host disease through several pathways, including the secretion of metabolites.[33] In addition, a direct correlation between diet and the type and amount of gut bacteria has been reported.[151] The impact of diet on gut microbiota–host interactions is increasingly recognized and explored (Table 5). The Western diet is characterized by high levels of protein, sugar, saturated fat, refined grains, alcohol, salt, high‐fructose corn syrup, and low levels of fiber.[152] It has been found to induce microbial dysbiosis, increasing the abundance of Fusobacterium spp., E. coli, and Enterobacter spp. and decreasing the abundance of Faecalibacterium prausnitzii, Roseburia hominis, and Bifidobacterium spp., thus leading to inflammatory responses in the host,[153] which increases the risk of CRC. A plant‐based diet has been found to increase the abundance of Bifidobacterium spp. and Lactobaccilus spp. and decrease the abundance of B. fragilis and C. perfringens, thereby reducing inflammatory responses.[154] Foxtail millet consumption has been shown to increase the abundance of Bifidobacterium spp. and Bacteroidales_S‐24‐7, thereby attenuating colonic inflammation and reducing colitis‐associated CRC in mouse models.[155] Research into the effect of diet on CRC‐associated gut microbiota–host interactions is still lacking. Given that diet is the most important factor influencing the dynamics of the gut microbiota, comprehensive studies of gut microbiota–host interactions shaped by diet have the potential to provide insights into the mechanisms underlying CRC.5TableDiet‐correlated gut microbiota–host interactionsDietGut microbiotaHost interactionIncreaseDecreaseWestern dietFusobacterium spp.Escherichia coliEnterobacter spp.Faecalibacterium prausnitziiRoseburia hominisBifidobacterium spp.ProinflammatoryPlant‐based dietBifidobacterium spp.Lactobaccilus spp.Bacteroides fragilisClostridium perfringensAnti‐inflammatoryFoxtail millet consumptionBifidobacterium spp.Bacteroidales_S‐24‐7∖Anti‐inflammatoryPotential Roles of Gut Microbiota and Its Metabolites in CRC Diagnosis and TreatmentOwing to the dysbiosis of gut microbiota, several species are involved in CRC diagnosis and treatment, which could be used as therapeutic targets. Herein, we summarized the applications of gut microbiota in screening, prognosis, and treatment of CRC (Figure 4).4FigureThe role of gut microbiota in CRC diagnosis and treatment. Detection of fecal bacteria including F. nucleatum, serum antibodies against F. nucleatum and gut microbiota metabolites including BAs and SCFAs could play roles in CRC screening. Fecal bacteria including two species of Bacteroides, Lachnospiraceae, Clostridiales, and Clostridium could be used to detect adenomas. F. nucleatum can be used in prognostic predictions for CRC patients. Treatment methods including chemotherapy, immunotherapy, and radiotherapy could disturb microbial community, while the composition of the gut microbiota could, in turn, affect the treatments. Methods including supplementation with probiotics, prebiotics and their metabolites, and fecal microbiota transplantation (FMT) could modify gut microbiota composition in order to treat CRC.Role of Gut Microbiota in CRC DiagnosisDue to the emerging clinical demand of CRC screening and treatment, which remarkably improves CRC prognosis,[156] research and development on accurate and noninvasive diagnostic methods are of necessity. In addition to traditional (endoscopy) and nascent (fecal immunochemical test (FIT) and circulating tumor DNA) diagnostic methods,[157] fecal microbial markers are a promising and desirable diagnostic tool as they seem accurate, economical, and noninvasive.[6]CRC ScreeningEarly detection of CRC through screening has been widely accepted as a main path in CRC prevention and treatment, and it significantly improves the overall survival rate of patients.[158] Fecal samples are most ideal for screening because of the noninvasive collection method. FIT has been applied in clinical settings in recent years, but its sensitivity for CRC is limited.[159] FIT using fecal DNA has >90% sensitivity in CRC detection, but <50% sensitivity in detecting advanced colorectal adenomas.[160]Fecal microbial markers are being considered to screen patients for CRC with enhanced sensitivity and accuracy. Based on microbiota‐based screening, several bacterial species with alterations in abundance were selected and compared to FIT and a fecal occult blood test.[161] Among the selected bacteria, addition of F. nucleatum screening enhanced the accuracy and sensitivity of FIT,[161b,162] which reached a sensitivity and specificity of 84.6% and 92.3%, respectively, when combined with Bifidobacterium[163] and a sensitivity and specificity of 84.6% and 63.1%, respectively, when combined with colibactin‐producing bacteria.[164] In addition, serum antibodies against F. nucleatum were also useful in CRC detection.[165] Importantly, detection of adenomas is also a key factor in CRC prevention. Combination of the abundance of five bacterial species and other clinical parameters reached an AUC of 0.90, indicating the potential value of fecal microbial markers in colorectal adenoma detection.[166] Interestingly, an increased abundance of F. nucleatum was also detected in the fecal samples of patients with adenomas, and this can be evaluated in further studies.[161b]Additionally, gut microbiota metabolites have the potential in screening for CRC. Divergence of BAs and SCFAs were determined in fecal extracts.[167] Higher levels of acetate, valeric acid, isobutyric acid, and isovaleric acid, and lower levels of butyrate, linoleic acid, glycerol, oleic acid, and trans‐oleic acid were detected in patients with CRC than in healthy individuals.[167] However, further large‐scale clinical studies should be conducted to investigate the feasibility of CRC screening using fecal microbial markers, gut microbiota, and its metabolites.Prediction of CRC PrognosisFecal microbial markers are correlated to the clinical outcomes of CRC and are useful in predicting CRC prognosis.[25] F. nucleatum is a key factor in prognostication; its abundance in CRC tumors is negatively correlated with patients’ survival.[168] Importantly, further research on the value of bacterial markers in CRC prognostication must be conducted, with a wider range of microorganisms and limited interference factors.Role of Gut Microbiota in CRC TreatmentChemotherapy and immunotherapy have dramatically improved the survival of patients, but the side effects and sequelae have become increasingly significant. These therapies disturb the gut microbiota leading to dysbiosis which can be reversed after treatment.[169] More importantly, the gut microbiota can enhance treatment efficacy and reduce adverse effects.[170]ChemotherapyChemotherapy disturbs the microbial community, leading to a reduction in microbial diversity and changes in the abundance of several bacteria.[171] For example, treatment with 5‐fluorouracil (5‐FU) can result in the enrichment of Proteobacteria, and decrease of Firmicutes and Actinobacteria, resulting in a reduction of inflammatory reactions through interaction with the NF‐κB signaling pathway and production of SCFAs.[172] Conversely, the gut microbiota can also affect chemotherapy within a mechanistic framework: translocation, immunomodulation, metabolism, enzymatic degradation, and reduced diversity and ecological variation (TIMER).[169] The curative effects of many widely applied agents, including 5‐FU,[172] gemcitabine,[173] oxaliplatin,[174] and cyclophosphamide,[175] are regulated by gut microbiota using the TIMER mechanism. In vivo studies have proven that a lack of gut microorganisms can diminish the therapeutic effects of drugs on tumor‐infiltrating myeloid‐derived cells and lead to ROS production and cytotoxicity.[174] Notably, F. nucleatum has been shown to enhance the resistance of colonized tumors to the therapeutic effects of 5‐FU and oxaliplatin through the activation of cell autophagy.[40] Therefore, chemotherapy can be augmented by therapeutic agents targeting F. nucleatum to improve treatment outcomes, and detection of this bacterium may predict the potency of chemotherapy, thus, it should be considered in the future.ImmunotherapyInhibitory signals of T cell activation can be reversed by immune checkpoint inhibitors (ICIs) to enable tumor‐reactive T cells to induce significant antitumor responses.[176] This type of immunotherapy has not been widely applied in clinical settings but has attracted great attention as a promising therapeutic pathway in CRC treatment,[177] especially in patients with CRC who have high levels of microsatellite instability and/or DNA mismatch repair‐deficient metastasis.[178] Interestingly, immunotherapy alters the composition of the gut microbiota,[179] which has a role in the immune responses generated by immunotherapy.[180] The gut microbiota regulates a few pivotal ICIs, including the programmed cell death 1 (PD‐1)/PD‐1 ligand 1[181] and cytotoxic T lymphocyte‐associated antigen 4 axes.[182] Several bacteria, including B. fragilis,[182a] Akkermansia muciniphila,[181a] Alistipes shahii,[174] Bifidobacterium spp.,[181b,d] Faecalibacterium spp.,[183] and Eubacterium limosum,[184] are advantageous to immunotherapy. Bacterial supplements of Lactobacillus, Ruminococcus, and Alistipes can enhance the therapeutic response to ICIs,[174] and bacteria, such as Akkermansia muciniphila, accumulate in immunotherapy responders.[185] However, some of the side effects of immunotherapy are correlated with the gut microbiota,[182a] and resistance to immunotherapy is associated with several bacteria, including Bacteroidetes.[186] Therefore, additional treatment targeting these bacteria might be conducive to the therapeutic efficacy of immunotherapy toward cancers, including CRC.[174,187]Probiotics and PrebioticsWith the increasing awareness of the importance of gut microbiota in tumorigenesis and cancer treatment outcomes, restoring intestinal microbiota homeostasis has become a potential CRC prevention and treatment measure. Probiotics and prebiotics are emerging biotherapeutics, which modify the gut microbiota, thus, benefiting the host.[188]Probiotics are microorganisms which benefit the human body if taken in moderation.[188] Lactobacillus and Bifidobacterium are the most studied probiotics in CRC treatment.[189] As the concept of probiotics evolved over the past few decades, it is now understood that the effects of probiotics are not only microbiota‐mediated, but also host‐mediated through the induction of physiological and metabolic changes. Probiotic administration corrects microbial dysbiosis and maintains the intestinal microbial balance by occupying host tissues, preventing colonization by pathogenic bacteria, exerting immunomodulatory effects, and enhancing gut barrier function.[190] Evidence has indicated that probiotics could diminish tumor incidence and act as a preventive treatment for CRC. For instance, Lactobacillus plantarum decreased tumor development by increasing the innate immune response through a set of reactions, including dendritic cell maturation which led to the polarization of Th1 responses, migration of CD8+ and natural killer cells, reduction of tumor growth, and prolongation of survival of mice with CRC.[191] Furthermore, clinical trials have indicated that a lower incidence of moderate and higher atypia‐graded tumors were found in patients receiving a preparation of Lactobacillus casei than in patients not receiving this probiotic.[192]Prebiotics are substrates which are selectively utilized by host microorganisms that confer health benefits.[188] At present, prebiotics are predominantly carbohydrate‐based, but other substances, such as polyphenols and polyunsaturated fatty acids, may also play a prebiotic role.[188] Prebiotics exert their beneficial health effects in the intestines mainly by stimulating the growth and selective fermentation of probiotics, interacting with pathogens and preventing colonization, playing an anti‐inflammatory role, exerting selective cytotoxicity on tumor cells, inhibiting the apoptosis of normal epithelial cells, and enhancing IgA secretion that protects the intestinal epithelium.[190] Butyrate treatment promotes epithelial cell proliferation, polyp formation, and ultimately leads to tumor progression in Apcmin/+; Msh2−/− mice.[193] Though the strength of evidence for prebiotic interventions lags behind that for probiotics, prebiotics may improve the abundance of four symbiotic microbes, which can be opportunistic pathogens in patients with CRC.[194]Although the results of animal experiments are highly encouraging, the quantity and quality of clinal trials related to this field remains limited. It has been extremely challenging to conduct randomized clinical trials with large sample sizes, proper randomization, analysis, and validation to obtain sufficient evidence to support the benefit of prebiotic treatment in CRC.Other Microbiota‐Related Therapeutic ApproachesOther microbiota‐related therapeutic approaches which may be effective against CRC are also being considered. These include antibiotics and fecal microbiota transplantation (FMT). Antibiotic treatment may kill intestinal microbiota and reverse harmful dysbiosis primarily through the elimination of carcinogenic B. fragilis, mucin degradation, inflammation, and DNA methylation.[195] Metronidazole treatment reduced cancer cell proliferation and shrunk tumor volume in mice bearing a colon cancer xenograft.[78] Another study also reported that an antibiotic cocktail composed of ampicillin, neomycin, metronidazole, and vancomycin depleted the gut microbiota and attenuated colon tumor formation in mice fed a high‐fat diet.[196] However, the role of antibiotic treatment in cancer management is controversial as a register‐based study showed a robust association between antibiotic treatment and an increased risk of proximal CRC.[197]FMT from healthy donors to individuals with cancer restores microbial homeostasis, which may be helpful for improving various gastrointestinal diseases, including irritable bowel syndrome, Clostridium difficile infection, and CRC.[198] FMT also increases microbial diversity without disruption of the microbial gut ecology in contrast to antibiotic treatment, and its long‐term implantation allows it to be designed as a single‐dose regimen, thus, adding therapeutic benefits to probiotics and prebiotics, whose effects are short‐term.[199] A recent study reported that FMT from wild mice to laboratory mice improved host fitness and resistance against AOM/DSS‐induced colorectal tumorigenesis.[200] The practical application of FMT in patients with CRC awaits trial results on its effect (in combination with cancer immunotherapy or chemotherapy), which are in progress.[201] Other novel approaches could include bacteriocins[202] or bacteriophages[203] to modify the gut microbiota. More studies are imperative to evaluate the clinical application potential of these engineered products in CRC.Conclusions and OutlookDifferences in the composition and abundance of the gut microbiota in patients with CRC patients and interaction between the gut microbiota and CRC have been reported. The gut microbiota and its metabolites interact closely with host epithelial cells and have a crucial role in CRC. As research elucidates the role played by intestinal flora during carcinogenesis, it offers unprecedented opportunities to explore applications in CRC diagnosis, treatment, and prognosis, although many obstacles remain.Some questions are still to be answered by future research. Evidence such as the increased abundance of F. nucleatum, E. coli, or B. fragilis in CRC provides an opportunity for these organisms to be targeted as biomarkers in conjunction with conventional diagnostics. However, due to the diversity of sequencing methods, it is difficult to reach a consensus on the composition of the gut microbiota. Therapeutic approaches targeting the microbiome are gaining attention in clinical applications, yet their implementation remains challenging due to the numerous effects of the gut microbiota on host biology, many of which are currently unknown. More importantly, it should be of great concern that lifestyle, drugs, genetics, and other factors could have a significant impact on the remodeling of the gut microbiota. However, these influencing factors have been ignored and not corrected in many cancer studies, thus confounding the real facts and leading to potentially mistaken conclusions. Care should be taken to control for confounding factors in order to find the key bacteria and mechanisms that really influence the pathogenesis of cancers, including CRC, when analyzing the complex and diverse sequencing data of large sample size. For the metabolites, there is still a lack of evidence on the source of the metabolites detected in feces or serum, and there is still a debate on whether they are secreted by the gut microbiota or the host, or whether they are ingested from the diet. Clarification of metabolite sources will facilitate research into subsequent treatment modalities for CRC.Exploring the significance of clinical transformation is an important direction for future microbial research. There could be three major potential applications of gut microbiota in CRC, including noninvasive diagnostic tools, restoration of microbial dysbiosis or probiotic supplementation for CRC prevention, or modulation of gut microbes to enhance therapeutic responses. Bacteria‐based therapy could be achieved by selective elimination of oncogenic microbes, fecal transplantation of antitumor species, and altering the composition of the microbiota through oral probiotic supplementation or targeted phage therapy. However, large‐scale clinical trials based on rigorous animal studies are needed to further establish their efficacy and safety in the clinic. Thus, such applications still remain a long way from routine use.To proclaim the expected clinical potential of the gut microbiota in CRC, researchers must decipher whether specific strains or the collective capabilities of some microbiota, influence the development of disease. Further studies are needed to help fully determine the pathogenic role of the gut microbiota in carcinogenesis and its response to treatment, and to address the challenges that impede the achievement of personalized medicine, by focusing on specific individuals including early‐onset patients. With the vigorous development in this rapidly developing field, gut microbiota will become a crucial part of future diagnosis, cancer prevention, and treatment measures.AcknowledgementsThe authors acknowledge Dr. Jucheng Bai from Peking University Third Hospital for the modification of figures. This research was supported in part by the National Key Research and Development Program of China (2018YFA0800700), the National Natural Science Foundation of China (Nos. 82130022, 31925021, 81972702, 91959110, 82273104, and 62173005), Peking University Clinical Scientist Training Program Project (BMU2023PYJH021), and the National Health and Family Planning Commission Foundation of China (Grant No. 2020YB57).Conflict of InterestThe authors declare no conflict of interest.Author ContributionsR.Q., Y.Z., and Y.M. contributed equally to the work. All authors have contributed to the article and approved its publication. R.Q., Y.Z., Y.M., X.Z., and L.S.: designing, writing, and figure preparation. L.S., C.J., Z.Z., and W.F.: designing, funding acquisition, reviewing, and editing.R. L. Siegel, K. D. Miller, N. S. Wagle, A. Jemal, Ca‐Cancer J. Clin. 2023, 73, 17.a) S. Bian, Y. Hou, X. Zhou, X. Li, J. Yong, Y. Wang, W. Wang, J. Yan, B. Hu, H. Guo, J. Wang, S. Gao, Y. Mao, J. Dong, P. Zhu, D. Xiu, L. Yan, L. Wen, J. Qiao, F. Tang, W. Fu, Science 2018, 362, 1060;b) S. Mo, P. Tang, W. Luo, L. Zhang, Y. Li, X. Hu, X. Ma, Y. Chen, Y. Bao, X. He, G. Fu, X. Xu, X. Rao, X. Li, R. Guan, S. Chen, Y. Deng, T. Lv, P. Mu, Q. Zheng, S. Wang, F. Liu, Y. Li, W. Sheng, D. Huang, C. Hu, J. Gao, Z. Zhang, S. Cai, H. Clevers, et al., Adv. Sci. 2022, 9, 2204097.E. S. Oh, A. Petronis, Nat. Rev. Genet. 2021, 22, 533.A. Janney, F. Powrie, E. H. Mann, Nature 2020, 585, 509.S. Yachida, S. Mizutani, H. Shiroma, S. Shiba, T. Nakajima, T. Sakamoto, H. Watanabe, K. Masuda, Y. Nishimoto, M. Kubo, F. Hosoda, H. Rokutan, M. Matsumoto, H. Takamaru, M. Yamada, T. Matsuda, M. Iwasaki, T. Yamaji, T. Yachida, T. Soga, K. Kurokawa, A. Toyoda, Y. Ogura, T. Hayashi, M. Hatakeyama, H. Nakagama, Y. Saito, S. Fukuda, T. Shibata, T. Yamada, Nat. Med. 2019, 25, 968.S. H. Wong, J. Yu, Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 690.M. Schmitt, F. R. Greten, Nat. Rev. Immunol. 2021, 21, 653.X. Liu, X. Tong, Y. Zou, X. Lin, H. Zhao, L. Tian, Z. Jie, Q. Wang, Z. Zhang, H. Lu, L. Xiao, X. Qiu, J. Zi, R. Wang, X. Xu, H. Yang, J. Wang, Y. Zong, W. Liu, Y. Hou, S. Zhu, H. Jia, T. Zhang, Nat. Genet. 2022, 54, 52.S. Heilbronner, B. Krismer, H. Brötz‐Oesterhelt, A. Peschel, Nat. Rev. Microbiol. 2021, 19, 726.a) J. Li, W. Hou, S. Lin, L. Wang, C. Pan, F. Wu, J. Liu, Adv. Sci. 2022, 9, 2104006;b) J. Cai, L. Sun, F. J. Gonzalez, Cell Host Microbe 2022, 30, 289.a) S. Rezasoltani, H. Asadzadeh Aghdaei, H. Dabiri, A. Akhavan Sepahi, M. H. Modarressi, E. Nazemalhosseini Mojarad, Microb. Pathog. 2018, 124, 244;b) E. Saus, S. Iraola‐Guzmán, J. R. Willis, A. Brunet‐Vega, T. Gabaldón, Mol. Aspects Med. 2019, 69, 93.a) J. M. Brown, S. L. Hazen, Nat. Rev. Microbiol. 2018, 16, 171;b) L. Ge, J. Qi, B. Shao, Z. Ruan, Y. Ren, S. Sui, X. Wu, X. Sun, S. Liu, S. Li, C. Xu, W. Song, Gut Microbes 2022, 14, 2013764;c) M. D. Gershon, K. G. Margolis, J. Clin. Invest. 2021, 131, 143768.R. Qu, Y. Ma, L. Tao, X. Bao, X. Zhou, B. Wang, F. Li, S. Lu, L. Tuo, S. Zhan, Z. Zhang, W. Fu, Chin. J. Cancer Res. 2021, 33, 500,A. P. Bhatt, M. R. Redinbo, S. J. Bultman, Ca‐Cancer J. Clin. 2017, 67, 326.G. D. Sepich‐Poore, L. Zitvogel, R. Straussman, J. Hasty, J. A. Wargo, R. Knight, Science 2021, 371, 4552.a) Z. E. Stine, Z. T. Schug, J. M. Salvino, C. V. Dang, Nat. Rev. Drug Discovery 2021, 21, 141;b) F. Kong, C. Fang, Y. Zhang, L. Duan, D. Du, G. Xu, X. Li, H. Li, Y. Yin, H. Xu, K. Zhang, Adv. Sci. 2022, 9, 2105523.Y. S. Chen, J. Li, R. Menon, A. Jayaraman, K. Lee, Y. Huang, W. M. Dashwood, K. Zhang, D. Sun, R. H. Dashwood, Gut Microbes 2021, 13, 1972756.J. E. Wilkinson, E. A. Franzosa, C. Everett, C. Li, F. B. Hu, D. F. Wirth, M. Song, A. T. Chan, E. Rimm, W. S. Garrett, C. Huttenhower, Nat. Med. 2021, 27, 766.Z. Dai, O. O. Coker, G. Nakatsu, W. K. K. Wu, L. Zhao, Z. Chen, F. K. L. Chan, K. Kristiansen, J. J. Y. Sung, S. H. Wong, J. Yu, Microbiome 2018, 6, 70.Y. He, W. Wu, H. M. Zheng, P. Li, D. McDonald, H. F. Sheng, M. X. Chen, Z. H. Chen, G. Y. Ji, Z. D. Zheng, P. Mujagond, X. J. Chen, Z. H. Rong, P. Chen, L. Y. Lyu, X. Wang, C. B. Wu, N. Yu, Y. J. Xu, J. Yin, J. Raes, R. Knight, W. J. Ma, H. W. Zhou, Nat. Med. 2018, 24, 1532.B. A. Peters, C. Dominianni, J. A. Shapiro, T. R. Church, J. Wu, G. Miller, E. Yuen, H. Freiman, I. Lustbader, J. Salik, C. Friedlander, R. B. Hayes, J. Ahn, Microbiome 2016, 4, 69.B. Flemer, D. B. Lynch, J. M. Brown, I. B. Jeffery, F. J. Ryan, M. J. Claesson, M. O'Riordain, F. Shanahan, P. W. O'Toole, Gut 2017, 66, 633.Q. Feng, S. Liang, H. Jia, A. Stadlmayr, L. Tang, Z. Lan, D. Zhang, H. Xia, X. Xu, Z. Jie, L. Su, X. Li, X. Li, J. Li, L. Xiao, U. Huber‐Schönauer, D. Niederseer, X. Xu, J. Y. Al‐Aama, H. Yang, J. Wang, K. Kristiansen, M. Arumugam, H. Tilg, C. Datz, J. Wang, Nat. Commun. 2015, 6, 6528.A. D. Kostic, E. Chun, L. Robertson, J. N. Glickman, C. A. Gallini, M. Michaud, T. E. Clancy, D. C. Chung, P. Lochhead, G. L. Hold, E. M. El‐Omar, D. Brenner, C. S. Fuchs, M. Meyerson, W. S. Garrett, Cell Host Microbe 2013, 14, 207.G. Nakatsu, H. Zhou, W. K. K. Wu, S. H. Wong, O. O. Coker, Z. Dai, X. Li, C. H. Szeto, N. Sugimura, T. Y. Lam, A. C. Yu, X. Wang, Z. Chen, M. C. Wong, S. C. Ng, M. T. V. Chan, P. K. S. Chan, F. K. L. Chan, J. J. Sung, J. Yu, Gastroenterology 2018, 155, 529.S. Ogino, A. T. Chan, C. S. Fuchs, E. Giovannucci, Gut 2011, 60, 397.G. D. Hannigan, M. B. Duhaime, M. T. t. Ruffin, C. C. Koumpouras, P. D. Schloss, mBio 2018, 9, 02248.O. O. Coker, G. Nakatsu, R. Z. Dai, W. K. K. Wu, S. H. Wong, S. C. Ng, F. K. L. Chan, J. J. Y. Sung, J. Yu, Gut 2019, 68, 654.M. Xue, H. Liang, X. Ji, Z. Zhou, Y. Liu, T. Sun, L. Zhang, J. Nutr. Biochem. 2020, 82, 108396.S. H. Wong, L. Zhao, X. Zhang, G. Nakatsu, J. Han, W. Xu, X. Xiao, T. N. Y. Kwong, H. Tsoi, W. K. K. Wu, B. Zeng, F. K. L. Chan, J. J. Y. Sung, H. Wei, J. Yu, Gastroenterology 2017, 153, 1621.a) J. Yu, Q. Feng, S. H. Wong, D. Zhang, Q. Y. Liang, Y. Qin, L. Tang, H. Zhao, J. Stenvang, Y. Li, X. Wang, X. Xu, N. Chen, W. K. Wu, J. Al‐Aama, H. J. Nielsen, P. Kiilerich, B. A. Jensen, T. O. Yau, Z. Lan, H. Jia, J. Li, L. Xiao, T. Y. Lam, S. C. Ng, A. S. Cheng, V. W. Wong, F. K. Chan, X. Xu, H. Yang, et al., Gut 2017, 66, 70;b) Y. Gao, D. Bi, R. Xie, M. Li, J. Guo, H. Liu, X. Guo, J. Fang, T. Ding, H. Zhu, Y. Cao, M. Xing, J. Zheng, Q. Xu, Q. Xu, Q. Wei, H. Qin, Signal Transduction Targeted Ther. 2021, 6, 398;c) Y. Wu, N. Jiao, R. Zhu, Y. Zhang, D. Wu, A. J. Wang, S. Fang, L. Tao, Y. Li, S. Cheng, X. He, P. Lan, C. Tian, N. N. Liu, L. Zhu, Nat. Commun. 2021, 12, 3063.Q. Liang, J. Chiu, Y. Chen, Y. Huang, A. Higashimori, J. Fang, H. Brim, H. Ashktorab, S. C. Ng, S. S. M. Ng, S. Zheng, F. K. L. Chan, J. J. Y. Sung, J. Yu, Clin. Cancer Res. 2017, 23, 2061.H. Tilg, T. E. Adolph, R. R. Gerner, A. R. Moschen, Cancer Cell 2018, 33, 954.a) J. Goc, M. Lv, N. J. Bessman, A. L. Flamar, S. Sahota, H. Suzuki, F. Teng, G. G. Putzel, G. Eberl, D. R. Withers, J. C. Arthur, M. A. Shah, G. F. Sonnenberg, Cell 2021, 184, 5015;b) P. Liu, C. Gao, H. Chen, C. T. Vong, X. Wu, X. Tang, S. Wang, Y. Wang, Acta Pharm. Sin. B 2021, 11, 2798;c) S. Beyaz, C. Chung, H. Mou, K. E. Bauer‐Rowe, M. E. Xifaras, I. Ergin, L. Dohnalova, M. Biton, K. Shekhar, O. Eskiocak, K. Papciak, K. Ozler, M. Almeqdadi, B. Yueh, M. Fein, D. Annamalai, E. Valle‐Encinas, A. Erdemir, K. Dogum, V. Shah, A. Alici‐Garipcan, H. V. Meyer, D. M. Özata, E. Elinav, A. Kucukural, P. Kumar, J. P. McAleer, J. G. Fox, C. A. Thaiss, A. Regev, et al., Cell Stem Cell 2021, 28, 1922.E. Cremonesi, V. Governa, J. F. G. Garzon, V. Mele, F. Amicarella, M. G. Muraro, E. Trella, V. Galati‐Fournier, D. Oertli, S. R. Däster, R. A. Droeser, B. Weixler, M. Bolli, R. Rosso, U. Nitsche, N. Khanna, A. Egli, S. Keck, J. Slotta‐Huspenina, L. M. Terracciano, P. Zajac, G. C. Spagnoli, S. Eppenberger‐Castori, K. P. Janssen, L. Borsig, G. Iezzi, Gut 2018, 67, 1984.T. Secher, S. Normand, M. Chamaillard, Gut Microbes 2013, 4, 353.H. Zhu, W. Y. Xu, Z. Hu, H. Zhang, Y. Shen, S. Lu, C. Wei, Z. G. Wang, J. Exp. Clin. Cancer Res. 2017, 36, 2.R. Kesselring, J. Glaesner, A. Hiergeist, E. Naschberger, H. Neumann, S. M. Brunner, A. K. Wege, C. Seebauer, G. Köhl, S. Merkl, R. S. Croner, C. Hackl, M. Stürzl, M. F. Neurath, A. Gessner, H. J. Schlitt, E. K. Geissler, S. Fichtner‐Feigl, Cancer Cell 2016, 29, 684.S. M. Man, Q. Zhu, L. Zhu, Z. Liu, R. Karki, A. Malik, D. Sharma, L. Li, R. K. Malireddi, P. Gurung, G. Neale, S. R. Olsen, R. A. Carter, D. J. McGoldrick, G. Wu, D. Finkelstein, P. Vogel, R. J. Gilbertson, T. D. Kanneganti, Cell 2015, 162, 45.T. Yu, F. Guo, Y. Yu, T. Sun, D. Ma, J. Han, Y. Qian, I. Kryczek, D. Sun, N. Nagarsheth, Y. Chen, H. Chen, J. Hong, W. Zou, J. Y. Fang, Cell 2017, 170, 548.C. A. Brennan, S. L. Clay, S. L. Lavoie, S. Bae, J. K. Lang, D. Fonseca‐Pereira, K. G. Rosinski, N. Ou, J. N. Glickman, W. S. Garrett, Gut Microbes 2021, 13, 1987780.M. R. Rubinstein, X. Wang, W. Liu, Y. Hao, G. Cai, Y. W. Han, Cell Host Microbe 2013, 14, 195.Y. Yang, W. Weng, J. Peng, L. Hong, L. Yang, Y. Toiyama, R. Gao, M. Liu, M. Yin, C. Pan, H. Li, B. Guo, Q. Zhu, Q. Wei, M. P. Moyer, P. Wang, S. Cai, A. Goel, H. Qin, Y. Ma, Gastroenterology 2017, 152, 851.X. Ye, R. Wang, R. Bhattacharya, D. R. Boulbes, F. Fan, L. Xia, H. Adoni, N. J. Ajami, M. C. Wong, D. P. Smith, J. F. Petrosino, S. Venable, W. Qiao, V. Baladandayuthapani, D. Maru, L. M. Ellis, Cancer Prev. Res. 2017, 10, 398.S. Chen, T. Su, Y. Zhang, A. Lee, J. He, Q. Ge, L. Wang, J. Si, W. Zhuo, L. Wang, Gut Microbes 2020, 11, 511.H. Liu, J. Du, S. Chao, S. Li, H. Cai, H. Zhang, G. Chen, P. Liu, P. Bu, Adv. Sci. 2022, 9, 2105222.M. R. Rubinstein, J. E. Baik, S. M. Lagana, R. P. Han, W. J. Raab, D. Sahoo, P. Dalerba, T. C. Wang, Y. W. Han, EMBO Rep. 2019, 20, 47638.C. Palmela, C. Chevarin, Z. Xu, J. Torres, G. Sevrin, R. Hirten, N. Barnich, S. C. Ng, J. F. Colombel, Gut 2018, 67, 574.I. Sobhani, H. Rotkopf, K. Khazaie, Gut Microbes 2020, 12, 1800898.K. A. Lee, M. K. Luong, H. Shaw, P. Nathan, V. Bataille, T. D. Spector, Br. J. Cancer 2021, 125, 1197.P. J. Dziubańska‐Kusibab, H. Berger, F. Battistini, B. A. M. Bouwman, A. Iftekhar, R. Katainen, T. Cajuso, N. Crosetto, M. Orozco, L. A. Aaltonen, T. F. Meyer, Nat. Med. 2020, 26, 1063.a) J. C. Arthur, E. Perez‐Chanona, M. Mühlbauer, S. Tomkovich, J. M. Uronis, T. J. Fan, B. J. Campbell, T. Abujamel, B. Dogan, A. B. Rogers, J. M. Rhodes, A. Stintzi, K. W. Simpson, J. J. Hansen, T. O. Keku, A. A. Fodor, C. Jobin, Science 2012, 338, 120;b) S. Tomkovich, Y. Yang, K. Winglee, J. Gauthier, M. Mühlbauer, X. Sun, M. Mohamadzadeh, X. Liu, P. Martin, G. P. Wang, E. Oswald, A. A. Fodor, C. Jobin, Cancer Res. 2017, 77, 2620.N. Dalal, R. Jalandra, N. Bayal, A. K. Yadav, Harshulika, M. Sharma, G. K. Makharia, P. Kumar, R. Singh, P. R. Solanki, A. Kumar, J. Cancer Res. Clin. Oncol. 2021, 147, 3141.A. Bertocchi, S. Carloni, P. S. Ravenda, G. Bertalot, I. Spadoni, A. Lo Cascio, S. Gandini, M. Lizier, D. Braga, F. Asnicar, N. Segata, C. Klaver, P. Brescia, E. Rossi, A. Anselmo, S. Guglietta, A. Maroli, P. Spaggiari, N. Tarazona, A. Cervantes, S. Marsoni, L. Lazzari, M. G. Jodice, C. Luise, M. Erreni, S. Pece, P. P. Di Fiore, G. Viale, A. Spinelli, C. Pozzi, et al., Cancer Cell 2021, 39, 708.S. Wu, K. J. Rhee, E. Albesiano, S. Rabizadeh, X. Wu, H. R. Yen, D. L. Huso, F. L. Brancati, E. Wick, F. McAllister, F. Housseau, D. M. Pardoll, C. L. Sears, Nat. Med. 2009, 15, 1016.L. Chung, E. Thiele Orberg, A. L. Geis, J. L. Chan, K. Fu, C. E. DeStefano Shields, C. M. Dejea, P. Fathi, J. Chen, B. B. Finard, A. J. Tam, F. McAllister, H. Fan, X. Wu, S. Ganguly, A. Lebid, P. Metz, S. W. Van Meerbeke, D. L. Huso, E. C. Wick, D. M. Pardoll, F. Wan, S. Wu, C. L. Sears, F. Housseau, Cell Host Microbe 2018, 23, 203.A. L. Geis, H. Fan, X. Wu, S. Wu, D. L. Huso, J. L. Wolfe, C. L. Sears, D. M. Pardoll, F. Housseau, Cancer Discovery 2015, 5, 1098.L. DeDecker, B. Coppedge, J. Avelar‐Barragan, W. Karnes, K. Whiteson, Gut Microbes 2021, 13, 1854641.A. C. Goodwin, C. E. Destefano Shields, S. Wu, D. L. Huso, X. Wu, T. R. Murray‐Stewart, A. Hacker‐Prietz, S. Rabizadeh, P. M. Woster, C. L. Sears, R. A. Casero Jr, Proc. Natl. Acad. Sci. USA 2011, 108, 15354.J. Allen, S. Hao, C. L. Sears, W. Timp, Infect. Immun. 2019, 87.a) J. C. Taylor, X. Gao, J. Xu, M. Holder, J. Petrosino, R. Kumar, W. Liu, M. Höök, C. Mackenzie, A. Hillhouse, W. Brashear, M. P. Nunez, Y. Xu, PLoS Pathog. 2021, 17, 1009182;b) L. Aymeric, F. Donnadieu, C. Mulet, L. du Merle, G. Nigro, A. Saffarian, M. Bérard, C. Poyart, S. Robine, B. Regnault, P. Trieu‐Cuot, P. J. Sansonetti, S. Dramsi, Proc. Natl. Acad. Sci. USA 2018, 115, E283.J. Butt, B. Romero‐Hernández, B. Pérez‐Gómez, M. Willhauck‐Fleckenstein, D. Holzinger, V. Martin, V. Moreno, C. Linares, T. Dierssen‐Sotos, A. Barricarte, A. Tardón, J. M. Altzibar, E. Moreno‐Osset, F. Franco, R. O. Requena, J. M. Huerta, A. Michel, T. Waterboer, G. Castaño‐Vinyals, M. Kogevinas, M. Pollán, A. Boleij, S. de Sanjosé, R. Del Campo, H. Tjalsma, N. Aragonés, M. Pawlita, Int. J. Cancer 2016, 138, 1670.a) R. Kumar, J. L. Herold, D. Schady, J. Davis, S. Kopetz, M. Martinez‐Moczygemba, B. E. Murray, F. Han, Y. Li, E. Callaway, R. S. Chapkin, W. M. Dashwood, R. H. Dashwood, T. Berry, C. Mackenzie, Y. Xu, PLoS Pathog. 2017, 13, 1006440;b) Y. Zhang, Y. Weng, H. Gan, X. Zhao, F. Zhi, Biochem. Biophys. Res. Commun. 2018, 506, 907.Q. Guo, J. Z. Goldenberg, C. Humphrey, R. El Dib, B. C. Johnston, Cochrane Database Syst. Rev. 2019, 4, 004827.X. Zhang, D. Yu, D. Wu, X. Gao, F. Shao, M. Zhao, J. Wang, J. Ma, W. Wang, X. Qin, Y. Chen, P. Xia, S. Wang, Cell Host Microbe 2023, 31, 418.M. K. Stoeva, J. Garcia‐So, N. Justice, J. Myers, S. Tyagi, M. Nemchek, P. J. McMurdie, O. Kolterman, J. Eid, Gut Microbes 2021, 13, 1.A. Koh, F. De Vadder, P. Kovatcheva‐Datchary, F. Bäckhed, Cell 2016, 165, 1332.D. Chen, D. Jin, S. Huang, J. Wu, M. Xu, T. Liu, W. Dong, X. Liu, S. Wang, W. Zhong, Y. Liu, R. Jiang, M. Piao, B. Wang, H. Cao, Cancer Lett 2020, 469, 456.M. M. Leonard, F. Valitutti, H. Karathia, M. Pujolassos, V. Kenyon, B. Fanelli, J. Troisi, P. Subramanian, S. Camhi, A. Colucci, G. Serena, S. Cucchiara, C. M. Trovato, B. Malamisura, R. Francavilla, L. Elli, N. A. Hasan, A. R. Zomorrodi, R. Colwell, A. Fasano, Proc. Natl. Acad. Sci. USA 2021, 118.Q. Li, W. Hu, W. X. Liu, L. Y. Zhao, D. Huang, X. D. Liu, H. Chan, Y. Zhang, J. D. Zeng, O. O. Coker, W. Kang, S. S. M. Ng, L. Zhang, S. H. Wong, T. Gin, M. T. V. Chan, J. L. Wu, J. Yu, W. K. K. Wu, Gastroenterology 2021, 160, 1179.a) P. Hu, W. Song, Y. Shan, M. Du, M. Huang, C. Song, L. Zhang, Food Funct. 2015, 6, 2257;b) P. Chondrou, A. Karapetsas, D. E. Kiousi, D. Tsela, A. Tiptiri‐Kourpeti, I. Anestopoulos, I. Kotsianidis, E. Bezirtzoglou, A. Pappa, A. Galanis, Benefic. Microbes 2018, 9, 975;c) S. Nozari, Y. Faridvand, A. Etesami, M. Ahmad Khan Beiki, S. A. Miresmaeili Mazrakhondi, J. Abdolalizadeh, Lett. Appl. Microbiol. 2019, 69, 148.Y. Shi, L. Meng, C. Zhang, F. Zhang, Y. Fang, Microbiol. Res. 2021, 255, 126921.V. da Silva Duarte, B. C. Dos Santos Cruz, A. Tarrah, R. Sousa Dias, L. de Paula Dias Moreira, W. J. F. Lemos Junior, L. C. Fidélis Silva, G. Rocha Santana, L. Licursi de Oliveira, M. D. C. Gouveia Peluzio, H. C. Mantovani, V. Corich, A. Giacomini, S. O. de Paula, Microorganisms 2020, 8.S. Shen, D. Huo, C. Ma, S. Jiang, J. Zhang, Microbiol. Spectrum 2021, 9, 0009021.a) A. Malik, D. Sharma, R. K. S. Malireddi, C. S. Guy, T. C. Chang, S. R. Olsen, G. Neale, P. Vogel, T. D. Kanneganti, Immunity 2018, 49, 515;b) T. Wang, C. Fan, A. Yao, X. Xu, G. Zheng, Y. You, C. Jiang, X. Zhao, Y. Hou, M. C. Hung, X. Lin, Immunity 2018, 49, 504.R. Gao, C. Kong, H. Li, L. Huang, X. Qu, N. Qin, H. Qin, Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 2457.Y. Zhu, T. Shi, X. Lu, Z. Xu, J. Qu, Z. Zhang, G. Shi, S. Shen, Y. Hou, Y. Chen, T. Wang, EMBO J. 2021, 40, 105320.S. Bullman, C. S. Pedamallu, E. Sicinska, T. E. Clancy, X. Zhang, D. Cai, D. Neuberg, K. Huang, F. Guevara, T. Nelson, O. Chipashvili, T. Hagan, M. Walker, A. Ramachandran, B. Diosdado, G. Serna, N. Mulet, S. Landolfi, Y. C. S. Ramon, R. Fasani, A. J. Aguirre, K. Ng, E. Élez, S. Ogino, J. Tabernero, C. S. Fuchs, W. C. Hahn, P. Nuciforo, M. Meyerson, Science 2017, 358, 1443.W. Liu, X. Zhang, H. Xu, S. Li, H. C. Lau, Q. Chen, B. Zhang, L. Zhao, H. Chen, J. J. Sung, J. Yu, Gastroenterology 2021, 160, 2395.M. S. Shah, T. DeSantis, J. M. Yamal, T. Weir, E. P. Ryan, J. L. Cope, E. B. Hollister, PLoS One 2018, 13, 0207002.H. Omar Al‐Hassi, O. Ng, M. Brookes, Gut 2018, 67, 3952.C. L. Murphy, M. Barrett, P. Pellanda, S. Killeen, M. McCourt, E. Andrews, M O’ Riordain, F. Shanahan, P. O'Toole, Gut Microbes 2021, 13, 1.J. Yu, Y. Chen, X. Fu, X. Zhou, Y. Peng, L. Shi, T. Chen, Y. Wu, Int. J. Cancer 2016, 139, 1318.D. Dodd, M. H. Spitzer, W. Van Treuren, B. D. Merrill, A. J. Hryckowian, S. K. Higginbottom, A. Le, T. M. Cowan, G. P. Nolan, M. A. Fischbach, J. L. Sonnenburg, Nature 2017, 551, 648.K. A. Krautkramer, J. Fan, F. Bäckhed, Nat. Rev. Microbiol. 2021, 19, 77.S. J. O'Keefe, Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 691.W. Jia, G. Xie, W. Jia, Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 111.a) T. Korem, D. Zeevi, N. Zmora, O. Weissbrod, N. Bar, M. Lotan‐Pompan, T. Avnit‐Sagi, N. Kosower, G. Malka, M. Rein, J. Suez, B. Z. Goldberg, A. Weinberger, A. A. Levy, E. Elinav, E. Segal, Cell Metab. 2017, 25, 1243;b) D. Zeevi, T. Korem, N. Zmora, D. Israeli, D. Rothschild, A. Weinberger, O. Ben‐Yacov, D. Lador, T. Avnit‐Sagi, M. Lotan‐Pompan, J. Suez, J. A. Mahdi, E. Matot, G. Malka, N. Kosower, M. Rein, G. Zilberman‐Schapira, L. Dohnalová, M. Pevsner‐Fischer, R. Bikovsky, Z. Halpern, E. Elinav, E. Segal, Cell 2015, 163, 1079.S. R. Sinha, Y. Haileselassie, L. P. Nguyen, C. Tropini, M. Wang, L. S. Becker, D. Sim, K. Jarr, E. T. Spear, G. Singh, H. Namkoong, K. Bittinger, M. A. Fischbach, J. L. Sonnenburg, A. Habtezion, Cell Host Microbe 2020, 27, 659.a) M. P. Taranto, G. Perez‐Martinez, G. Font de Valdez, Res. Microbiol. 2006, 157, 720;b) R. Coleman, P. J. Lowe, D. Billington, Biochim. Biophys. Acta 1980, 599, 294.E. S. Friedman, Y. Li, T. D. Shen, J. Jiang, L. Chau, L. Adorini, F. Babakhani, J. Edwards, D. Shapiro, C. Zhao, R. M. Carr, K. Bittinger, H. Li, G. D. Wu, Gastroenterology 2018, 155, 1741.S. Ocvirk, S. J. D. O'Keefe, Semin. Cancer Biol. 2020, 73, 347.B. Guan, J. Tong, H. Hao, Z. Yang, K. Chen, H. Xu, A. Wang, Acta Pharm. Sin. B 2022, 12, 2129.J. M. Ridlon, P. G. Wolf, H. R. Gaskins, Gut Microbes 2016, 7, 201.S. C. Harris, S. Devendran, C. Méndez‐García, S. M. Mythen, C. L. Wright, C. J. Fields, A. G. Hernandez, I. Cann, P. B. Hylemon, J. M. Ridlon, Gut Microbes 2018, 9, 523.a) L. Sun, J. Cai, F. J. Gonzalez, Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 335;b) T. Fu, S. Coulter, E. Yoshihara, T. G. Oh, S. Fang, F. Cayabyab, Q. Zhu, T. Zhang, M. Leblanc, S. Liu, M. He, W. Waizenegger, E. Gasser, B. Schnabl, A. R. Atkins, R. T. Yu, R. Knight, C. Liddle, M. Downes, R. M. Evans, Cell 2019, 176, 1098.a) M. Song, A. T. Chan, J. Sun, Gastroenterology 2020, 158, 322;b) T. Kühn, M. Stepien, M. López‐Nogueroles, A. Damms‐Machado, D. Sookthai, T. Johnson, M. Roca, A. Hüsing, S. G. Maldonado, A. J. Cross, N. Murphy, H. Freisling, S. Rinaldi, A. Scalbert, V. Fedirko, G. Severi, M. C. Boutron‐Ruault, F. R. Mancini, S. A. Sowah, H. Boeing, P. Jakszyn, M. J. Sánchez, S. Merino, S. Colorado‐Yohar, A. Barricarte, K. T. Khaw, J. A. Schmidt, A. Perez‐Cornago, A. Trichopoulou, A. Karakatsani, et al., J. Natl. Cancer Inst. 2020, 112, 516.J. M. Ridlon, J. S. Bajaj, Acta Pharm. Sin. B 2015, 5, 99.D. Dermadi, S. Valo, S. Ollila, R. Soliymani, N. Sipari, M. Pussila, L. Sarantaus, J. Linden, M. Baumann, M. Nyström, Cancer Res. 2017, 77, 3352.a) L. Sun, J. Cai, F. J. Gonzalez, Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 335;b) J. Zhou, M. Liu, Y. Zhai, W. Xie, Mol. Endocrinol. 2008, 22, 868.a) J. Ma, Y. Hong, N. Zheng, G. Xie, Y. Lyu, Y. Gu, C. Xi, L. Chen, G. Wu, Y. Li, X. Tao, J. Zhong, Z. Huang, W. Wu, L. Yuan, M. Lin, X. Lu, W. Zhang, W. Jia, L. Sheng, H. Li, Gut Microbes 2020, 11, 1450;b) Y. Yao, X. Li, B. Xu, L. Luo, Q. Guo, X. Wang, L. Sun, Z. Zhang, P. Li, Cell Commun. Signaling 2022, 20, 71.M. Zhang, Y. Lai, V. Krupalnik, P. Guo, X. Guo, J. Zhou, Y. Xu, Z. Yu, L. Liu, A. Jiang, W. Li, M. M. Abdul, G. Ma, N. Li, X. Fu, Y. Lv, M. Jiang, M. Tariq, S. Kanwal, H. Liu, X. Xu, H. Zhang, Y. Huang, L. Wang, S. Chen, I. A. Babarinde, Z. Luo, D. Wang, T. Zhou, C. Ward, et al., Sci. Adv. 2020, 6, 1593.R. Y. Gao, C. T. Shearn, D. J. Orlicky, K. D. Battista, E. E. Alexeev, I. M. Cartwright, J. M. Lanis, R. E. Kostelecky, C. Ju, S. P. Colgan, B. P. Fennimore, Mucosal. Immunol. 2021, 14, 479.Y. L. Loke, M. T. Chew, Y. F. Ngeow, W. W. D. Lim, S. C. Peh, Front. Cell. Infect. Microbiol. 2020, 10, 603086.L. Farhana, P. Nangia‐Makker, E. Arbit, K. Shango, S. Sarkar, H. Mahmud, T. Hadden, Y. Yu, A. P. Majumdar, Stem Cell Res. Ther. 2016, 7, 181.P. Arvind, E. D. Papavassiliou, G. J. Tsioulias, B. W. Duceman, C. I. Lovelace, W. Geng, L. Staiano‐Coico, B. Rigas, Mol. Immunol. 1994, 31, 607.T. Rossi, D. Vergara, F. Fanini, M. Maffia, S. Bravaccini, F. Pirini, Int. J. Mol. Sci. 2020, 21, 5786.T. T. Nguyen, S. Lian, T. T. Ung, Y. Xia, J. Y. Han, Y. D. Jung, J. Cell. Biochem. 2017, 118, 2958.M. Makishima, T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, D. J. Mangelsdorf, Science 2002, 296, 1313.J. M. Ridlon, S. C. Harris, S. Bhowmik, D. J. Kang, P. B. Hylemon, Gut Microbes 2016, 7, 22.H. Zhang, H. Xu, C. Zhang, Q. Tang, F. Bi, Cell Death Discovery 2021, 7, 207.M. T. Sorbara, E. G. Pamer, Nat. Rev. Microbiol. 2022, 20, 365.K. Makki, E. C. Deehan, J. Walter, F. Bäckhed, Cell Host Microbe 2018, 23, 705.a) A. Rauf, A. A. Khalil, U. U. Rahman, A. Khalid, S. Naz, M. A. Shariati, M. Rebezov, E. Z. Urtecho, R. de Albuquerque, S. Anwar, A. Alamri, R. K. Saini, K. R. R. Rengasamy, Crit. Rev. Food Sci. Nutr. 2021, 62, 6034;b) S. A. Smith, S. A. Ogawa, L. Chau, K. A. Whelan, K. E. Hamilton, J. Chen, L. Tan, E. Z. Chen, S. Keilbaugh, F. Fogt, M. Bewtra, J. Braun, R. J. Xavier, C. B. Clish, B. Slaff, A. M. Weljie, F. D. Bushman, J. D. Lewis, H. Li, S. R. Master, M. J. Bennett, H. Nakagawa, G. D. Wu, J. Clin. Invest. 2021, 131, 133371.M. J. Pichler, C. Yamada, B. Shuoker, C. Alvarez‐Silva, A. Gotoh, M. L. Leth, E. Schoof, T. Katoh, M. Sakanaka, T. Katayama, C. Jin, N. G. Karlsson, M. Arumugam, S. Fushinobu, M. Abou Hachem, Nat. Commun. 2020, 11, 3285.a) C. Bücher, J. Burtscher, K. J. Domig, Compr. Rev. Food Sci. Food Saf. 2021, 20, 4299;b) B. Dalile, L. Van Oudenhove, B. Vervliet, K. Verbeke, Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 461.W. Yang, T. Yu, X. Huang, A. J. Bilotta, L. Xu, Y. Lu, J. Sun, F. Pan, J. Zhou, W. Zhang, S. Yao, C. L. Maynard, N. Singh, S. M. Dann, Z. Liu, Y. Cong, Nat. Commun. 2020, 11, 4457.G. E. Kaiko, S. H. Ryu, O. I. Koues, P. L. Collins, L. Solnica‐Krezel, E. J. Pearce, E. L. Pearce, E. M. Oltz, T. S. Stappenbeck, Cell 2016, 165, 1708.K. Daly, S. P. Shirazi‐Beechey, DNA Cell Biol. 2006, 25, 49.N. Singh, A. Gurav, S. Sivaprakasam, E. Brady, R. Padia, H. Shi, M. Thangaraju, P. D. Prasad, S. Manicassamy, D. H. Munn, J. R. Lee, S. Offermanns, V. Ganapathy, Immunity 2014, 40, 128.D. Kirat, S. Kato, Exp. Physiol. 2006, 91, 835.J. Yang, J. Yu, Protein Cell 2018, 9, 474.K. Gronke, P. P. Hernández, J. Zimmermann, C. S. N. Klose, M. Kofoed‐Branzk, F. Guendel, M. Witkowski, C. Tizian, L. Amann, F. Schumacher, H. Glatt, A. Triantafyllopoulou, A. Diefenbach, Nature 2019, 566, 249.J. Chen, L. Vitetta, Proc. Natl. Acad. Sci. USA 2021, 118.E. R. Cobo, V. Kissoon‐Singh, F. Moreau, R. Holani, K. Chadee, Infect. Immun. 2017, 85.D. Cheng, J. H. Xu, J. Y. Li, S. Y. Wang, T. F. Wu, Q. K. Chen, T. Yu, Exp. Cell Res. 2018, 368, 101.B. Waclawiková, A. Codutti, K. Alim, S. El Aidy, Gut Microbes 2022, 14, 1997296.a) D. R. Donohoe, D. Holley, L. B. Collins, S. A. Montgomery, A. C. Whitmore, A. Hillhouse, K. P. Curry, S. W. Renner, A. Greenwalt, E. P. Ryan, V. Godfrey, M. T. Heise, D. S. Threadgill, A. Han, J. A. Swenberg, D. W. Threadgill, S. J. Bultman, Cancer Discovery 2014, 4, 1387;b) D. R. Donohoe, L. B. Collins, A. Wali, R. Bigler, W. Sun, S. J. Bultman, Mol. Cell 2012, 48, 612.D. C. Yu, J. S. Waby, H. Chirakkal, C. A. Staton, B. M. Corfe, Mol Cancer 2010, 9, 276.L. Zuo, M. Lu, Q. Zhou, W. Wei, Y. Wang, Food Chem. Toxicol. 2013, 62, 892.X. Wu, Y. Wu, L. He, L. Wu, X. Wang, Z. Liu, J Cancer 2018, 9, 2510.Y. He, L. Fu, Y. Li, W. Wang, M. Gong, J. Zhang, X. Dong, J. Huang, Q. Wang, C. R. Mackay, Y. X. Fu, Y. Chen, X. Guo, Cell Metab. 2021, 33, 988.M. Depner, D. H. Taft, P. V. Kirjavainen, K. M. Kalanetra, A. M. Karvonen, S. Peschel, E. Schmausser‐Hechfellner, C. Roduit, R. Frei, R. Lauener, A. Divaret‐Chauveau, J. C. Dalphin, J. Riedler, M. Roponen, M. Kabesch, H. Renz, J. Pekkanen, F. M. Farquharson, P. Louis, D. A. Mills, E. von Mutius, M. J. Ege, Nat. Med. 2020, 26, 1766.T. Y. Ryu, K. Kim, T. S. Han, M. O. Lee, J. Lee, J. Choi, K. B. Jung, E. J. Jeong, D. M. An, C. R. Jung, J. H. Lim, J. Jung, K. Park, M. S. Lee, M. Y. Kim, S. J. Oh, K. Hur, R. Hamamoto, D. S. Park, D. S. Kim, M. Y. Son, H. S. Cho, ISME J. 2022, 16, 1205.D. Ternes, M. Tsenkova, V. I. Pozdeev, M. Meyers, E. Koncina, S. Atatri, M. Schmitz, J. Karta, M. Schmoetten, A. Heinken, F. Rodriguez, C. Delbrouck, A. Gaigneaux, A. Ginolhac, T. T. D. Nguyen, L. Grandmougin, A. Frachet‐Bour, C. Martin‐Gallausiaux, M. Pacheco, L. Neuberger‐Castillo, P. Miranda, N. Zuegel, J. Y. Ferrand, M. Gantenbein, T. Sauter, D. J. Slade, I. Thiele, J. Meiser, S. Haan, P. Wilmes, et al., Nat. Metab. 2022, 4, 458.S. Bae, C. M. Ulrich, M. L. Neuhouser, O. Malysheva, L. B. Bailey, L. Xiao, E. C. Brown, K. L. Cushing‐Haugen, Y. Zheng, T. Y. Cheng, J. W. Miller, R. Green, D. S. Lane, S. A. Beresford, M. A. Caudill, Cancer Res. 2014, 74, 7442.X. Liu, H. Liu, C. Yuan, Y. Zhang, W. Wang, S. Hu, L. Liu, Y. Wang, Biomarkers Med. 2017, 11, 443.K. A. Guertin, X. S. Li, B. I. Graubard, D. Albanes, S. J. Weinstein, J. J. Goedert, Z. Wang, S. L. Hazen, R. Sinha, Cancer Epidemiol., Biomarkers Prev. 2017, 26, 945.R. Jalandra, N. Dalal, A. K. Yadav, D. Verma, M. Sharma, R. Singh, A. Khosla, A. Kumar, P. R. Solanki, Appl. Microbiol. Biotechnol. 2021, 105, 7651.O. O. Coker, C. Liu, W. K. K. Wu, S. H. Wong, W. Jia, J. J. Y. Sung, J. Yu, Microbiome 2022, 10, 35.M. Beaumont, A. M. Neyrinck, M. Olivares, J. Rodriguez, A. de Rocca Serra, M. Roumain, L. B. Bindels, P. D. Cani, P. Evenepoel, G. G. Muccioli, J. B. Demoulin, N. M. Delzenne, FASEB J. 2018, 32, 6681.N. Venkateswaran, M. C. Lafita‐Navarro, Y. H. Hao, J. A. Kilgore, L. Perez‐Castro, J. Braverman, N. Borenstein‐Auerbach, M. Kim, N. P. Lesner, P. Mishra, T. Brabletz, J. W. Shay, R. J. DeBerardinis, N. S. Williams, O. H. Yilmaz, M. Conacci‐Sorrell, Genes Dev. 2019, 33, 1236.Y. Zhang, H. Yu, J. Zhang, H. Gao, S. Wang, S. Li, P. Wei, J. Liang, G. Yu, X. Wang, X. Li, D. Li, W. Yang, J. Clin. Invest. 2021, 131, 146187.W. R. Russell, L. Hoyles, H. J. Flint, M. E. Dumas, Curr. Opin. Microbiol. 2013, 16, 246.T. Wilmanski, N. Rappaport, C. Diener, S. M. Gibbons, N. D. Price, Gut Microbes 2021, 13, 1.L. Wang, M. Gao, G. Kang, H. Huang, Front. Nutr. 2021, 8, 798038.K. Ganesan, S. Guo, S. Fayyaz, G. Zhang, B. Xu, Cancers 2019, 11, 1285.C. Gur, Y. Ibrahim, B. Isaacson, R. Yamin, J. Abed, M. Gamliel, J. Enk, Y. Bar‐On, N. Stanietsky‐Kaynan, S. Coppenhagen‐Glazer, N. Shussman, G. Almogy, A. Cuapio, E. Hofer, D. Mevorach, A. Tabib, R. Ortenberg, G. Markel, K. Miklić, S. Jonjic, C. A. Brennan, W. S. Garrett, G. Bachrach, O. Mandelboim, Immunity 2015, 42, 344.J. Abed, J. E. Emgård, G. Zamir, M. Faroja, G. Almogy, A. Grenov, A. Sol, R. Naor, E. Pikarsky, K. A. Atlan, A. Mellul, S. Chaushu, A. L. Manson, A. M. Earl, N. Ou, C. A. Brennan, W. S. Garrett, G. Bachrach, Cell Host Microbe 2016, 20, 215.H. N. Bell, R. J. Rebernick, J. Goyert, R. Singhal, M. Kuljanin, S. A. Kerk, W. Huang, N. K. Das, A. Andren, S. Solanki, S. L. Miller, P. K. Todd, E. R. Fearon, C. A. Lyssiotis, S. P. Gygi, J. D. Mancias, Y. M. Shah, Cancer Cell 2021, 40, 185.Z. T. Shakour, N. G. Shehab, A. S. Gomaa, L. A. Wessjohann, M. A. Farag, Biotechnol. Adv. 2022, 54, 107784.A. Christ, M. Lauterbach, E. Latz, Immunity 2019, 51, 794.F. M. Ruemmele, Ann. Nutr. Metab. 2016, 68, 33.L. A. Bolte, A. Vich Vila, F. Imhann, V. Collij, R. Gacesa, V. Peters, C. Wijmenga, A. Kurilshikov, M. J. E. Campmans‐Kuijpers, J. Fu, G. Dijkstra, A. Zhernakova, R. K. Weersma, Gut 2021, 70, 1287.B. Zhang, Y. Xu, S. Liu, H. Lv, Y. Hu, Y. Wang, Z. Li, J. Wang, X. Ji, H. Ma, X. Wang, S. Wang, Nutrients 2020, 12, 2367.B. Lauby‐Secretan, N. Vilahur, F. Bianchini, N. Guha, K. Straif, N. Engl. J. Med. 2018, 378, 1734.J. Li, X. Zhou, X. Liu, J. Ren, J. Wang, W. Wang, Y. Zheng, X. Shi, T. Sun, Z. Li, A. Kang, F. Tang, L. Wen, W. Fu, Clin. Chem. 2019, 65, 916.R. L. Siegel, K. D. Miller, A. Goding Sauer, S. A. Fedewa, L. F. Butterly, J. C. Anderson, A. Cercek, R. A. Smith, A. Jemal, Ca‐Cancer J. Clin. 2020, 70, 145.Y. Zhang, Q. Wu, L. Xu, H. Wang, X. Liu, S. Li, T. Hu, Y. Liu, Q. Peng, Z. Chen, X. Wu, J. B. Fan, Clin. Epigenet. 2021, 13, 90.J. M. Carethers, Annu. Rev. Med. 2020, 71, 59.a) N. T. Baxter, M. T. Ruffin, M. A. Rogers, P. D. Schloss, Genome Med. 2016, 8, 37;b) S. H. Wong, T. N. Y. Kwong, T. C. Chow, A. K. C. Luk, R. Z. W. Dai, G. Nakatsu, T. Y. T. Lam, L. Zhang, J. C. Y. Wu, F. K. L. Chan, S. S. M. Ng, M. C. S. Wong, S. C. Ng, W. K. K. Wu, J. Yu, J. J. Y. Sung, Gut 2017, 66, 1441;c) N. T. Baxter, C. C. Koumpouras, M. A. Rogers, M. T. t. Ruffin, P. D. Schloss, Microbiome 2016, 4, 59.G. Zeller, J. Tap, A. Y. Voigt, S. Sunagawa, J. R. Kultima, P. I. Costea, A. Amiot, J. Böhm, F. Brunetti, N. Habermann, R. Hercog, M. Koch, A. Luciani, D. R. Mende, M. A. Schneider, P. Schrotz‐King, C. Tournigand, J. Tran Van Nhieu, T. Yamada, J. Zimmermann, V. Benes, M. Kloor, C. M. Ulrich, M. von Knebel Doeberitz, I. Sobhani, P. Bork, Mol. Syst. Biol. 2014, 10, 766.S. Guo, L. Li, B. Xu, M. Li, Q. Zeng, H. Xiao, Y. Xue, Y. Wu, Y. Wang, W. Liu, G. Zhang, Clin. Chem. 2018, 64, 1327.V. Eklöf, A. Löfgren‐Burström, C. Zingmark, S. Edin, P. Larsson, P. Karling, O. Alexeyev, J. Rutegård, M. L. Wikberg, R. Palmqvist, Int. J. Cancer 2017, 141, 2528.M. Mutignani, R. Penagini, G. Gargari, S. Guglielmetti, M. Cintolo, A. Airoldi, P. Leone, P. Carnevali, C. Ciafardini, G. Petrocelli, F. Mascaretti, B. Oreggia, L. Dioscoridi, F. Cavalcoli, M. Primignani, F. Pugliese, P. Bertuccio, P. Soru, C. Magistro, G. Ferrari, M. C. Speciani, G. Bonato, M. Bini, P. Cantù, F. Caprioli, M. Vangeli, E. Forti, S. Mazza, G. Tosetti, R. Bonzi, et al., Cancers 2021, 13, 6363.J. P. Zackular, M. A. Rogers, M. T. Ruffin, P. D. Schloss, Cancer Prev. Res. 2014, 7, 1112.X. Wang, J. Wang, B. Rao, L. Deng, Exp. Ther. Med. 2017, 13, 2848.K. Mima, R. Nishihara, Z. R. Qian, Y. Cao, Y. Sukawa, J. A. Nowak, J. Yang, R. Dou, Y. Masugi, M. Song, A. D. Kostic, M. Giannakis, S. Bullman, D. A. Milner, H. Baba, E. L. Giovannucci, L. A. Garraway, G. J. Freeman, G. Dranoff, W. S. Garrett, C. Huttenhower, M. Meyerson, J. A. Meyerhardt, A. T. Chan, C. S. Fuchs, S. Ogino, Gut 2016, 65, 1973.J. L. Alexander, I. D. Wilson, J. Teare, J. R. Marchesi, J. K. Nicholson, J. M. Kinross, Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356.L. Zitvogel, Y. Ma, D. Raoult, G. Kroemer, T. F. Gajewski, Science 2018, 359, 1366.A. E. Frankel, L. A. Coughlin, J. Kim, T. W. Froehlich, Y. Xie, E. P. Frenkel, A. Y. Koh, Neoplasia 2017, 19, 848.A. P. García‐González, A. D. Ritter, S. Shrestha, E. C. Andersen, L. S. Yilmaz, A. J. M. Walhout, Cell 2017, 169, 431.M. Baretti, E. Karunasena, M. Zahurak, R. Walker, Y. Zhao, T. R. Pisanic 2nd, T. H. Wang, T. F. Greten, A. G. Duffy, E. Gootjes, G. Meijer, H. M. W. Verheul, N. Ahuja, J. G. Herman, N. S. Azad, Clin. Transl. Sci. 2021, 14, 954.N. Iida, A. Dzutsev, C. A. Stewart, L. Smith, N. Bouladoux, R. A. Weingarten, D. A. Molina, R. Salcedo, T. Back, S. Cramer, R. M. Dai, H. Kiu, M. Cardone, S. Naik, A. K. Patri, E. Wang, F. M. Marincola, K. M. Frank, Y. Belkaid, G. Trinchieri, R. S. Goldszmid, Science 2013, 342, 967.a) S. Viaud, F. Saccheri, G. Mignot, T. Yamazaki, R. Daillère, D. Hannani, D. P. Enot, C. Pfirschke, C. Engblom, M. J. Pittet, A. Schlitzer, F. Ginhoux, L. Apetoh, E. Chachaty, P. L. Woerther, G. Eberl, M. Bérard, C. Ecobichon, D. Clermont, C. Bizet, V. Gaboriau‐Routhiau, N. Cerf‐Bensussan, P. Opolon, N. Yessaad, E. Vivier, B. Ryffel, C. O. Elson, J. Doré, G. Kroemer, P. Lepage, et al., Science 2013, 342, 971;b) R. Daillère, M. Vétizou, N. Waldschmitt, T. Yamazaki, C. Isnard, V. Poirier‐Colame, C. P. M. Duong, C. Flament, P. Lepage, M. P. Roberti, B. Routy, N. Jacquelot, L. Apetoh, S. Becharef, S. Rusakiewicz, P. Langella, H. Sokol, G. Kroemer, D. Enot, A. Roux, A. Eggermont, E. Tartour, L. Johannes, P. L. Woerther, E. Chachaty, J. C. Soria, E. Golden, S. Formenti, M. Plebanski, M. Madondo, et al., Immunity 2016, 45, 931.S. C. Wei, C. R. Duffy, J. P. Allison, Cancer Discovery 2018, 8, 1069.K. Ganesh, Z. K. Stadler, A. Cercek, R. B. Mendelsohn, J. Shia, N. H. Segal, L. A. Diaz Jr., Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361.a) M. J. Overman, R. McDermott, J. L. Leach, S. Lonardi, H. J. Lenz, M. A. Morse, J. Desai, A. Hill, M. Axelson, R. A. Moss, M. V. Goldberg, Z. A. Cao, J. M. Ledeine, G. A. Maglinte, S. Kopetz, T. André, Lancet Oncol. 2017, 18, 1182;b) M. J. Overman, S. Lonardi, K. Y. M. Wong, H. J. Lenz, F. Gelsomino, M. Aglietta, M. A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, M. Svrcek, R. A. Moss, J. M. Ledeine, Z. A. Cao, S. Kamble, S. Kopetz, T. André, J. Clin. Oncol. 2018, 36, 773.J. Schluter, J. U. Peled, B. P. Taylor, K. A. Markey, M. Smith, Y. Taur, R. Niehus, A. Staffas, A. Dai, E. Fontana, L. A. Amoretti, R. J. Wright, S. Morjaria, M. Fenelus, M. S. Pessin, N. J. Chao, M. Lew, L. Bohannon, A. Bush, A. D. Sung, T. M. Hohl, M. A. Perales, M. R. M. van den Brink, J. B. Xavier, Nature 2020, 588, 303.L. Derosa, M. D. Hellmann, M. Spaziano, D. Halpenny, M. Fidelle, H. Rizvi, N. Long, A. J. Plodkowski, K. C. Arbour, J. E. Chaft, J. A. Rouche, L. Zitvogel, G. Zalcman, L. Albiges, B. Escudier, B. Routy, Ann. Oncol. 2018, 29, 1437.a) B. Routy, E. Le Chatelier, L. Derosa, C. P. M. Duong, M. T. Alou, R. Daillère, A. Fluckiger, M. Messaoudene, C. Rauber, M. P. Roberti, M. Fidelle, C. Flament, V. Poirier‐Colame, P. Opolon, C. Klein, K. Iribarren, L. Mondragón, N. Jacquelot, B. Qu, G. Ferrere, C. Clémenson, L. Mezquita, J. R. Masip, C. Naltet, S. Brosseau, C. Kaderbhai, C. Richard, H. Rizvi, F. Levenez, N. Galleron, et al., Science 2018, 359, 91;b) A. Sivan, L. Corrales, N. Hubert, J. B. Williams, K. Aquino‐Michaels, Z. M. Earley, F. W. Benyamin, Y. M. Lei, B. Jabri, M. L. Alegre, E. B. Chang, T. F. Gajewski, Science 2015, 350, 1084;c) V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews, T. V. Karpinets, P. A. Prieto, D. Vicente, K. Hoffman, S. C. Wei, A. P. Cogdill, L. Zhao, C. W. Hudgens, D. S. Hutchinson, T. Manzo, M. Petaccia de Macedo, T. Cotechini, T. Kumar, W. S. Chen, S. M. Reddy, R. Szczepaniak Sloane, J. Galloway‐Pena, H. Jiang, P. L. Chen, E. J. Shpall, K. Rezvani, A. M. Alousi, R. F. Chemaly, S. Shelburne, L. M. Vence, et al., Science 2018, 359, 97;d) V. Matson, J. Fessler, R. Bao, T. Chongsuwat, Y. Zha, M. L. Alegre, J. J. Luke, T. F. Gajewski, Science 2018, 359, 104.a) M. Vétizou, J. M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. P. Roberti, C. P. Duong, V. Poirier‐Colame, A. Roux, S. Becharef, S. Formenti, E. Golden, S. Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquelot, D. P. Enot, M. Bérard, J. Nigou, P. Opolon, A. Eggermont, P. L. Woerther, E. Chachaty, N. Chaput, et al., Science 2015, 350, 1079;b) J. M. Pitt, M. Vétizou, R. Daillère, M. P. Roberti, T. Yamazaki, B. Routy, P. Lepage, I. G. Boneca, M. Chamaillard, G. Kroemer, L. Zitvogel, Immunity 2016, 44, 1255.N. Chaput, P. Lepage, C. Coutzac, E. Soularue, K. Le Roux, C. Monot, L. Boselli, E. Routier, L. Cassard, M. Collins, T. Vaysse, L. Marthey, A. Eggermont, V. Asvatourian, E. Lanoy, C. Mateus, C. Robert, F. Carbonnel, Ann. Oncol. 2017, 28, 1368.J. U. Peled, S. M. Devlin, A. Staffas, M. Lumish, R. Khanin, E. R. Littmann, L. Ling, S. Kosuri, M. Maloy, J. B. Slingerland, K. F. Ahr, K. A. Porosnicu Rodriguez, Y. Shono, A. E. Slingerland, M. D. Docampo, A. D. Sung, D. Weber, A. M. Alousi, B. Gyurkocza, D. M. Ponce, J. N. Barker, M. A. Perales, S. A. Giralt, Y. Taur, E. G. Pamer, R. R. Jenq, M. R. M. van den Brink, J. Clin. Oncol. 2017, 35, 1650.R. Z. Gharaibeh, C. Jobin, Gut 2019, 68, 385.K. Dubin, M. K. Callahan, B. Ren, R. Khanin, A. Viale, L. Ling, D. No, A. Gobourne, E. Littmann, C. Huttenhower, E. G. Pamer, J. D. Wolchok, Nat. Commun. 2016, 7, 10391.T. Tanoue, S. Morita, D. R. Plichta, A. N. Skelly, W. Suda, Y. Sugiura, S. Narushima, H. Vlamakis, I. Motoo, K. Sugita, A. Shiota, K. Takeshita, K. Yasuma‐Mitobe, D. Riethmacher, T. Kaisho, J. M. Norman, D. Mucida, M. Suematsu, T. Yaguchi, V. Bucci, T. Inoue, Y. Kawakami, B. Olle, B. Roberts, M. Hattori, R. J. Xavier, K. Atarashi, K. Honda, Nature 2019, 565, 600.G. R. Gibson, R. Hutkins, M. E. Sanders, S. L. Prescott, R. A. Reimer, S. J. Salminen, K. Scott, C. Stanton, K. S. Swanson, P. D. Cani, K. Verbeke, G. Reid, Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 491.I. Mármol, C. Sánchez‐de‐Diego, A. Pradilla Dieste, E. Cerrada, M. J. Rodriguez Yoldi, Int. J. Mol. Sci. 2017, 18, 197.W. Fong, Q. Li, J. Yu, Oncogene 2020, 39, 4925.J. Hu, C. Wang, L. Ye, W. Yang, H. Huang, F. Meng, S. Shi, Z. Ding, J. Biosci. 2015, 40, 269.L. Zaharuddin, N. M. Mokhtar, K. N. Muhammad Nawawi, R. A. Raja Ali, BMC Gastroenterol. 2019, 19, 131.A. Belcheva, T. Irrazabal, S. J. Robertson, C. Streutker, H. Maughan, S. Rubino, E. H. Moriyama, J. K. Copeland, A. Surendra, S. Kumar, B. Green, K. Geddes, R. C. Pezo, W. W. Navarre, M. Milosevic, B. C. Wilson, S. E. Girardin, T. M. S. Wolever, W. Edelmann, D. S. Guttman, D. J. Philpott, A. Martin, Cell 2014, 158, 288.X. Xie, Y. He, H. Li, D. Yu, L. Na, T. Sun, D. Zhang, X. Shi, Y. Xia, T. Jiang, S. Rong, S. Yang, X. Ma, G. Xu, Nutrition 2019, 61, 132.a) C. E. DeStefano Shields, S. W. Van Meerbeke, F. Housseau, H. Wang, D. L. Huso, R. A. Casero Jr, H. M. O'Hagan, C. L. Sears, J. Infect. Dis. 2016, 214, 122;b) N. Ijssennagger, C. Belzer, G. J. Hooiveld, J. Dekker, S. W. van Mil, M. Müller, M. Kleerebezem, R. van der Meer, Proc. Natl. Acad. Sci. USA 2015, 112, 10038;c) N. Hattori, T. Niwa, T. Ishida, K. Kobayashi, T. Imai, A. Mori, K. Kimura, T. Mori, Y. Asami, T. Ushijima, Cancer Sci. 2019, 110, 147.J. Yang, H. Wei, Y. Zhou, C. H. Szeto, C. Li, Y. Lin, O. O. Coker, H. C. H. Lau, A. W. H. Chan, J. J. Y. Sung, J. Yu, Gastroenterology 2021, 162, 135.S. S. M. Lu, Z. Mohammed, C. Häggström, R. Myte, E. Lindquist, Å. Gylfe, B. Van Guelpen, S. Harlid, J Natl Cancer Inst 2021, 114, 38.R. E. Ooijevaar, E. M. Terveer, H. W. Verspaget, E. J. Kuijper, J. J. Keller, Annu. Rev. Med. 2019, 70, 335.A. R. Weingarden, B. P. Vaughn, Gut Microbes 2017, 8, 238.S. P. Rosshart, B. G. Vassallo, D. Angeletti, D. S. Hutchinson, A. P. Morgan, K. Takeda, H. D. Hickman, J. A. McCulloch, J. H. Badger, N. J. Ajami, G. Trinchieri, F. Pardo‐Manuel de Villena, J. W. Yewdell, B. Rehermann, Cell 2017, 171, 1015.G. R. D'Haens, C. Jobin, Gastroenterology 2019, 157, 624.S. Kommineni, D. J. Bretl, V. Lam, R. Chakraborty, M. Hayward, P. Simpson, Y. Cao, P. Bousounis, C. J. Kristich, N. H. Salzman, Nature 2015, 526, 719.K. Kingwell, Nat. Rev. Drug Discovery 2015, 14, 515. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advanced Science Wiley http://www.deepdyve.com/lp/wiley/role-of-the-gut-microbiota-and-its-metabolites-in-tumorigenesis-or-FnhJa5Sn8R

Loading next page...

References (288)

( J. P. Zackular , M. A. Rogers , M. T. Ruffin , P. D. Schloss , Cancer Prev. Res. 2014, 7, 1112.)
J. P. Zackular , M. A. Rogers , M. T. Ruffin , P. D. Schloss , Cancer Prev. Res. 2014, 7, 1112.
J. P. Zackular , M. A. Rogers , M. T. Ruffin , P. D. Schloss , Cancer Prev. Res. 2014, 7, 1112., J. P. Zackular , M. A. Rogers , M. T. Ruffin , P. D. Schloss , Cancer Prev. Res. 2014, 7, 1112.
Sama Rezasoltani, H. Aghdaei, H. Dabiri, A. Sepahi, M. Modarressi, E. Mojarad (2018)
The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer.
Microbial pathogenesis, 124
E. Saus, S. Iraola-Guzmán, J. Willis, A. Brunet-Vega, T. Gabaldón (2019)
Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential
Molecular Aspects of Medicine, 69
( X. Xie , Y. He , H. Li , D. Yu , L. Na , T. Sun , D. Zhang , X. Shi , Y. Xia , T. Jiang , S. Rong , S. Yang , X. Ma , G. Xu , Nutrition 2019, 61, 132.30711862)
X. Xie , Y. He , H. Li , D. Yu , L. Na , T. Sun , D. Zhang , X. Shi , Y. Xia , T. Jiang , S. Rong , S. Yang , X. Ma , G. Xu , Nutrition 2019, 61, 132.30711862
X. Xie , Y. He , H. Li , D. Yu , L. Na , T. Sun , D. Zhang , X. Shi , Y. Xia , T. Jiang , S. Rong , S. Yang , X. Ma , G. Xu , Nutrition 2019, 61, 132.30711862, X. Xie , Y. He , H. Li , D. Yu , L. Na , T. Sun , D. Zhang , X. Shi , Y. Xia , T. Jiang , S. Rong , S. Yang , X. Ma , G. Xu , Nutrition 2019, 61, 132.30711862
Barbora Waclawiková, Agnese Codutti, K. Alim, S. Aidy (2022)
Gut microbiota-motility interregulation: insights from in vivo, ex vivo and in silico studies
Gut Microbes, 14
N. Chaput, P. Lepage, C. Coutzac, É. Soularue, K. Roux, C. Monot, L. Boselli, É. Routier, L. Cassard, M. Collins, T. Vaysse, L. Marthey, A. Eggermont, V. Asvatourian, E. Lanoy, C. Mateus, C. Robert, F. Carbonnel (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Annals of Oncology, 28
T. Sécher, S. Normand, M. Chamaillard (2013)
NOD2 prevents emergence of disease-predisposing microbiota
Gut Microbes, 4
Yanan Zhu, T. Shi, Xia Lu, Zhen Xu, Junxing Qu, Zhiyong Zhang, Guoping Shi, S. Shen, Yayi Hou, Yu-gen Chen, Tingting Wang (2021)
Fungal‐induced glycolysis in macrophages promotes colon cancer by enhancing innate lymphoid cell secretion of IL‐22
The EMBO Journal, 40
Meilan Xue, Hui Liang, Xinqiang Ji, Zhitong Zhou, Y. Liu, Ting Sun, Li Zhang (2020)
Effects of fucoidan on gut flora and tumor prevention in 1,2-dimethylhydrazine-induced colorectal carcinogenesis.
The Journal of nutritional biochemistry, 82
Shujie Chen, Tingting Su, Ying Zhang, Allen Lee, Jiamin He, Qiwei Ge, Lan Wang, Jianmin Si, W. Zhuo, Liangjing Wang (2020)
Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7
Gut Microbes, 11
Katie Kingwell (2015)
Bacteriophage therapies re-enter clinical trials
Nature Reviews Drug Discovery, 14
Ritesh Kumar, Jennifer Herold, D. Schady, Jennifer Davis, S. Kopetz, M. Martinez-Moczygemba, B. Murray, Fang Han, Yu Li, E. Callaway, R. Chapkin, W. Dashwood, R. Dashwood, T. Berry, C. Mackenzie, Yi Xu (2017)
Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development
PLoS Pathogens, 13
Jason Ridlon, P. Wolf, H. Gaskins (2016)
Taurocholic acid metabolism by gut microbes and colon cancer
Gut Microbes, 7
( R. Y. Gao , C. T. Shearn , D. J. Orlicky , K. D. Battista , E. E. Alexeev , I. M. Cartwright , J. M. Lanis , R. E. Kostelecky , C. Ju , S. P. Colgan , B. P. Fennimore , Mucosal. Immunol. 2021, 14, 479.33004979)
R. Y. Gao , C. T. Shearn , D. J. Orlicky , K. D. Battista , E. E. Alexeev , I. M. Cartwright , J. M. Lanis , R. E. Kostelecky , C. Ju , S. P. Colgan , B. P. Fennimore , Mucosal. Immunol. 2021, 14, 479.33004979
R. Y. Gao , C. T. Shearn , D. J. Orlicky , K. D. Battista , E. E. Alexeev , I. M. Cartwright , J. M. Lanis , R. E. Kostelecky , C. Ju , S. P. Colgan , B. P. Fennimore , Mucosal. Immunol. 2021, 14, 479.33004979, R. Y. Gao , C. T. Shearn , D. J. Orlicky , K. D. Battista , E. E. Alexeev , I. M. Cartwright , J. M. Lanis , R. E. Kostelecky , C. Ju , S. P. Colgan , B. P. Fennimore , Mucosal. Immunol. 2021, 14, 479.33004979
( K. A. Guertin , X. S. Li , B. I. Graubard , D. Albanes , S. J. Weinstein , J. J. Goedert , Z. Wang , S. L. Hazen , R. Sinha , Cancer Epidemiol., Biomarkers Prev. 2017, 26, 945.28077427)
K. A. Guertin , X. S. Li , B. I. Graubard , D. Albanes , S. J. Weinstein , J. J. Goedert , Z. Wang , S. L. Hazen , R. Sinha , Cancer Epidemiol., Biomarkers Prev. 2017, 26, 945.28077427
K. A. Guertin , X. S. Li , B. I. Graubard , D. Albanes , S. J. Weinstein , J. J. Goedert , Z. Wang , S. L. Hazen , R. Sinha , Cancer Epidemiol., Biomarkers Prev. 2017, 26, 945.28077427, K. A. Guertin , X. S. Li , B. I. Graubard , D. Albanes , S. J. Weinstein , J. J. Goedert , Z. Wang , S. L. Hazen , R. Sinha , Cancer Epidemiol., Biomarkers Prev. 2017, 26, 945.28077427
Matthew Sorbara, E. Pamer (2022)
Microbiome-based therapeutics
Nature Reviews Microbiology, 20
Wei Jia, G. Xie, Weiping Jia (2018)
Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Nature Reviews Gastroenterology & Hepatology, 15
E. Oh, A. Petronis (2021)
Origins of human disease: the chrono-epigenetic perspective
Nature Reviews Genetics, 22
Konrad Gronke, Pedro Hernández, Jakob Zimmermann, Christoph Klose, Michael Kofoed-Branzk, Fabian Guendel, M. Witkowski, Caroline Tizian, Lukas Amann, F. Schumacher, H. Glatt, A. Triantafyllopoulou, A. Diefenbach (2019)
Interleukin-22 protects intestinal stem cells against genotoxic stress
Nature, 566
M. Schmitt, F. Greten (2021)
The inflammatory pathogenesis of colorectal cancer
Nature Reviews Immunology, 21
L. Derosa, L. Derosa, M. Hellmann, M. Hellmann, M. Spaziano, D. Halpenny, Marine Fidelle, Marine Fidelle, H. Rizvi, N. Long, A. Plodkowski, K. Arbour, J. Chaft, J. Chaft, J. Rouche, L. Zitvogel, G. Zalcman, L. Albiges, B. Escudier, B. Routy (2018)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Annals of Oncology, 29
A. Goodwin, C. Shields, Shaoguang Wu, D. Huso, Xinqun Wu, Tracy Murray-Stewart, A. Hacker-Prietz, S. Rabizadeh, P. Woster, C. Sears, R. Casero (2011)
Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis
Proceedings of the National Academy of Sciences, 108
N. Dalal, Rekha Jalandra, N. Bayal, A. Yadav, Harshulika, Minakshi Sharma, G. Makharia, Pramod Kumar, Rajeev Singh, P. Solanki, Anil Kumar (2021)
Gut microbiota-derived metabolites in CRC progression and causation
Journal of Cancer Research and Clinical Oncology, 147
D. Kirat, S. Kato (2006)
Monocarboxylate transporter 1 (MCT1) mediates transport of short‐chain fatty acids in bovine caecum
Experimental Physiology, 91
D. Zeevi, Tal Korem, N. Zmora, D. Israeli, Daphna Rothschild, A. Weinberger, Orly Ben-Yacov, Dar Lador, T. Avnit-Sagi, M. Lotan-Pompan, Jotham Suez, Jemal Mahdi, Elad Matot, Gal Malka, Noa Kosower, Michal Rein, Gili Zilberman-Schapira, L. Dohnalová, M. Pevsner-Fischer, Rony Bikovsky, Z. Halpern, E. Elinav, E. Segal (2015)
Personalized Nutrition by Prediction of Glycemic Responses
Cell, 163
Xiaomei Liu, Heng Liu, Caijun Yuan, Yinxu Zhang, W. Wang, Shuding Hu, Lei Liu, Ying Wang (2017)
Preoperative serum TMAO level is a new prognostic marker for colorectal cancer.
Biomarkers in medicine, 11 5
Alexa Weingarden, B. Vaughn (2017)
Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease
Gut Microbes, 8
( G. Zeller , J. Tap , A. Y. Voigt , S. Sunagawa , J. R. Kultima , P. I. Costea , A. Amiot , J. Böhm , F. Brunetti , N. Habermann , R. Hercog , M. Koch , A. Luciani , D. R. Mende , M. A. Schneider , P. Schrotz‐King , C. Tournigand , J. Tran Van Nhieu , T. Yamada , J. Zimmermann , V. Benes , M. Kloor , C. M. Ulrich , M. von Knebel Doeberitz , I. Sobhani , P. Bork , Mol. Syst. Biol. 2014, 10, 766.25432777)
G. Zeller , J. Tap , A. Y. Voigt , S. Sunagawa , J. R. Kultima , P. I. Costea , A. Amiot , J. Böhm , F. Brunetti , N. Habermann , R. Hercog , M. Koch , A. Luciani , D. R. Mende , M. A. Schneider , P. Schrotz‐King , C. Tournigand , J. Tran Van Nhieu , T. Yamada , J. Zimmermann , V. Benes , M. Kloor , C. M. Ulrich , M. von Knebel Doeberitz , I. Sobhani , P. Bork , Mol. Syst. Biol. 2014, 10, 766.25432777
G. Zeller , J. Tap , A. Y. Voigt , S. Sunagawa , J. R. Kultima , P. I. Costea , A. Amiot , J. Böhm , F. Brunetti , N. Habermann , R. Hercog , M. Koch , A. Luciani , D. R. Mende , M. A. Schneider , P. Schrotz‐King , C. Tournigand , J. Tran Van Nhieu , T. Yamada , J. Zimmermann , V. Benes , M. Kloor , C. M. Ulrich , M. von Knebel Doeberitz , I. Sobhani , P. Bork , Mol. Syst. Biol. 2014, 10, 766.25432777, G. Zeller , J. Tap , A. Y. Voigt , S. Sunagawa , J. R. Kultima , P. I. Costea , A. Amiot , J. Böhm , F. Brunetti , N. Habermann , R. Hercog , M. Koch , A. Luciani , D. R. Mende , M. A. Schneider , P. Schrotz‐King , C. Tournigand , J. Tran Van Nhieu , T. Yamada , J. Zimmermann , V. Benes , M. Kloor , C. M. Ulrich , M. von Knebel Doeberitz , I. Sobhani , P. Bork , Mol. Syst. Biol. 2014, 10, 766.25432777
Jiong Cai, Lulu Sun, F. Gonzalez (2022)
Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis.
Cell host & microbe, 30 3
Ying-Shiuan Chen, Jia Li, R. Menon, A. Jayaraman, Kyongbum Lee, Yun Huang, W. Dashwood, Kecheng Zhang, Deqiang Sun, R. Dashwood (2021)
Dietary spinach reshapes the gut microbiome in an Apc-mutant genetic background: mechanistic insights from integrated multi-omics
Gut Microbes, 13
( S. P. Rosshart , B. G. Vassallo , D. Angeletti , D. S. Hutchinson , A. P. Morgan , K. Takeda , H. D. Hickman , J. A. McCulloch , J. H. Badger , N. J. Ajami , G. Trinchieri , F. Pardo‐Manuel de Villena , J. W. Yewdell , B. Rehermann , Cell 2017, 171, 1015.29056339)
S. P. Rosshart , B. G. Vassallo , D. Angeletti , D. S. Hutchinson , A. P. Morgan , K. Takeda , H. D. Hickman , J. A. McCulloch , J. H. Badger , N. J. Ajami , G. Trinchieri , F. Pardo‐Manuel de Villena , J. W. Yewdell , B. Rehermann , Cell 2017, 171, 1015.29056339
S. P. Rosshart , B. G. Vassallo , D. Angeletti , D. S. Hutchinson , A. P. Morgan , K. Takeda , H. D. Hickman , J. A. McCulloch , J. H. Badger , N. J. Ajami , G. Trinchieri , F. Pardo‐Manuel de Villena , J. W. Yewdell , B. Rehermann , Cell 2017, 171, 1015.29056339, S. P. Rosshart , B. G. Vassallo , D. Angeletti , D. S. Hutchinson , A. P. Morgan , K. Takeda , H. D. Hickman , J. A. McCulloch , J. H. Badger , N. J. Ajami , G. Trinchieri , F. Pardo‐Manuel de Villena , J. W. Yewdell , B. Rehermann , Cell 2017, 171, 1015.29056339
Xiaoliang Xie, Yaqin He, Hai Li, Dong Yu, Li Na, Ting Sun, Dong Zhang, Xinrong Shi, Yuhan Xia, T. Jiang, Shikuo Rong, Shaoqi Yang, Xiaoqiang Ma, Guangxian Xu (2019)
Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients.
Nutrition, 61
Yongzhi Yang, Wen-hao Weng, J. Peng, Leiming Hong, Lei Yang, Y. Toiyama, R. Gao, Minfeng Liu, Mingming Yin, Cheng Pan, Hao Li, B. Guo, Qing-chao Zhu, Q. Wei, M. Moyer, Ping Wang, S. Cai, A. Goel, H. Qin, Yanlei Ma (2017)
Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
Gastroenterology, 152 4
V. Gopalakrishnan, C. Spencer, L. Nezi, A. Reuben, M. Andrews, T. Karpinets, P. Prieto, D. Vicente, K. Hoffman, S. Wei, Alexandria Cogdill, L. Zhao, C. Hudgens, D. Hutchinson, T. Manzo, M. Macedo, T. Cotechini, T. Kumar, W. Chen, S. Reddy, R. Sloane, J. Galloway-Peña, H. Jiang, P. Chen, E. Shpall, K. Rezvani, A. Alousi, R. Chemaly, S. Shelburne, L. Vence, P. Okhuysen, V. Jensen, A. Swennes, F. McAllister, E. Sanchez, Y. Zhang, E. Chatelier, L. Zitvogel, N. Pons, J. Austin-Breneman, L. Haydu, E. Burton, J. Gardner, E. Sirmans, J. Hu, A. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. Glitza, W. Hwu, S. Patel, S. Woodman, R. Amaria, M. Davies, J. Gershenwald, P. Hwu, J. Lee, J. Zhang, L. Coussens, Z. Cooper, P. Futreal, C. Daniel, N. Ajami, J. Petrosino, M. Tetzlaff, P. Sharma, J. Allison, R. Jenq, J. Wargo (2018)
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Science, 359
Marie Vetizou, J. Pitt, Romain Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. Roberti, Connie Duong, V. poirier-colame, A. Roux, S. Becharef, S. Formenti, E. Golden, S. Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquelot, D. Enot, M. Bérard, J. Nigou, P. Opolon, A. Eggermont, P. Woerther, E. Chachaty, N. Chaput, C. Robert, C. Mateus, G. Kroemer, D. Raoult, I. Boneca, F. Carbonnel, M. Chamaillard, L. Zitvogel (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Science, 350
( Y. L. Loke , M. T. Chew , Y. F. Ngeow , W. W. D. Lim , S. C. Peh , Front. Cell. Infect. Microbiol. 2020, 10, 603086.33364203)
Y. L. Loke , M. T. Chew , Y. F. Ngeow , W. W. D. Lim , S. C. Peh , Front. Cell. Infect. Microbiol. 2020, 10, 603086.33364203
Y. L. Loke , M. T. Chew , Y. F. Ngeow , W. W. D. Lim , S. C. Peh , Front. Cell. Infect. Microbiol. 2020, 10, 603086.33364203, Y. L. Loke , M. T. Chew , Y. F. Ngeow , W. W. D. Lim , S. C. Peh , Front. Cell. Infect. Microbiol. 2020, 10, 603086.33364203
C. Brennan, Slater Clay, Sydney Lavoie, Sena Bae, Jessica Lang, Diogo Fonseca-Pereira, Kathryn Rosinski, N. Ou, J. Glickman, W. Garrett (2021)
Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression
Gut Microbes, 13
C. Palmela, C. Chevarin, Zhilu Xu, J. Torres, G. Sevrin, R. Hirten, N. Barnich, S. Ng, J. Colombel (2007)
Adherent-invasive Escherichia coli in inflammatory bowel disease
Gut, 67
( G. R. D'Haens , C. Jobin , Gastroenterology 2019, 157, 624.31220424)
G. R. D'Haens , C. Jobin , Gastroenterology 2019, 157, 624.31220424
G. R. D'Haens , C. Jobin , Gastroenterology 2019, 157, 624.31220424, G. R. D'Haens , C. Jobin , Gastroenterology 2019, 157, 624.31220424
Jiahui Yu, Yongyu Chen, Xiangsheng Fu, Xian Zhou, Yan Peng, Lei Shi, Ting Chen, Yaxin Wu (2016)
Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway
International Journal of Cancer, 139
Xinqiang Wu, Yuanbing Wu, Liangmei He, Longhuo Wu, Xiangcai Wang, Zhiping Liu (2018)
Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer
Journal of Cancer, 9
Zhenwei Dai, O. Coker, Geicho Nakatsu, William Wu, Liuyang Zhao, Zigui Chen, F. Chan, K. Kristiansen, J. Sung, S. Wong, Jun Yu (2018)
Additional file 6: of Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers
Liyana Zaharuddin, N. Mokhtar, K. Nawawi, R. Ali (2019)
A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer
BMC Gastroenterology, 19
K. Mima, Reiko Nishihara, Z. Qian, Yin Cao, Y. Sukawa, J. Nowak, Juhong Yang, Ruoxu Dou, Y. Masugi, M. Song, A. Kostic, M. Giannakis, S. Bullman, D. Milner, H. Baba, E. Giovannucci, L. Garraway, G. Freeman, G. Dranoff, W. Garrett, C. Huttenhower, M. Meyerson, J. Meyerhardt, A. Chan, C. Fuchs, S. Ogino (2015)
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Gut, 65
M. Rubinstein, Xiaowei Wang, Wendy Liu, Yujun Hao, G. Cai, Yiping Han (2013)
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.
Cell host & microbe, 14 2
( M. S. Shah , T. DeSantis , J. M. Yamal , T. Weir , E. P. Ryan , J. L. Cope , E. B. Hollister , PLoS One 2018, 13, 0207002.)
M. S. Shah , T. DeSantis , J. M. Yamal , T. Weir , E. P. Ryan , J. L. Cope , E. B. Hollister , PLoS One 2018, 13, 0207002.
M. S. Shah , T. DeSantis , J. M. Yamal , T. Weir , E. P. Ryan , J. L. Cope , E. B. Hollister , PLoS One 2018, 13, 0207002., M. S. Shah , T. DeSantis , J. M. Yamal , T. Weir , E. P. Ryan , J. L. Cope , E. B. Hollister , PLoS One 2018, 13, 0207002.
Shuhui Bian, Yu Hou, Xin Zhou, Xianlong Li, Jun Yong, Yicheng Wang, Wendong Wang, Jia Yan, Boqiang Hu, Hongshan Guo, Jilian Wang, Shuai Gao, Yunuo Mao, Ji Dong, Ping Zhu, D. Xiu, Liying Yan, Lu Wen, J. Qiao, Fuchou Tang, W. Fu (2018)
Single-cell multiomics sequencing and analyses of human colorectal cancer
Science, 362
Fanlei Kong, Chao Fang, Yan Zhang, Lixia Duan, Dou Du, G. Xu, Xiaolong Li, Hongyan Li, Yifei Yin, Huixiong Xu, Kun Zhang (2022)
Abundance and Metabolism Disruptions of Intratumoral Microbiota by Chemical and Physical Actions Unfreeze Tumor Treatment Resistance
Advanced Science, 9
Yunfeng Zhang, Qian Wu, Linhao Xu, Hong Wang, Xin Liu, Sihui Li, T. Hu, Yanying Liu, Quanzhou Peng, Zhiwei Chen, Xianrui Wu, Jian-Bing Fan (2021)
Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay
Clinical Epigenetics, 13
( W. Fong , Q. Li , J. Yu , Oncogene 2020, 39, 4925.32514151)
W. Fong , Q. Li , J. Yu , Oncogene 2020, 39, 4925.32514151
W. Fong , Q. Li , J. Yu , Oncogene 2020, 39, 4925.32514151, W. Fong , Q. Li , J. Yu , Oncogene 2020, 39, 4925.32514151
Alice Bertocchi, S. Carloni, P. Ravenda, G. Bertalot, I. Spadoni, Antonino Cascio, S. Gandini, Michela Lizier, D. Braga, F. Asnicar, N. Segata, Chris Klaver, P. Brescia, E. Rossi, A. Anselmo, S. Guglietta, A. Maroli, P. Spaggiari, N. Tarazona, A. Cervantes, S. Marsoni, L. Lazzari, Maria Jodice, C. Luise, M. Erreni, S. Pece, P. Fiore, G. Viale, A. Spinelli, C. Pozzi, G. Penna, M. Rescigno (2021)
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.
Cancer cell
T. Rossi, D. Vergara, F. Fanini, M. Maffia, S. Bravaccini, Francesca Pirini (2020)
Microbiota-Derived Metabolites in Tumor Progression and Metastasis
International Journal of Molecular Sciences, 21
Kassem Makki, E. Deehan, J. Walter, F. Bäckhed (2018)
The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease.
Cell host & microbe, 23 6
Naoko Hattori, T. Niwa, T. Ishida, Kyosuke Kobayashi, T. Imai, Akiko Mori, Kana Kimura, Takeshige Mori, Y. Asami, T. Ushijima (2018)
Antibiotics suppress colon tumorigenesis through inhibition of aberrant DNA methylation in an azoxymethane and dextran sulfate sodium colitis model
Cancer Science, 110
V. Eklöf, Anna Löfgren-Burström, C. Zingmark, S. Edin, Pär Larsson, P. Karling, O. Alexeyev, J. Rutegård, Maria Wikberg, R. Palmqvist (2017)
Cancer‐associated fecal microbial markers in colorectal cancer detection
International Journal of Cancer, 141
Lulu Sun, Jie Cai, F. Gonzalez (2021)
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Nature Reviews Gastroenterology & Hepatology, 18
S. O'keefe (2016)
Diet, microorganisms and their metabolites, and colon cancer
Nature Reviews Gastroenterology &Hepatology, 13
Li Ge, Jie Qi, Bo Shao, Zhenzhen Ruan, Yueran Ren, Shu-jing Sui, Xinpei Wu, Xueqiang Sun, Shuman Liu, Sha Li, Changqing Xu, Wengang Song (2022)
Microbial hydrogen economy alleviates colitis by reprogramming colonocyte metabolism and reinforcing intestinal barrier
Gut Microbes, 14
M. Song, A. Chan, Jun Sun (2020)
Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer.
Gastroenterology
Xusheng Zhang, Dou Yu, Di Wu, Xintong Gao, F. Shao, Min Zhao, Jiang Wang, Jian-Juan Ma, Wenzhao Wang, Xiwen Qin, Yi Chen, P. Xia, Shuo Wang (2023)
Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance.
Cell host & microbe, 31 3
Ankit Malik, D. Sharma, S. Malireddi, C. Guy, Ti‐Cheng Chang, Scott Olsen, G. Neale, P. Vogel, T. Kanneganti (2018)
SYK‐CARD9 Signaling Axis Promotes Gut Fungi‐Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer
Immunity, 49
( M. T. Sorbara , E. G. Pamer , Nat. Rev. Microbiol. 2022, 20, 365.34992261)
M. T. Sorbara , E. G. Pamer , Nat. Rev. Microbiol. 2022, 20, 365.34992261
M. T. Sorbara , E. G. Pamer , Nat. Rev. Microbiol. 2022, 20, 365.34992261, M. T. Sorbara , E. G. Pamer , Nat. Rev. Microbiol. 2022, 20, 365.34992261
Nielson Baxter, M. Ruffin, M. Rogers, P. Schloss (2016)
Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions
Genome Medicine, 8
C. Gur, Y. Ibrahim, Batya Isaacson, Rachel Yamin, Jawad Abed, M. Gamliel, Jonatan Enk, Y. Bar-On, Noah Stanietsky-Kaynan, S. Coppenhagen-Glazer, N. Shussman, G. Almogy, Angelica Cuapio, E. Hofer, D. Mevorach, A. Tabib, R. Ortenberg, G. Markel, Karmela Miklić, S. Jonjić, C. Brennan, W. Garrett, G. Bachrach, O. Mandelboim (2015)
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.
Immunity, 42 2
( A. L. Geis , H. Fan , X. Wu , S. Wu , D. L. Huso , J. L. Wolfe , C. L. Sears , D. M. Pardoll , F. Housseau , Cancer Discovery 2015, 5, 1098.26201900)
A. L. Geis , H. Fan , X. Wu , S. Wu , D. L. Huso , J. L. Wolfe , C. L. Sears , D. M. Pardoll , F. Housseau , Cancer Discovery 2015, 5, 1098.26201900
A. L. Geis , H. Fan , X. Wu , S. Wu , D. L. Huso , J. L. Wolfe , C. L. Sears , D. M. Pardoll , F. Housseau , Cancer Discovery 2015, 5, 1098.26201900, A. L. Geis , H. Fan , X. Wu , S. Wu , D. L. Huso , J. L. Wolfe , C. L. Sears , D. M. Pardoll , F. Housseau , Cancer Discovery 2015, 5, 1098.26201900
F. Ruemmele (2016)
Role of Diet in Inflammatory Bowel Disease
Annals of Nutrition and Metabolism, 68
M. Rubinstein, J. Baik, S. Lagana, Richard Han, W. Raab, D. Sahoo, P. Dalerba, T. Wang, Yiping Han (2019)
Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β‐catenin modulator Annexin A1
EMBO reports, 20
R. Ooijevaar, E. Terveer, H. Verspaget, E. Kuijper, J. Keller (2019)
Clinical Application and Potential of Fecal Microbiota Transplantation.
Annual review of medicine, 70
( N. Chaput , P. Lepage , C. Coutzac , E. Soularue , K. Le Roux , C. Monot , L. Boselli , E. Routier , L. Cassard , M. Collins , T. Vaysse , L. Marthey , A. Eggermont , V. Asvatourian , E. Lanoy , C. Mateus , C. Robert , F. Carbonnel , Ann. Oncol. 2017, 28, 1368.28368458)
N. Chaput , P. Lepage , C. Coutzac , E. Soularue , K. Le Roux , C. Monot , L. Boselli , E. Routier , L. Cassard , M. Collins , T. Vaysse , L. Marthey , A. Eggermont , V. Asvatourian , E. Lanoy , C. Mateus , C. Robert , F. Carbonnel , Ann. Oncol. 2017, 28, 1368.28368458
N. Chaput , P. Lepage , C. Coutzac , E. Soularue , K. Le Roux , C. Monot , L. Boselli , E. Routier , L. Cassard , M. Collins , T. Vaysse , L. Marthey , A. Eggermont , V. Asvatourian , E. Lanoy , C. Mateus , C. Robert , F. Carbonnel , Ann. Oncol. 2017, 28, 1368.28368458, N. Chaput , P. Lepage , C. Coutzac , E. Soularue , K. Le Roux , C. Monot , L. Boselli , E. Routier , L. Cassard , M. Collins , T. Vaysse , L. Marthey , A. Eggermont , V. Asvatourian , E. Lanoy , C. Mateus , C. Robert , F. Carbonnel , Ann. Oncol. 2017, 28, 1368.28368458
Burkhardt Flemer, Denise Lynch, J. Brown, I. Jeffery, F. Ryan, M. Claesson, M. O'Riordain, F. Shanahan, P. O’Toole (2016)
Tumour-associated and non-tumour-associated microbiota in colorectal cancer
Gut, 66
Tal Korem, D. Zeevi, N. Zmora, O. Weissbrod, N. Bar, M. Lotan-Pompan, T. Avnit-Sagi, Noa Kosower, Gal Malka, Michal Rein, Jotham Suez, B. Goldberg, A. Weinberger, A. Levy, E. Elinav, E. Segal (2017)
Bread Affects Clinical Parameters and Induces Gut Microbiome-Associated Personal Glycemic Responses.
Cell metabolism, 25 6
Jingtao Hu, Chunfeng Wang, L. Ye, Wen-Tao Yang, Haibin Huang, F. Meng, Shaohua Shi, Z. Ding (2015)
Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice
Journal of Biosciences, 40
Yao He, Liuhui Fu, Yiping Li, Wenyan Wang, M. Gong, Jing Zhang, Xin Dong, Jiaoyan Huang, Quanbo Wang, C. Mackay, yang-xin fu, Yun Chen, Xiaohuan Guo (2021)
Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity.
Cell metabolism
Bowei Zhang, Yingchuan Xu, Shuang Liu, Huan Lv, Yaozhong Hu, Yaya Wang, Zhi Li, Jin Wang, Xuemeng Ji, Hui Ma, Xiaowen Wang, Shuo Wang (2020)
Dietary Supplementation of Foxtail Millet Ameliorates Colitis-Associated Colorectal Cancer in Mice via Activation of Gut Receptors and Suppression of the STAT3 Pathway
Nutrients, 12
Tingting Wang, C. Fan, Anran Yao, Xingwei Xu, G. Zheng, Y. You, Changying Jiang, Xueqiang Zhao, Yayi Hou, M. Hung, Xin Lin (2018)
The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota‐Mediated Expansion of Myeloid‐Derived Suppressor Cells
Immunity, 49
( V. Eklöf , A. Löfgren‐Burström , C. Zingmark , S. Edin , P. Larsson , P. Karling , O. Alexeyev , J. Rutegård , M. L. Wikberg , R. Palmqvist , Int. J. Cancer 2017, 141, 2528.28833079)
V. Eklöf , A. Löfgren‐Burström , C. Zingmark , S. Edin , P. Larsson , P. Karling , O. Alexeyev , J. Rutegård , M. L. Wikberg , R. Palmqvist , Int. J. Cancer 2017, 141, 2528.28833079
V. Eklöf , A. Löfgren‐Burström , C. Zingmark , S. Edin , P. Larsson , P. Karling , O. Alexeyev , J. Rutegård , M. L. Wikberg , R. Palmqvist , Int. J. Cancer 2017, 141, 2528.28833079, V. Eklöf , A. Löfgren‐Burström , C. Zingmark , S. Edin , P. Larsson , P. Karling , O. Alexeyev , J. Rutegård , M. L. Wikberg , R. Palmqvist , Int. J. Cancer 2017, 141, 2528.28833079
TaChung Yu, Fangfang Guo, Yanan Yu, T. Sun, Dangdang Ma, Ji-Xuan Han, Yun Qian, Ilona Kryczek, Danfeng Sun, N. Nagarsheth, Yingxuan Chen, Haoyan Chen, Jie Hong, W. Zou, J. Fang (2017)
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Cell, 170
R. Gao, C. Kong, Hao Li, Linsheng Huang, Xiao Qu, Nan Qin, Huanlong Qin (2017)
Dysbiosis signature of mycobiota in colon polyp and colorectal cancer
European Journal of Clinical Microbiology & Infectious Diseases, 36
Kumar Ganesan, Songhe Guo, S. Fayyaz, Ge Zhang, Baojun Xu (2019)
Targeting Programmed Fusobacterium nucleatum Fap2 for Colorectal Cancer Therapy
Cancers, 11
( C. L. Murphy , M. Barrett , P. Pellanda , S. Killeen , M. McCourt , E. Andrews , M O’ Riordain , F. Shanahan , P. O'Toole , Gut Microbes 2021, 13, 1.)
C. L. Murphy , M. Barrett , P. Pellanda , S. Killeen , M. McCourt , E. Andrews , M O’ Riordain , F. Shanahan , P. O'Toole , Gut Microbes 2021, 13, 1.
C. L. Murphy , M. Barrett , P. Pellanda , S. Killeen , M. McCourt , E. Andrews , M O’ Riordain , F. Shanahan , P. O'Toole , Gut Microbes 2021, 13, 1., C. L. Murphy , M. Barrett , P. Pellanda , S. Killeen , M. McCourt , E. Andrews , M O’ Riordain , F. Shanahan , P. O'Toole , Gut Microbes 2021, 13, 1.
H. Tilg, T. Adolph, R. Gerner, A. Moschen (2018)
The Intestinal Microbiota in Colorectal Cancer.
Cancer cell, 33 6
Danny Yu, Jennifer Waby, H. Chirakkal, C. Staton, B. Corfe (2010)
Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation
Molecular Cancer, 9
( J. L. Alexander , I. D. Wilson , J. Teare , J. R. Marchesi , J. K. Nicholson , J. M. Kinross , Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356.28270698)
J. L. Alexander , I. D. Wilson , J. Teare , J. R. Marchesi , J. K. Nicholson , J. M. Kinross , Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356.28270698
J. L. Alexander , I. D. Wilson , J. Teare , J. R. Marchesi , J. K. Nicholson , J. M. Kinross , Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356.28270698, J. L. Alexander , I. D. Wilson , J. Teare , J. R. Marchesi , J. K. Nicholson , J. M. Kinross , Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356.28270698
Houbao Zhu, Wang-yang Xu, Zhiqiang Hu, Hongxing Zhang, Yan Shen, Shun-yuan Lu, Chaochun Wei, Zhu-Gang Wang (2017)
RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer
Journal of Experimental & Clinical Cancer Research : CR, 36
Lina Wang, Mengxue Gao, G. Kang, He Huang (2021)
The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease
Frontiers in Nutrition, 8
Rekha Jalandra, N. Dalal, A. Yadav, Damini Verma, Minakshi Sharma, Rajeev Singh, A. Khosla, Anil Kumar, P. Solanki (2021)
Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer
Applied Microbiology and Biotechnology, 105
K. Lee, M. Luong, H. Shaw, P. Nathan, V. Bataille, T. Spector (2021)
The gut microbiome: what the oncologist ought to know
British Journal of Cancer, 125
R. Gharaibeh, C. Jobin (2018)
Microbiota and cancer immunotherapy: in search of microbial signals
Gut, 68
M. Depner, Diana Taft, P. Kirjavainen, K. Kalanetra, A. Karvonen, S. Peschel, E. Schmausser-Hechfellner, C. Roduit, R. Frei, R. Lauener, A. Divaret‐Chauveau, J. Dalphin, J. Riedler, M. Roponen, M. Kabesch, H. Renz, J. Pekkanen, F. Farquharson, P. Louis, D. Mills, E. Mutius, Jon v, J. Genuneit, A. Hyvärinen, S. Illi, L. Laurent, P. Pfefferle, B. Schaub, M. Ege (2020)
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma
Nature Medicine, 26
S. Rosshart, Brian Vassallo, Davide Angeletti, D. Hutchinson, Andrew Morgan, K. Takeda, H. Hickman, J. McCulloch, J. Badger, N. Ajami, G. Trinchieri, F. Villena, J. Yewdell, B. Rehermann (2017)
Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance
Cell, 171
T. Tanoue, S. Morita, D. Plichta, Ashwin Skelly, W. Suda, Y. Sugiura, S. Narushima, H. Vlamakis, I. Motoo, K. Sugita, A. Shiota, Kozue Takeshita, K. Yasuma-Mitobe, D. Riethmacher, T. Kaisho, J. Norman, D. Mucida, M. Suematsu, T. Yaguchi, V. Bucci, Takashi Inoue, Y. Kawakami, B. Ollé, Bruce Roberts, M. Hattori, R. Xavier, K. Atarashi, K. Honda (2019)
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Nature, 565
( C. A. Brennan , S. L. Clay , S. L. Lavoie , S. Bae , J. K. Lang , D. Fonseca‐Pereira , K. G. Rosinski , N. Ou , J. N. Glickman , W. S. Garrett , Gut Microbes 2021, 13, 1987780.34781821)
C. A. Brennan , S. L. Clay , S. L. Lavoie , S. Bae , J. K. Lang , D. Fonseca‐Pereira , K. G. Rosinski , N. Ou , J. N. Glickman , W. S. Garrett , Gut Microbes 2021, 13, 1987780.34781821
C. A. Brennan , S. L. Clay , S. L. Lavoie , S. Bae , J. K. Lang , D. Fonseca‐Pereira , K. G. Rosinski , N. Ou , J. N. Glickman , W. S. Garrett , Gut Microbes 2021, 13, 1987780.34781821, C. A. Brennan , S. L. Clay , S. L. Lavoie , S. Bae , J. K. Lang , D. Fonseca‐Pereira , K. G. Rosinski , N. Ou , J. N. Glickman , W. S. Garrett , Gut Microbes 2021, 13, 1987780.34781821
Lauren Dedecker, Bretton Coppedge, Julio Avelar-Barragan, William Karnes, K. Whiteson (2021)
Microbiome distinctions between the CRC carcinogenic pathways
Gut Microbes, 13
K. Ganesh, Z. Stadler, A. Cercek, R. Mendelsohn, J. Shia, N. Segal, L. Diaz (2019)
Immunotherapy in colorectal cancer: rationale, challenges and potential
Nature Reviews Gastroenterology & Hepatology, 16
( M. J. Pichler , C. Yamada , B. Shuoker , C. Alvarez‐Silva , A. Gotoh , M. L. Leth , E. Schoof , T. Katoh , M. Sakanaka , T. Katayama , C. Jin , N. G. Karlsson , M. Arumugam , S. Fushinobu , M. Abou Hachem , Nat. Commun. 2020, 11, 3285.32620774)
M. J. Pichler , C. Yamada , B. Shuoker , C. Alvarez‐Silva , A. Gotoh , M. L. Leth , E. Schoof , T. Katoh , M. Sakanaka , T. Katayama , C. Jin , N. G. Karlsson , M. Arumugam , S. Fushinobu , M. Abou Hachem , Nat. Commun. 2020, 11, 3285.32620774
M. J. Pichler , C. Yamada , B. Shuoker , C. Alvarez‐Silva , A. Gotoh , M. L. Leth , E. Schoof , T. Katoh , M. Sakanaka , T. Katayama , C. Jin , N. G. Karlsson , M. Arumugam , S. Fushinobu , M. Abou Hachem , Nat. Commun. 2020, 11, 3285.32620774, M. J. Pichler , C. Yamada , B. Shuoker , C. Alvarez‐Silva , A. Gotoh , M. L. Leth , E. Schoof , T. Katoh , M. Sakanaka , T. Katayama , C. Jin , N. G. Karlsson , M. Arumugam , S. Fushinobu , M. Abou Hachem , Nat. Commun. 2020, 11, 3285.32620774
L. Bolte, A. Vila, F. Imhann, V. Collij, R. Gacesa, V. Peters, C. Wijmenga, A. Kurilshikov, M. Campmans-Kuijpers, Jingyuan Fu, G. Dijkstra, A. Zhernakova, R. Weersma (2021)
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome
Gut, 70
Geicho Nakatsu, Haokui Zhou, W. Wu, S. Wong, O. Coker, Zhenwei Dai, Xiangchun Li, C. Szeto, Naoki Sugimura, T. Lam, A. Yu, Xiansong Wang, Zigui Chen, M. Wong, S. Ng, M. Chan, P. Chan, F. Chan, J. Sung, Jun Yu (2018)
Alterations in Enteric Virome Are Associated With Colorectal Cancer and Survival Outcomes.
Gastroenterology, 155 2
( R. E. Ooijevaar , E. M. Terveer , H. W. Verspaget , E. J. Kuijper , J. J. Keller , Annu. Rev. Med. 2019, 70, 335.30403550)
R. E. Ooijevaar , E. M. Terveer , H. W. Verspaget , E. J. Kuijper , J. J. Keller , Annu. Rev. Med. 2019, 70, 335.30403550
R. E. Ooijevaar , E. M. Terveer , H. W. Verspaget , E. J. Kuijper , J. J. Keller , Annu. Rev. Med. 2019, 70, 335.30403550, R. E. Ooijevaar , E. M. Terveer , H. W. Verspaget , E. J. Kuijper , J. J. Keller , Annu. Rev. Med. 2019, 70, 335.30403550
Zachary Stine, Z. Schug, J. Salvino, C. Dang (2021)
Targeting cancer metabolism in the era of precision oncology
Nature Reviews. Drug Discovery, 21
Yucheng Zhang, Yijie Weng, Huoye Gan, Xinmei Zhao, Fachao Zhi (2018)
Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease.
Biochemical and biophysical research communications, 506 4
(2021)
Cell 2021, 184, 5015; b)
( E. Cremonesi , V. Governa , J. F. G. Garzon , V. Mele , F. Amicarella , M. G. Muraro , E. Trella , V. Galati‐Fournier , D. Oertli , S. R. Däster , R. A. Droeser , B. Weixler , M. Bolli , R. Rosso , U. Nitsche , N. Khanna , A. Egli , S. Keck , J. Slotta‐Huspenina , L. M. Terracciano , P. Zajac , G. C. Spagnoli , S. Eppenberger‐Castori , K. P. Janssen , L. Borsig , G. Iezzi , Gut 2018, 67, 1984.29437871)
E. Cremonesi , V. Governa , J. F. G. Garzon , V. Mele , F. Amicarella , M. G. Muraro , E. Trella , V. Galati‐Fournier , D. Oertli , S. R. Däster , R. A. Droeser , B. Weixler , M. Bolli , R. Rosso , U. Nitsche , N. Khanna , A. Egli , S. Keck , J. Slotta‐Huspenina , L. M. Terracciano , P. Zajac , G. C. Spagnoli , S. Eppenberger‐Castori , K. P. Janssen , L. Borsig , G. Iezzi , Gut 2018, 67, 1984.29437871
E. Cremonesi , V. Governa , J. F. G. Garzon , V. Mele , F. Amicarella , M. G. Muraro , E. Trella , V. Galati‐Fournier , D. Oertli , S. R. Däster , R. A. Droeser , B. Weixler , M. Bolli , R. Rosso , U. Nitsche , N. Khanna , A. Egli , S. Keck , J. Slotta‐Huspenina , L. M. Terracciano , P. Zajac , G. C. Spagnoli , S. Eppenberger‐Castori , K. P. Janssen , L. Borsig , G. Iezzi , Gut 2018, 67, 1984.29437871, E. Cremonesi , V. Governa , J. F. G. Garzon , V. Mele , F. Amicarella , M. G. Muraro , E. Trella , V. Galati‐Fournier , D. Oertli , S. R. Däster , R. A. Droeser , B. Weixler , M. Bolli , R. Rosso , U. Nitsche , N. Khanna , A. Egli , S. Keck , J. Slotta‐Huspenina , L. M. Terracciano , P. Zajac , G. C. Spagnoli , S. Eppenberger‐Castori , K. P. Janssen , L. Borsig , G. Iezzi , Gut 2018, 67, 1984.29437871
R. Kesselring, Joachim Glaesner, A. Hiergeist, E. Naschberger, H. Neumann, S. Brunner, A. Wege, C. Seebauer, G. Köhl, S. Merkl, R. Croner, C. Hackl, M. Stürzl, M. Neurath, A. Gessner, H. Schlitt, E. Geissler, S. Fichtner-Feigl (2016)
IRAK-M Expression in Tumor Cells Supports Colorectal Cancer Progression through Reduction of Antimicrobial Defense and Stabilization of STAT3.
Cancer cell, 29 5
Semir Beyaz, C. Chung, Haiwei Mou, Khristian Bauer-Rowe, Michael Xifaras, Ilgin Ergin, L. Dohnalová, Moshe Biton, K. Shekhar, Onur Eskiocak, Katherine Papciak, Kadir Ozler, Mohammad Almeqdadi, Brian Yueh, M. Fein, Damodaran Annamalai, Eider Valle-Encinas, A. Erdemir, Karoline Dogum, Vyom Shah, Aybuke Alici-Garipcan, H. Meyer, Deniz Özata, E. Elinav, Alper Kucukural, Pawan Kumar, J. McAleer, J. Fox, Christoph Thaiss, A. Regev, J. Roper, S. Orkin, Ömer Yilmaz (2021)
Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis.
Cell stem cell
E. Friedman, Yun Li, T. Shen, Jack Jiang, L. Chau, L. Adorini, F. Babakhani, J. Edwards, D. Shapiro, Chunyu Zhao, R. Carr, K. Bittinger, Hongzhe Li, Gary Wu (2018)
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
Gastroenterology, 155 6
W. Fong, Qing Li, Jun Yu (2020)
Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer
Oncogene, 39
E. Cremonesi, Valeria Governa, J. Garzon, V. Mele, Francesca Amicarella, M. Muraro, E. Trella, Virginie Galati-Fournier, D. Oertli, S. Däster, R. Droeser, B. Weixler, M. Bolli, R. Rosso, U. Nitsche, N. Khanna, A. Egli, Simone Keck, J. Slotta-Huspenina, L. Terracciano, P. Zajac, G. Spagnoli, S. Eppenberger-Castori, K. Janssen, L. Borsig, G. Iezzi (2018)
Gut microbiota modulate T cell trafficking into human colorectal cancer
Gut, 67
Qing Li, Wei Hu, Weixin Liu, Liuyang Zhao, Dan Huang, Xiao-Dong Liu, H. Chan, Yuchen Zhang, Ju-deng Zeng, O. Coker, W. Kang, S. Ng, Lin Zhang, S. Wong, T. Gin, M. Chan, Jian-Lin Wu, Jun Yu, W. Wu (2020)
Streptococcus thermophilus inhibits colorectal tumorigenesis through secreting β-galactosidase.
Gastroenterology
Yuanqi Wu, N. Jiao, Ruixin Zhu, Yida Zhang, Dingfeng Wu, An-jun Wang, Sa Fang, Liwen Tao, Yichen Li, Sijing Cheng, Xiaosheng He, P. Lan, Chuan Tian, Ningning Liu, Lixin Zhu (2020)
Identification of microbial markers across populations in early detection of colorectal cancer
Nature Communications, 12
( M. Baretti , E. Karunasena , M. Zahurak , R. Walker , Y. Zhao , T. R. Pisanic 2nd , T. H. Wang , T. F. Greten , A. G. Duffy , E. Gootjes , G. Meijer , H. M. W. Verheul , N. Ahuja , J. G. Herman , N. S. Azad , Clin. Transl. Sci. 2021, 14, 954.33811727)
M. Baretti , E. Karunasena , M. Zahurak , R. Walker , Y. Zhao , T. R. Pisanic 2nd , T. H. Wang , T. F. Greten , A. G. Duffy , E. Gootjes , G. Meijer , H. M. W. Verheul , N. Ahuja , J. G. Herman , N. S. Azad , Clin. Transl. Sci. 2021, 14, 954.33811727
M. Baretti , E. Karunasena , M. Zahurak , R. Walker , Y. Zhao , T. R. Pisanic 2nd , T. H. Wang , T. F. Greten , A. G. Duffy , E. Gootjes , G. Meijer , H. M. W. Verheul , N. Ahuja , J. G. Herman , N. S. Azad , Clin. Transl. Sci. 2021, 14, 954.33811727, M. Baretti , E. Karunasena , M. Zahurak , R. Walker , Y. Zhao , T. R. Pisanic 2nd , T. H. Wang , T. F. Greten , A. G. Duffy , E. Gootjes , G. Meijer , H. M. W. Verheul , N. Ahuja , J. G. Herman , N. S. Azad , Clin. Transl. Sci. 2021, 14, 954.33811727
Liam Chung, Erik Orberg, A. Geis, June Chan, Kai Fu, C. Shields, Christine Dejea, Payam Fathi, Jie Chen, Benjamin Finard, A. Tam, F. McAllister, H. Fan, Xinqun Wu, S. Ganguly, Andriana Lebid, P. Metz, S. Meerbeke, D. Huso, E. Wick, D. Pardoll, F. Wan, Shaoguang Wu, C. Sears, F. Housseau (2018)
Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells.
Cell host & microbe, 23 2
( R. Z. Gharaibeh , C. Jobin , Gut 2019, 68, 385.30530851)
R. Z. Gharaibeh , C. Jobin , Gut 2019, 68, 385.30530851
R. Z. Gharaibeh , C. Jobin , Gut 2019, 68, 385.30530851, R. Z. Gharaibeh , C. Jobin , Gut 2019, 68, 385.30530851
Paulina Dziubańska-Kusibab, Hilmar Berger, F. Battistini, Britta Bouwman, A. Iftekhar, Riku Katainen, Tatiana Cajuso, N. Crosetto, M. Orozco, L. Aaltonen, T. Meyer (2020)
Colibactin DNA-damage signature indicates mutational impact in colorectal cancer
Nature Medicine, 26
Niranjan Venkateswaran, M. Lafita-Navarro, Yi‐Heng Hao, Jessica Kilgore, Lizbeth Perez-Castro, Jonathan Braverman, N. Borenstein-Auerbach, Min Kim, Nicholas Lesner, Prashant Mishra, T. Brabletz, J. Shay, R. Deberardinis, R. Deberardinis, N. Williams, Ömer Yilmaz, Ömer Yilmaz, Maralice Conacci-Sorrell (2019)
MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer
Genes & Development, 33
M. Makishima, T. Lu, W. Xie, G. Whitfield, H. Domoto, R. Evans, M. Haussler, D. Mangelsdorf (2002)
Vitamin D Receptor As an Intestinal Bile Acid Sensor
Science, 296
V. Harris, Asad Ali, S. Fuentes, K. Korpela, M. Kazi, J. Tate, U. Parashar, W. Wiersinga, C. Giaquinto, C. Weerth, W. Vos (2017)
Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan
Gut Microbes, 9
Jawad Abed, Johanna Emgård, G. Zamir, M. Faroja, G. Almogy, Amalie Grenov, Asaf Sol, R. Naor, E. Pikarsky, K. Atlan, Anna Mellul, S. Chaushu, A. Manson, A. Earl, N. Ou, C. Brennan, W. Garrett, G. Bachrach (2016)
Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc.
Cell host & microbe, 20 2
S. Wong, Thomas Kwong, T. Chow, A. Luk, R. Dai, Geicho Nakatsu, Thomas Lam, Lin Zhang, Justin Wu, F. Chan, S. Ng, M. Wong, S. Ng, W. Wu, Jun Yu, J. Sung (2016)
Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia
Gut, 66
( D. C. Yu , J. S. Waby , H. Chirakkal , C. A. Staton , B. M. Corfe , Mol Cancer 2010, 9, 276.20950431)
D. C. Yu , J. S. Waby , H. Chirakkal , C. A. Staton , B. M. Corfe , Mol Cancer 2010, 9, 276.20950431
D. C. Yu , J. S. Waby , H. Chirakkal , C. A. Staton , B. M. Corfe , Mol Cancer 2010, 9, 276.20950431, D. C. Yu , J. S. Waby , H. Chirakkal , C. A. Staton , B. M. Corfe , Mol Cancer 2010, 9, 276.20950431
Jonas Schluter, J. Peled, Bradford Taylor, K. Markey, Melody Smith, Y. Taur, R. Niehus, A. Staffas, Anqi Dai, E. Fontana, L. Amoretti, R. Wright, S. Morjaria, Maly Fenelus, M. Pessin, N. Chao, M. Lew, L. Bohannon, Amy Bush, A. Sung, T. Hohl, M. Perales, M. Brink, J. Xavier (2020)
The gut microbiota is associated with immune cell dynamics in humans
Nature, 588
Jingyi Li, Xin Zhou, Xiaomeng Liu, Jie Ren, Jilian Wang, Wendong Wang, Yuxuan Zheng, Xinyun Shi, Tao Sun, Zhifei Li, Anding Kang, Fuchou Tang, Lu Wen, W. Fu (2019)
Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing.
Clinical chemistry
( E. S. Friedman , Y. Li , T. D. Shen , J. Jiang , L. Chau , L. Adorini , F. Babakhani , J. Edwards , D. Shapiro , C. Zhao , R. M. Carr , K. Bittinger , H. Li , G. D. Wu , Gastroenterology 2018, 155, 1741.30144429)
E. S. Friedman , Y. Li , T. D. Shen , J. Jiang , L. Chau , L. Adorini , F. Babakhani , J. Edwards , D. Shapiro , C. Zhao , R. M. Carr , K. Bittinger , H. Li , G. D. Wu , Gastroenterology 2018, 155, 1741.30144429
E. S. Friedman , Y. Li , T. D. Shen , J. Jiang , L. Chau , L. Adorini , F. Babakhani , J. Edwards , D. Shapiro , C. Zhao , R. M. Carr , K. Bittinger , H. Li , G. D. Wu , Gastroenterology 2018, 155, 1741.30144429, E. S. Friedman , Y. Li , T. D. Shen , J. Jiang , L. Chau , L. Adorini , F. Babakhani , J. Edwards , D. Shapiro , C. Zhao , R. M. Carr , K. Bittinger , H. Li , G. D. Wu , Gastroenterology 2018, 155, 1741.30144429
( A. E. Frankel , L. A. Coughlin , J. Kim , T. W. Froehlich , Y. Xie , E. P. Frenkel , A. Y. Koh , Neoplasia 2017, 19, 848.28923537)
A. E. Frankel , L. A. Coughlin , J. Kim , T. W. Froehlich , Y. Xie , E. P. Frenkel , A. Y. Koh , Neoplasia 2017, 19, 848.28923537
A. E. Frankel , L. A. Coughlin , J. Kim , T. W. Froehlich , Y. Xie , E. P. Frenkel , A. Y. Koh , Neoplasia 2017, 19, 848.28923537, A. E. Frankel , L. A. Coughlin , J. Kim , T. W. Froehlich , Y. Xie , E. P. Frenkel , A. Y. Koh , Neoplasia 2017, 19, 848.28923537
Dallas Donohoe, L. Collins, A. Wali, R. Bigler, Wei Sun, S. Bultman (2012)
The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation.
Molecular cell, 48 4
( G. E. Kaiko , S. H. Ryu , O. I. Koues , P. L. Collins , L. Solnica‐Krezel , E. J. Pearce , E. L. Pearce , E. M. Oltz , T. S. Stappenbeck , Cell 2016, 165, 1708.27264604)
G. E. Kaiko , S. H. Ryu , O. I. Koues , P. L. Collins , L. Solnica‐Krezel , E. J. Pearce , E. L. Pearce , E. M. Oltz , T. S. Stappenbeck , Cell 2016, 165, 1708.27264604
G. E. Kaiko , S. H. Ryu , O. I. Koues , P. L. Collins , L. Solnica‐Krezel , E. J. Pearce , E. L. Pearce , E. M. Oltz , T. S. Stappenbeck , Cell 2016, 165, 1708.27264604, G. E. Kaiko , S. H. Ryu , O. I. Koues , P. L. Collins , L. Solnica‐Krezel , E. J. Pearce , E. L. Pearce , E. M. Oltz , T. S. Stappenbeck , Cell 2016, 165, 1708.27264604
G. Sepich-Poore, L. Zitvogel, R. Straussman, J. Hasty, J. Wargo, R. Knight (2021)
The microbiome and human cancer
Science, 371
Martin Beaumont, A. Neyrinck, M. Olivares, Julie Rodriguez, Audrey Serra, Martin Roumain, L. Bindels, Patrice Cani, P. Evenepoel, G. Muccioli, J. Demoulin, N. Delzenne (2018)
The gut microbiota metabolite indole alleviates liver inflammation in mice
The FASEB Journal, 32
J. Brown, Stanley Hazen (2018)
Microbial modulation of cardiovascular disease
Nature Reviews Microbiology, 16
J. Butt, Beatriz Romero-Hernández, B. Pérez-Gómez, Martina Willhauck‐Fleckenstein, D. Holzinger, V. Martín, V. Moreno, C. Linares, T. Dierssen-Sotos, A. Barricarte, A. Tardón, J. Altzibar, E. Moreno-Osset, Francisco Franco, R. Requena, J. Huerta, A. Michel, T. Waterboer, G. Castaño‐Vinyals, M. Kogevinas, M. Pollán, A. Boleij, S. Sanjosé, R. Campo, H. Tjalsma, N. Aragonés, M. Pawlita (2016)
Association of Streptococcus gallolyticus subspecies gallolyticus with colorectal cancer: Serological evidence
International Journal of Cancer, 138
Si Man, Qifan Zhu, Liqin Zhu, Zhiping Liu, Rajendra Karki, Ankit Malik, D. Sharma, Liyuan Li, R. Malireddi, Prajwal Gurung, G. Neale, Scott Olsen, R. Carter, D. McGoldrick, Gang Wu, D. Finkelstein, P. Vogel, R. Gilbertson, T. Kanneganti (2015)
Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer
Cell, 162
( D. Ternes , M. Tsenkova , V. I. Pozdeev , M. Meyers , E. Koncina , S. Atatri , M. Schmitz , J. Karta , M. Schmoetten , A. Heinken , F. Rodriguez , C. Delbrouck , A. Gaigneaux , A. Ginolhac , T. T. D. Nguyen , L. Grandmougin , A. Frachet‐Bour , C. Martin‐Gallausiaux , M. Pacheco , L. Neuberger‐Castillo , P. Miranda , N. Zuegel , J. Y. Ferrand , M. Gantenbein , T. Sauter , D. J. Slade , I. Thiele , J. Meiser , S. Haan , P. Wilmes , et al., Nat. Metab. 2022, 4, 458.35437333)
D. Ternes , M. Tsenkova , V. I. Pozdeev , M. Meyers , E. Koncina , S. Atatri , M. Schmitz , J. Karta , M. Schmoetten , A. Heinken , F. Rodriguez , C. Delbrouck , A. Gaigneaux , A. Ginolhac , T. T. D. Nguyen , L. Grandmougin , A. Frachet‐Bour , C. Martin‐Gallausiaux , M. Pacheco , L. Neuberger‐Castillo , P. Miranda , N. Zuegel , J. Y. Ferrand , M. Gantenbein , T. Sauter , D. J. Slade , I. Thiele , J. Meiser , S. Haan , P. Wilmes , et al., Nat. Metab. 2022, 4, 458.35437333
D. Ternes , M. Tsenkova , V. I. Pozdeev , M. Meyers , E. Koncina , S. Atatri , M. Schmitz , J. Karta , M. Schmoetten , A. Heinken , F. Rodriguez , C. Delbrouck , A. Gaigneaux , A. Ginolhac , T. T. D. Nguyen , L. Grandmougin , A. Frachet‐Bour , C. Martin‐Gallausiaux , M. Pacheco , L. Neuberger‐Castillo , P. Miranda , N. Zuegel , J. Y. Ferrand , M. Gantenbein , T. Sauter , D. J. Slade , I. Thiele , J. Meiser , S. Haan , P. Wilmes , et al., Nat. Metab. 2022, 4, 458.35437333, D. Ternes , M. Tsenkova , V. I. Pozdeev , M. Meyers , E. Koncina , S. Atatri , M. Schmitz , J. Karta , M. Schmoetten , A. Heinken , F. Rodriguez , C. Delbrouck , A. Gaigneaux , A. Ginolhac , T. T. D. Nguyen , L. Grandmougin , A. Frachet‐Bour , C. Martin‐Gallausiaux , M. Pacheco , L. Neuberger‐Castillo , P. Miranda , N. Zuegel , J. Y. Ferrand , M. Gantenbein , T. Sauter , D. J. Slade , I. Thiele , J. Meiser , S. Haan , P. Wilmes , et al., Nat. Metab. 2022, 4, 458.35437333
Dominik Ternes, M. Tsenkova, V. Pozdeev, Marianne Meyers, E. Koncina, Sura Atatri, M. Schmitz, J. Karta, M. Schmoetten, A. Heinken, F. Rodriguez, Catherine Delbrouck, A. Gaigneaux, A. Ginolhac, Tam Nguyen, Léa Grandmougin, Audrey Frachet-Bour, C. Martin-Gallausiaux, Maria Pacheco, Lorie Neuberger-Castillo, Paulo Miranda, N. Zuegel, J. Ferrand, M. Gantenbein, T. Sauter, D. Slade, I. Thiele, J. Meiser, S. Haan, P. Wilmes, E. Letellier (2022)
The gut microbial metabolite formate exacerbates colorectal cancer progression
Nature Metabolism, 4
R. Coleman, P. Lowe, D. Billington (1980)
Membrane lipid composition and susceptibility to bile salt damage.
Biochimica et biophysica acta, 599 1
( A. P. García‐González , A. D. Ritter , S. Shrestha , E. C. Andersen , L. S. Yilmaz , A. J. M. Walhout , Cell 2017, 169, 431.28431244)
A. P. García‐González , A. D. Ritter , S. Shrestha , E. C. Andersen , L. S. Yilmaz , A. J. M. Walhout , Cell 2017, 169, 431.28431244
A. P. García‐González , A. D. Ritter , S. Shrestha , E. C. Andersen , L. S. Yilmaz , A. J. M. Walhout , Cell 2017, 169, 431.28431244, A. P. García‐González , A. D. Ritter , S. Shrestha , E. C. Andersen , L. S. Yilmaz , A. J. M. Walhout , Cell 2017, 169, 431.28431244
R. Siegel, K. Miller, N. Wagle, A. Jemal (2023)
Cancer statistics, 2023
CA: A Cancer Journal for Clinicians, 73
Li Zuo, Man Lu, Qing Zhou, Wei Wei, Y. Wang (2013)
Butyrate suppresses proliferation and migration of RKO colon cancer cells though regulating endocan expression by MAPK signaling pathway.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
J. Wilkinson, E. Franzosa, Christine Everett, Chengchen Li, F. Hu, D. Wirth, M. Song, A. Chan, E. Rimm, W. Garrett, C. Huttenhower (2021)
A framework for microbiome science in public health
Nature Medicine, 27
Junli Ma, Ying Hong, N. Zheng, G. Xie, Yuanzhi Lyu, Yu Gu, Chuchu Xi, Linlin Chen, Gaosong Wu, Yue Li, Xin Tao, Jing Zhong, Zhenzhen Huang, Wenbin Wu, Lin Yuan, Min Lin, Xiong Lu, Weidong Zhang, W. Jia, Lili Sheng, Houkai Li (2020)
Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically
Gut Microbes, 11
A. Belcheva, Thergiory Irrazabal, S. Robertson, C. Streutker, H. Maughan, S. Rubino, E. Moriyama, J. Copeland, A. Surendra, Sachin Kumar, Blerta Green, Kaoru Geddes, R. Pezo, W. Navarre, M. Milosevic, B. Wilson, S. Girardin, T. Wolever, W. Edelmann, D. Guttman, D. Philpott, Alberto Martin (2014)
Gut Microbial Metabolism Drives Transformation of Msh2-Deficient Colon Epithelial Cells
Cell, 159
Danfeng Chen, Duochen Jin, Shumin Huang, Jingyi Wu, Mengque Xu, Tianyu Liu, Wenxiao Dong, Xiang Liu, Sinan Wang, Weilong Zhong, Yi Liu, Ruihuan Jiang, Meiyu Piao, Bangmao Wang, H. Cao (2019)
Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota.
Cancer letters
Z. Shakour, Naglaa Shehab, A. Gomaa, L. Wessjohann, M. Farag (2021)
Metabolic and biotransformation effects on dietary glucosinolates, their bioavailability, catabolism and biological effects in different organisms.
Biotechnology advances
( S. J. O'Keefe , Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 691.27848961)
S. J. O'Keefe , Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 691.27848961
S. J. O'Keefe , Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 691.27848961, S. J. O'Keefe , Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 691.27848961
Yan He, Wei Wu, Huimin Zheng, Pan Li, Daniel McDonald, Hua-fang Sheng, Muxuan Chen, Zi-hui Chen, G. Ji, Zhong-Dai-Xi Zheng, Prabhakar Mujagond, Xiao-Jiao Chen, Zu-hua Rong, Peng Chen, Li-Yi Lyu, Xian Wang, Chong-Bin Wu, Nan Yu, Yanfang Xu, Jia Yin, J. Raes, R. Knight, W. Ma, Hong-Wei Zhou (2018)
Regional variation limits applications of healthy gut microbiome reference ranges and disease models
Nature Medicine, 24
( L. Zaharuddin , N. M. Mokhtar , K. N. Muhammad Nawawi , R. A. Raja Ali , BMC Gastroenterol. 2019, 19, 131.31340751)
L. Zaharuddin , N. M. Mokhtar , K. N. Muhammad Nawawi , R. A. Raja Ali , BMC Gastroenterol. 2019, 19, 131.31340751
L. Zaharuddin , N. M. Mokhtar , K. N. Muhammad Nawawi , R. A. Raja Ali , BMC Gastroenterol. 2019, 19, 131.31340751, L. Zaharuddin , N. M. Mokhtar , K. N. Muhammad Nawawi , R. A. Raja Ali , BMC Gastroenterol. 2019, 19, 131.31340751
( J. M. Carethers , Annu. Rev. Med. 2020, 71, 59.31451044)
J. M. Carethers , Annu. Rev. Med. 2020, 71, 59.31451044
J. M. Carethers , Annu. Rev. Med. 2020, 71, 59.31451044, J. M. Carethers , Annu. Rev. Med. 2020, 71, 59.31451044
Soeren Ocvirk, S. O'keefe (2020)
Dietary fat, bile acid metabolism and colorectal cancer.
Seminars in cancer biology
( B. A. Peters , C. Dominianni , J. A. Shapiro , T. R. Church , J. Wu , G. Miller , E. Yuen , H. Freiman , I. Lustbader , J. Salik , C. Friedlander , R. B. Hayes , J. Ahn , Microbiome 2016, 4, 69.28038683)
B. A. Peters , C. Dominianni , J. A. Shapiro , T. R. Church , J. Wu , G. Miller , E. Yuen , H. Freiman , I. Lustbader , J. Salik , C. Friedlander , R. B. Hayes , J. Ahn , Microbiome 2016, 4, 69.28038683
B. A. Peters , C. Dominianni , J. A. Shapiro , T. R. Church , J. Wu , G. Miller , E. Yuen , H. Freiman , I. Lustbader , J. Salik , C. Friedlander , R. B. Hayes , J. Ahn , Microbiome 2016, 4, 69.28038683, B. A. Peters , C. Dominianni , J. A. Shapiro , T. R. Church , J. Wu , G. Miller , E. Yuen , H. Freiman , I. Lustbader , J. Salik , C. Friedlander , R. B. Hayes , J. Ahn , Microbiome 2016, 4, 69.28038683
Jason Ridlon, Spencer Harris, S. Bhowmik, Daejoong Kang, P. Hylemon (2016)
Consequences of bile salt biotransformations by intestinal bacteria
Gut Microbes, 7
O. Coker, Changan Liu, W. Wu, S. Wong, Wei Jia, J. Sung, Jun Yu (2022)
Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers
Microbiome, 10
( T. Tanoue , S. Morita , D. R. Plichta , A. N. Skelly , W. Suda , Y. Sugiura , S. Narushima , H. Vlamakis , I. Motoo , K. Sugita , A. Shiota , K. Takeshita , K. Yasuma‐Mitobe , D. Riethmacher , T. Kaisho , J. M. Norman , D. Mucida , M. Suematsu , T. Yaguchi , V. Bucci , T. Inoue , Y. Kawakami , B. Olle , B. Roberts , M. Hattori , R. J. Xavier , K. Atarashi , K. Honda , Nature 2019, 565, 600.30675064)
T. Tanoue , S. Morita , D. R. Plichta , A. N. Skelly , W. Suda , Y. Sugiura , S. Narushima , H. Vlamakis , I. Motoo , K. Sugita , A. Shiota , K. Takeshita , K. Yasuma‐Mitobe , D. Riethmacher , T. Kaisho , J. M. Norman , D. Mucida , M. Suematsu , T. Yaguchi , V. Bucci , T. Inoue , Y. Kawakami , B. Olle , B. Roberts , M. Hattori , R. J. Xavier , K. Atarashi , K. Honda , Nature 2019, 565, 600.30675064
T. Tanoue , S. Morita , D. R. Plichta , A. N. Skelly , W. Suda , Y. Sugiura , S. Narushima , H. Vlamakis , I. Motoo , K. Sugita , A. Shiota , K. Takeshita , K. Yasuma‐Mitobe , D. Riethmacher , T. Kaisho , J. M. Norman , D. Mucida , M. Suematsu , T. Yaguchi , V. Bucci , T. Inoue , Y. Kawakami , B. Olle , B. Roberts , M. Hattori , R. J. Xavier , K. Atarashi , K. Honda , Nature 2019, 565, 600.30675064, T. Tanoue , S. Morita , D. R. Plichta , A. N. Skelly , W. Suda , Y. Sugiura , S. Narushima , H. Vlamakis , I. Motoo , K. Sugita , A. Shiota , K. Takeshita , K. Yasuma‐Mitobe , D. Riethmacher , T. Kaisho , J. M. Norman , D. Mucida , M. Suematsu , T. Yaguchi , V. Bucci , T. Inoue , Y. Kawakami , B. Olle , B. Roberts , M. Hattori , R. J. Xavier , K. Atarashi , K. Honda , Nature 2019, 565, 600.30675064
Romain Daillère, Marie Vetizou, N. Waldschmitt, T. Yamazaki, C. Isnard, V. poirier-colame, Connie Duong, C. Flament, P. Lepage, M. Roberti, B. Routy, N. Jacquelot, L. Apetoh, S. Becharef, S. Rusakiewicz, P. Langella, H. Sokol, G. Kroemer, D. Enot, A. Roux, A. Eggermont, E. Tartour, L. Johannes, P. Woerther, E. Chachaty, J. Soria, E. Golden, S. Formenti, M. Plebanski, M. Madondo, P. Rosenstiel, D. Raoult, V. Cattoir, I. Boneca, M. Chamaillard, L. Zitvogel (2016)
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.
Immunity, 45 4
I. Sobhani, H. Rotkopf, K. Khazaie (2020)
Bacteria-related changes in host DNA methylation and the risk for CRC
Gut Microbes, 12
Q. Feng, Suisha Liang, Huijue Jia, A. Stadlmayr, Longqing Tang, Zhou Lan, Dongya Zhang, Huihua Xia, Xiaoying Xu, Zhuye Jie, L. Su, Xiaoping Li, Xin Li, Junhua Li, L. Xiao, U. Huber-Schönauer, D. Niederseer, Xun Xu, J. Al-Aama, H. Yang, Jian Wang, K. Kristiansen, Manimozhiyan Arumugam, H. Tilg, C. Datz, Jun Wang (2015)
Gut microbiome development along the colorectal adenoma–carcinoma sequence
Nature Communications, 6
S. Bullman, C. Pedamallu, E. Sicinska, T. Clancy, Xiaoyang Zhang, D. Cai, D. Neuberg, Katherine Huang, F. Guevara, T. Nelson, Otari Chipashvili, Timothy Hagan, M. Walker, A. Ramachandran, B. Diosdado, G. Serna, N. Mulet, S. Landolfi, S. Cajal, R. Fasani, A. Aguirre, K. Ng, E. Élez, S. Ogino, J. Tabernero, C. Fuchs, W. Hahn, P. Nuciforo, M. Meyerson (2017)
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Science, 358
Jie Zhou, Mingjie Liu, Yonggong Zhai, W. Xie (2008)
The antiapoptotic role of pregnane X receptor in human colon cancer cells.
Molecular endocrinology, 22 4
(2017)
Signal Transduction Targeted Ther. 2021, 6, 398; c)
T. Kühn, M. Stepien, M. López-Nogueroles, A. Damms-Machado, D. Sookthai, T. Johnson, M. Roca, A. Hüsing, S. Maldonado, A. Cross, N. Murphy, H. Freisling, S. Rinaldi, A. Scalbert, V. Fedirko, G. Severi, M. Boutron‐Ruault, F. Mancini, Solomon Sowah, H. Boeing, P. Jakszyn, María-José Sánchez, S. Merino, S. Colorado-Yohar, A. Barricarte, K. Khaw, Julie Schmidt, A. Perez-Cornago, A. Trichopoulou, A. Karakatsani, P. Thriskos, D. Palli, C. Agnoli, R. Tumino, C. Sacerdote, S. Panico, B. Bueno-de-Mesquita, C. Gils, A. Heath, M. Gunter, E. Riboli, A. Lahoz, M. Jenab, R. Kaaks (2019)
Pre-diagnostic plasma bile acid levels and colon cancer risk: A prospective study.
Journal of the National Cancer Institute
A. Rauf, A. Khalil, U. Rahman, Ahood Khalid, S. Naz, M. Shariati, M. Rebezov, Ewaldo Urtecho, R. Albuquerque, Sirajudheen Anwar, Abdulwahab Alamri, R. Saini, Kannan Rengasamy (2021)
Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review
Critical Reviews in Food Science and Nutrition, 62
( A. C. Goodwin , C. E. Destefano Shields , S. Wu , D. L. Huso , X. Wu , T. R. Murray‐Stewart , A. Hacker‐Prietz , S. Rabizadeh , P. M. Woster , C. L. Sears , R. A. Casero Jr , Proc. Natl. Acad. Sci. USA 2011, 108, 15354.21876161)
A. C. Goodwin , C. E. Destefano Shields , S. Wu , D. L. Huso , X. Wu , T. R. Murray‐Stewart , A. Hacker‐Prietz , S. Rabizadeh , P. M. Woster , C. L. Sears , R. A. Casero Jr , Proc. Natl. Acad. Sci. USA 2011, 108, 15354.21876161
A. C. Goodwin , C. E. Destefano Shields , S. Wu , D. L. Huso , X. Wu , T. R. Murray‐Stewart , A. Hacker‐Prietz , S. Rabizadeh , P. M. Woster , C. L. Sears , R. A. Casero Jr , Proc. Natl. Acad. Sci. USA 2011, 108, 15354.21876161, A. C. Goodwin , C. E. Destefano Shields , S. Wu , D. L. Huso , X. Wu , T. R. Murray‐Stewart , A. Hacker‐Prietz , S. Rabizadeh , P. M. Woster , C. L. Sears , R. A. Casero Jr , Proc. Natl. Acad. Sci. USA 2011, 108, 15354.21876161
( S. M. Man , Q. Zhu , L. Zhu , Z. Liu , R. Karki , A. Malik , D. Sharma , L. Li , R. K. Malireddi , P. Gurung , G. Neale , S. R. Olsen , R. A. Carter , D. J. McGoldrick , G. Wu , D. Finkelstein , P. Vogel , R. J. Gilbertson , T. D. Kanneganti , Cell 2015, 162, 45.26095253)
S. M. Man , Q. Zhu , L. Zhu , Z. Liu , R. Karki , A. Malik , D. Sharma , L. Li , R. K. Malireddi , P. Gurung , G. Neale , S. R. Olsen , R. A. Carter , D. J. McGoldrick , G. Wu , D. Finkelstein , P. Vogel , R. J. Gilbertson , T. D. Kanneganti , Cell 2015, 162, 45.26095253
S. M. Man , Q. Zhu , L. Zhu , Z. Liu , R. Karki , A. Malik , D. Sharma , L. Li , R. K. Malireddi , P. Gurung , G. Neale , S. R. Olsen , R. A. Carter , D. J. McGoldrick , G. Wu , D. Finkelstein , P. Vogel , R. J. Gilbertson , T. D. Kanneganti , Cell 2015, 162, 45.26095253, S. M. Man , Q. Zhu , L. Zhu , Z. Liu , R. Karki , A. Malik , D. Sharma , L. Li , R. K. Malireddi , P. Gurung , G. Neale , S. R. Olsen , R. A. Carter , D. J. McGoldrick , G. Wu , D. Finkelstein , P. Vogel , R. J. Gilbertson , T. D. Kanneganti , Cell 2015, 162, 45.26095253
Juanjuan Li, Weiliang Hou, Sisi Lin, Lu Wang, Chao Pan, Feng Wu, Jinyao Liu (2021)
Polydopamine Nanoparticle‐Mediated Dopaminergic Immunoregulation in Colitis
Advanced Science, 9
Peng Liu, Caifang Gao, Hongguo Chen, C. Vong, Xu Wu, Xudong Tang, Shengpeng Wang, Yitao Wang (2020)
Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies
Acta Pharmaceutica Sinica. B, 11
B. Routy, E. Chatelier, L. Derosa, Connie Duong, M. Alou, Romain Daillère, A. Fluckiger, M. Messaoudene, C. Rauber, M. Roberti, Marine Fidelle, C. Flament, V. poirier-colame, P. Opolon, C. Klein, Kristina Iribarren, L. Mondragón, N. Jacquelot, B. Qu, Gladys Ferrere, C. Clémenson, L. Mezquita, J. Masip, C. Naltet, S. Brosseau, C. Kaderbhai, C. Richard, H. Rizvi, F. Levenez, N. Galleron, B. Quinquis, N. Pons, B. Ryffel, V. Minard-Colin, P. Gonin, J. Soria, E. Deutsch, Y. Loriot, F. Ghiringhelli, G. Zalcman, F. Goldwasser, B. Escudier, M. Hellmann, A. Eggermont, D. Raoult, L. Albiges, G. Kroemer, L. Zitvogel (2018)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Science, 359
S. Sinha, Yeneneh Haileselassie, L. Nguyen, C. Tropini, Min Wang, L. Becker, Davis Sim, Karolin Jarr, Estelle Spear, Gulshan Singh, H. Namkoong, K. Bittinger, M. Fischbach, J. Sonnenburg, Aida Habtezion (2020)
Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation.
Cell host & microbe
( C. Gur , Y. Ibrahim , B. Isaacson , R. Yamin , J. Abed , M. Gamliel , J. Enk , Y. Bar‐On , N. Stanietsky‐Kaynan , S. Coppenhagen‐Glazer , N. Shussman , G. Almogy , A. Cuapio , E. Hofer , D. Mevorach , A. Tabib , R. Ortenberg , G. Markel , K. Miklić , S. Jonjic , C. A. Brennan , W. S. Garrett , G. Bachrach , O. Mandelboim , Immunity 2015, 42, 344.25680274)
C. Gur , Y. Ibrahim , B. Isaacson , R. Yamin , J. Abed , M. Gamliel , J. Enk , Y. Bar‐On , N. Stanietsky‐Kaynan , S. Coppenhagen‐Glazer , N. Shussman , G. Almogy , A. Cuapio , E. Hofer , D. Mevorach , A. Tabib , R. Ortenberg , G. Markel , K. Miklić , S. Jonjic , C. A. Brennan , W. S. Garrett , G. Bachrach , O. Mandelboim , Immunity 2015, 42, 344.25680274
C. Gur , Y. Ibrahim , B. Isaacson , R. Yamin , J. Abed , M. Gamliel , J. Enk , Y. Bar‐On , N. Stanietsky‐Kaynan , S. Coppenhagen‐Glazer , N. Shussman , G. Almogy , A. Cuapio , E. Hofer , D. Mevorach , A. Tabib , R. Ortenberg , G. Markel , K. Miklić , S. Jonjic , C. A. Brennan , W. S. Garrett , G. Bachrach , O. Mandelboim , Immunity 2015, 42, 344.25680274, C. Gur , Y. Ibrahim , B. Isaacson , R. Yamin , J. Abed , M. Gamliel , J. Enk , Y. Bar‐On , N. Stanietsky‐Kaynan , S. Coppenhagen‐Glazer , N. Shussman , G. Almogy , A. Cuapio , E. Hofer , D. Mevorach , A. Tabib , R. Ortenberg , G. Markel , K. Miklić , S. Jonjic , C. A. Brennan , W. S. Garrett , G. Bachrach , O. Mandelboim , Immunity 2015, 42, 344.25680274
Baoyi Guan, Jinlin Tong, Haiping Hao, Zhixu Yang, Keji Chen, Hao Xu, Anlu Wang (2021)
Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases
Acta Pharmaceutica Sinica. B, 12
S. Heilbronner, B. Krismer, H. Brötz-Oesterhelt, A. Peschel (2021)
The microbiome-shaping roles of bacteriocins
Nature Reviews Microbiology, 19
Songhe Guo, Linfang Li, Banglao Xu, Manghui Li, Qiuyao Zeng, Han Xiao, Ying Xue, Yixian Wu, Yidan Wang, Wanli Liu, Ge Zhang (2018)
A Simple and Novel Fecal Biomarker for Colorectal Cancer: Ratio of Fusobacterium Nucleatum to Probiotics Populations, Based on Their Antagonistic Effect.
Clinical chemistry, 64 9
( W. R. Russell , L. Hoyles , H. J. Flint , M. E. Dumas , Curr. Opin. Microbiol. 2013, 16, 246.23880135)
W. R. Russell , L. Hoyles , H. J. Flint , M. E. Dumas , Curr. Opin. Microbiol. 2013, 16, 246.23880135
W. R. Russell , L. Hoyles , H. J. Flint , M. E. Dumas , Curr. Opin. Microbiol. 2013, 16, 246.23880135, W. R. Russell , L. Hoyles , H. J. Flint , M. E. Dumas , Curr. Opin. Microbiol. 2013, 16, 246.23880135
(2016)
, 69. © 2023 The Authors
( K. Kingwell , Nat. Rev. Drug Discovery 2015, 14, 515.26228748)
K. Kingwell , Nat. Rev. Drug Discovery 2015, 14, 515.26228748
K. Kingwell , Nat. Rev. Drug Discovery 2015, 14, 515.26228748, K. Kingwell , Nat. Rev. Drug Discovery 2015, 14, 515.26228748
T. Fu, Sally Coulter, E. Yoshihara, Tae Oh, S. Fang, Fritz Cayabyab, Qiyun Zhu, Tong Zhang, Mathias Leblanc, Sihao Liu, Mingxiao He, W. Waizenegger, Emanuel Gasser, B. Schnabl, A. Atkins, R. Yu, R. Knight, C. Liddle, M. Downes, R. Evans (2019)
FXR Regulates Intestinal Cancer Stem Cell Proliferation
Cell, 176
M. Taranto, G. Pérez-Martínez, G. Valdez (2006)
Effect of bile acid on the cell membrane functionality of lactic acid bacteria for oral administration.
Research in microbiology, 157 8
( S. H. Wong , L. Zhao , X. Zhang , G. Nakatsu , J. Han , W. Xu , X. Xiao , T. N. Y. Kwong , H. Tsoi , W. K. K. Wu , B. Zeng , F. K. L. Chan , J. J. Y. Sung , H. Wei , J. Yu , Gastroenterology 2017, 153, 1621.28823860)
S. H. Wong , L. Zhao , X. Zhang , G. Nakatsu , J. Han , W. Xu , X. Xiao , T. N. Y. Kwong , H. Tsoi , W. K. K. Wu , B. Zeng , F. K. L. Chan , J. J. Y. Sung , H. Wei , J. Yu , Gastroenterology 2017, 153, 1621.28823860
S. H. Wong , L. Zhao , X. Zhang , G. Nakatsu , J. Han , W. Xu , X. Xiao , T. N. Y. Kwong , H. Tsoi , W. K. K. Wu , B. Zeng , F. K. L. Chan , J. J. Y. Sung , H. Wei , J. Yu , Gastroenterology 2017, 153, 1621.28823860, S. H. Wong , L. Zhao , X. Zhang , G. Nakatsu , J. Han , W. Xu , X. Xiao , T. N. Y. Kwong , H. Tsoi , W. K. K. Wu , B. Zeng , F. K. L. Chan , J. J. Y. Sung , H. Wei , J. Yu , Gastroenterology 2017, 153, 1621.28823860
L. Aymeric, F. Donnadieu, Céline Mulet, L. Merle, G. Nigro, A. Saffarian, M. Bérard, C. Poyart, S. Robine, B. Regnault, P. Trieu-Cuot, P. Sansonetti, S. Dramsi (2017)
Colorectal cancer specific conditions promote Streptococcus gallolyticus gut colonization
Proceedings of the National Academy of Sciences, 115
( T. Y. Ryu , K. Kim , T. S. Han , M. O. Lee , J. Lee , J. Choi , K. B. Jung , E. J. Jeong , D. M. An , C. R. Jung , J. H. Lim , J. Jung , K. Park , M. S. Lee , M. Y. Kim , S. J. Oh , K. Hur , R. Hamamoto , D. S. Park , D. S. Kim , M. Y. Son , H. S. Cho , ISME J. 2022, 16, 1205.34972816)
T. Y. Ryu , K. Kim , T. S. Han , M. O. Lee , J. Lee , J. Choi , K. B. Jung , E. J. Jeong , D. M. An , C. R. Jung , J. H. Lim , J. Jung , K. Park , M. S. Lee , M. Y. Kim , S. J. Oh , K. Hur , R. Hamamoto , D. S. Park , D. S. Kim , M. Y. Son , H. S. Cho , ISME J. 2022, 16, 1205.34972816
T. Y. Ryu , K. Kim , T. S. Han , M. O. Lee , J. Lee , J. Choi , K. B. Jung , E. J. Jeong , D. M. An , C. R. Jung , J. H. Lim , J. Jung , K. Park , M. S. Lee , M. Y. Kim , S. J. Oh , K. Hur , R. Hamamoto , D. S. Park , D. S. Kim , M. Y. Son , H. S. Cho , ISME J. 2022, 16, 1205.34972816, T. Y. Ryu , K. Kim , T. S. Han , M. O. Lee , J. Lee , J. Choi , K. B. Jung , E. J. Jeong , D. M. An , C. R. Jung , J. H. Lim , J. Jung , K. Park , M. S. Lee , M. Y. Kim , S. J. Oh , K. Hur , R. Hamamoto , D. S. Park , D. S. Kim , M. Y. Son , H. S. Cho , ISME J. 2022, 16, 1205.34972816
M. Mutignani, R. Penagini, G. Gargari, S. Guglielmetti, M. Cintolo, A. Airoldi, Pierfrancesco Leone, P. Carnevali, C. Ciafardini, Giulio Petrocelli, F. Mascaretti, B. Oreggia, L. Dioscoridi, F. Cavalcoli, M. Primignani, F. Pugliese, P. Bertuccio, P. Soru, C. Magistro, G. Ferrari, M. Speciani, G. Bonato, M. Bini, P. Cantù, F. Caprioli, M. Vangeli, E. Forti, S. Mazza, G. Tosetti, Rossella Bonzi, M. Vecchi, C. Vecchia, M. Rossi (2021)
Blood Bacterial DNA Load and Profiling Differ in Colorectal Cancer Patients Compared to Tumor-Free Controls
Cancers, 13
J. Carethers (2020)
Fecal DNA Testing for Colorectal Cancer Screening.
Annual review of medicine
A. Sivan, L. Corrales, N. Hubert, Jason Williams, K. Aquino-Michaels, Z. Earley, Franco Benyamin, Yuk Lei, B. Jabri, M. Alegre, E. Chang, T. Gajewski (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Science, 350
( M. K. Stoeva , J. Garcia‐So , N. Justice , J. Myers , S. Tyagi , M. Nemchek , P. J. McMurdie , O. Kolterman , J. Eid , Gut Microbes 2021, 13, 1.)
M. K. Stoeva , J. Garcia‐So , N. Justice , J. Myers , S. Tyagi , M. Nemchek , P. J. McMurdie , O. Kolterman , J. Eid , Gut Microbes 2021, 13, 1.
M. K. Stoeva , J. Garcia‐So , N. Justice , J. Myers , S. Tyagi , M. Nemchek , P. J. McMurdie , O. Kolterman , J. Eid , Gut Microbes 2021, 13, 1., M. K. Stoeva , J. Garcia‐So , N. Justice , J. Myers , S. Tyagi , M. Nemchek , P. J. McMurdie , O. Kolterman , J. Eid , Gut Microbes 2021, 13, 1.
( S. Kommineni , D. J. Bretl , V. Lam , R. Chakraborty , M. Hayward , P. Simpson , Y. Cao , P. Bousounis , C. J. Kristich , N. H. Salzman , Nature 2015, 526, 719.26479034)
S. Kommineni , D. J. Bretl , V. Lam , R. Chakraborty , M. Hayward , P. Simpson , Y. Cao , P. Bousounis , C. J. Kristich , N. H. Salzman , Nature 2015, 526, 719.26479034
S. Kommineni , D. J. Bretl , V. Lam , R. Chakraborty , M. Hayward , P. Simpson , Y. Cao , P. Bousounis , C. J. Kristich , N. H. Salzman , Nature 2015, 526, 719.26479034, S. Kommineni , D. J. Bretl , V. Lam , R. Chakraborty , M. Hayward , P. Simpson , Y. Cao , P. Bousounis , C. J. Kristich , N. H. Salzman , Nature 2015, 526, 719.26479034
Hannah Bell, Ryan Rebernick, J. Goyert, Rashi Singhal, Miljan Kuljanin, S. Kerk, Wesley Huang, Nupur Das, A. Andren, Sumeet Solanki, Shannon Miller, P. Todd, E. Fearon, C. Lyssiotis, S. Gygi, J. Mancias, Y. Shah (2021)
Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance.
Cancer cell
Manasi Shah, T. DeSantis, Jose-Miguel Yamal, T. Weir, E. Ryan, J. Cope, E. Hollister (2018)
Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer
PLoS ONE, 13
L. Zitvogel, Yuting Ma, D. Raoult, G. Kroemer, T. Gajewski (2018)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Science, 359
Dylan Dodd, M. Spitzer, W. Treuren, Bryan Merrill, A. Hryckowian, S. Higginbottom, Anthony Le, T. Cowan, G. Nolan, M. Fischbach, J. Sonnenburg (2017)
A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites
Nature, 551
Sushma Kommineni, Daniel Bretl, Vy Lam, Rajrupa Chakraborty, Michael Hayward, P. Simpson, Yumei Cao, Pavlos Bousounis, C. Kristich, N. Salzman (2015)
Bacteriocin production augments niche competition by enterococci in the mammalian GI tract
Nature, 526
( S. C. Wei , C. R. Duffy , J. P. Allison , Cancer Discovery 2018, 8, 1069.30115704)
S. C. Wei , C. R. Duffy , J. P. Allison , Cancer Discovery 2018, 8, 1069.30115704
S. C. Wei , C. R. Duffy , J. P. Allison , Cancer Discovery 2018, 8, 1069.30115704, S. C. Wei , C. R. Duffy , J. P. Allison , Cancer Discovery 2018, 8, 1069.30115704
A. Christ, M. Lauterbach, E. Latz (2019)
Western Diet and the Immune System: An Inflammatory Connection.
Immunity, 51 5
Xiaoxue Wang, Jianping Wang, B. Rao, Li Deng (2017)
Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals
Experimental and Therapeutic Medicine, 13
Shaoguang Wu, Ki-Jong Rhee, E. Albesiano, S. Rabizadeh, Xinqun Wu, Hung-Rong Yen, D. Huso, F. Brancati, E. Wick, F. McAllister, F. Housseau, D. Pardoll, C. Sears (2009)
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses
Nature Medicine, 15
G. D'Haens, C. Jobin (2019)
Fecal Microbial Transplantation For Diseases Beyond Recurrent Clostridium Difficile Infection.
Gastroenterology
( Y. S. Chen , J. Li , R. Menon , A. Jayaraman , K. Lee , Y. Huang , W. M. Dashwood , K. Zhang , D. Sun , R. H. Dashwood , Gut Microbes 2021, 13, 1972756.34494932)
Y. S. Chen , J. Li , R. Menon , A. Jayaraman , K. Lee , Y. Huang , W. M. Dashwood , K. Zhang , D. Sun , R. H. Dashwood , Gut Microbes 2021, 13, 1972756.34494932
Y. S. Chen , J. Li , R. Menon , A. Jayaraman , K. Lee , Y. Huang , W. M. Dashwood , K. Zhang , D. Sun , R. H. Dashwood , Gut Microbes 2021, 13, 1972756.34494932, Y. S. Chen , J. Li , R. Menon , A. Jayaraman , K. Lee , Y. Huang , W. M. Dashwood , K. Zhang , D. Sun , R. H. Dashwood , Gut Microbes 2021, 13, 1972756.34494932
Carola Bücher, J. Burtscher, K. Domig (2021)
Propionic acid bacteria in the food industry: An update on essential traits and detection methods.
Comprehensive reviews in food science and food safety
( B. Lauby‐Secretan , N. Vilahur , F. Bianchini , N. Guha , K. Straif , N. Engl. J. Med. 2018, 378, 1734.29580179)
B. Lauby‐Secretan , N. Vilahur , F. Bianchini , N. Guha , K. Straif , N. Engl. J. Med. 2018, 378, 1734.29580179
B. Lauby‐Secretan , N. Vilahur , F. Bianchini , N. Guha , K. Straif , N. Engl. J. Med. 2018, 378, 1734.29580179, B. Lauby‐Secretan , N. Vilahur , F. Bianchini , N. Guha , K. Straif , N. Engl. J. Med. 2018, 378, 1734.29580179
( T. T. Nguyen , S. Lian , T. T. Ung , Y. Xia , J. Y. Han , Y. D. Jung , J. Cell. Biochem. 2017, 118, 2958.28247965)
T. T. Nguyen , S. Lian , T. T. Ung , Y. Xia , J. Y. Han , Y. D. Jung , J. Cell. Biochem. 2017, 118, 2958.28247965
T. T. Nguyen , S. Lian , T. T. Ung , Y. Xia , J. Y. Han , Y. D. Jung , J. Cell. Biochem. 2017, 118, 2958.28247965, T. T. Nguyen , S. Lian , T. T. Ung , Y. Xia , J. Y. Han , Y. D. Jung , J. Cell. Biochem. 2017, 118, 2958.28247965
( S. S. M. Lu , Z. Mohammed , C. Häggström , R. Myte , E. Lindquist , Å. Gylfe , B. Van Guelpen , S. Harlid , J Natl Cancer Inst 2021, 114, 38.)
S. S. M. Lu , Z. Mohammed , C. Häggström , R. Myte , E. Lindquist , Å. Gylfe , B. Van Guelpen , S. Harlid , J Natl Cancer Inst 2021, 114, 38.
S. S. M. Lu , Z. Mohammed , C. Häggström , R. Myte , E. Lindquist , Å. Gylfe , B. Van Guelpen , S. Harlid , J Natl Cancer Inst 2021, 114, 38., S. S. M. Lu , Z. Mohammed , C. Häggström , R. Myte , E. Lindquist , Å. Gylfe , B. Van Guelpen , S. Harlid , J Natl Cancer Inst 2021, 114, 38.
Ruize Qu, Yanpeng Ma, L. Tao, X. Bao, Xin Zhou, Bingyan Wang, Fei Li, Siyi Lu, Lin Tuo, S. Zhan, Zhipeng Zhang, W. Fu (2021)
Features of colorectal cancer in China stratified by anatomic sites: A hospital-based study conducted in university-affiliated hospitals from 2014 to 2018
Chinese Journal of Cancer Research, 33
G. Gibson, R. Hutkins, M. Sanders, S. Prescott, R. Reimer, S. Salminen, K. Scott, C. Stanton, K. Swanson, Patrice Cani, K. Verbeke, G. Reid (2017)
Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics
Nature Reviews Gastroenterology &Hepatology, 14
( Z. T. Shakour , N. G. Shehab , A. S. Gomaa , L. A. Wessjohann , M. A. Farag , Biotechnol. Adv. 2022, 54, 107784.34102260)
Z. T. Shakour , N. G. Shehab , A. S. Gomaa , L. A. Wessjohann , M. A. Farag , Biotechnol. Adv. 2022, 54, 107784.34102260
Z. T. Shakour , N. G. Shehab , A. S. Gomaa , L. A. Wessjohann , M. A. Farag , Biotechnol. Adv. 2022, 54, 107784.34102260, Z. T. Shakour , N. G. Shehab , A. S. Gomaa , L. A. Wessjohann , M. A. Farag , Biotechnol. Adv. 2022, 54, 107784.34102260
A. Frankel, Laura Coughlin, Jiwoong Kim, T. Froehlich, Yang Xie, E. Frenkel, A. Koh (2017)
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients1
Neoplasia (New York, N.Y.), 19
J. Pitt, Marie Vetizou, Romain Daillère, M. Roberti, T. Yamazaki, B. Routy, P. Lepage, I. Boneca, M. Chamaillard, G. Kroemer, L. Zitvogel (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Immunity, 44 6
( J. Yang , H. Wei , Y. Zhou , C. H. Szeto , C. Li , Y. Lin , O. O. Coker , H. C. H. Lau , A. W. H. Chan , J. J. Y. Sung , J. Yu , Gastroenterology 2021, 162, 135.34461052)
J. Yang , H. Wei , Y. Zhou , C. H. Szeto , C. Li , Y. Lin , O. O. Coker , H. C. H. Lau , A. W. H. Chan , J. J. Y. Sung , J. Yu , Gastroenterology 2021, 162, 135.34461052
J. Yang , H. Wei , Y. Zhou , C. H. Szeto , C. Li , Y. Lin , O. O. Coker , H. C. H. Lau , A. W. H. Chan , J. J. Y. Sung , J. Yu , Gastroenterology 2021, 162, 135.34461052, J. Yang , H. Wei , Y. Zhou , C. H. Szeto , C. Li , Y. Lin , O. O. Coker , H. C. H. Lau , A. W. H. Chan , J. J. Y. Sung , J. Yu , Gastroenterology 2021, 162, 135.34461052
( E. R. Cobo , V. Kissoon‐Singh , F. Moreau , R. Holani , K. Chadee , Infect. Immun. 2017, 85.)
E. R. Cobo , V. Kissoon‐Singh , F. Moreau , R. Holani , K. Chadee , Infect. Immun. 2017, 85.
E. R. Cobo , V. Kissoon‐Singh , F. Moreau , R. Holani , K. Chadee , Infect. Immun. 2017, 85., E. R. Cobo , V. Kissoon‐Singh , F. Moreau , R. Holani , K. Chadee , Infect. Immun. 2017, 85.
( A. D. Kostic , E. Chun , L. Robertson , J. N. Glickman , C. A. Gallini , M. Michaud , T. E. Clancy , D. C. Chung , P. Lochhead , G. L. Hold , E. M. El‐Omar , D. Brenner , C. S. Fuchs , M. Meyerson , W. S. Garrett , Cell Host Microbe 2013, 14, 207.23954159)
A. D. Kostic , E. Chun , L. Robertson , J. N. Glickman , C. A. Gallini , M. Michaud , T. E. Clancy , D. C. Chung , P. Lochhead , G. L. Hold , E. M. El‐Omar , D. Brenner , C. S. Fuchs , M. Meyerson , W. S. Garrett , Cell Host Microbe 2013, 14, 207.23954159
A. D. Kostic , E. Chun , L. Robertson , J. N. Glickman , C. A. Gallini , M. Michaud , T. E. Clancy , D. C. Chung , P. Lochhead , G. L. Hold , E. M. El‐Omar , D. Brenner , C. S. Fuchs , M. Meyerson , W. S. Garrett , Cell Host Microbe 2013, 14, 207.23954159, A. D. Kostic , E. Chun , L. Robertson , J. N. Glickman , C. A. Gallini , M. Michaud , T. E. Clancy , D. C. Chung , P. Lochhead , G. L. Hold , E. M. El‐Omar , D. Brenner , C. S. Fuchs , M. Meyerson , W. S. Garrett , Cell Host Microbe 2013, 14, 207.23954159
L. Farhana, P. Nangia-Makker, Evan Arbit, K. Shango, Sarah Sarkar, Hamidah Mahmud, T. Hadden, Yingjie Yu, A. Majumdar (2016)
Bile acid: a potential inducer of colon cancer stem cells
Stem Cell Research & Therapy, 7
S. Ogino, A. Chan, C. Fuchs, E. Giovannucci (2010)
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field
Gut, 60
( G. D. Hannigan , M. B. Duhaime , M. T. t. Ruffin , C. C. Koumpouras , P. D. Schloss , mBio 2018, 9, 02248.)
G. D. Hannigan , M. B. Duhaime , M. T. t. Ruffin , C. C. Koumpouras , P. D. Schloss , mBio 2018, 9, 02248.
G. D. Hannigan , M. B. Duhaime , M. T. t. Ruffin , C. C. Koumpouras , P. D. Schloss , mBio 2018, 9, 02248., G. D. Hannigan , M. B. Duhaime , M. T. t. Ruffin , C. C. Koumpouras , P. D. Schloss , mBio 2018, 9, 02248.
A. Kostic, Eunyoung Chun, Lauren Robertson, J. Glickman, C. Gallini, M. Michaud, T. Clancy, D. Chung, P. Lochhead, G. Hold, E. El-Omar, D. Brenner, C. Fuchs, M. Meyerson, W. Garrett (2013)
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
Cell host & microbe, 14 2
O. Coker, Geicho Nakatsu, R. Dai, W. Wu, S. Wong, S. Ng, F. Chan, J. Sung, Jun Yu (2018)
Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer
Gut, 68
( R. Jalandra , N. Dalal , A. K. Yadav , D. Verma , M. Sharma , R. Singh , A. Khosla , A. Kumar , P. R. Solanki , Appl. Microbiol. Biotechnol. 2021, 105, 7651.34568962)
R. Jalandra , N. Dalal , A. K. Yadav , D. Verma , M. Sharma , R. Singh , A. Khosla , A. Kumar , P. R. Solanki , Appl. Microbiol. Biotechnol. 2021, 105, 7651.34568962
R. Jalandra , N. Dalal , A. K. Yadav , D. Verma , M. Sharma , R. Singh , A. Khosla , A. Kumar , P. R. Solanki , Appl. Microbiol. Biotechnol. 2021, 105, 7651.34568962, R. Jalandra , N. Dalal , A. K. Yadav , D. Verma , M. Sharma , R. Singh , A. Khosla , A. Kumar , P. R. Solanki , Appl. Microbiol. Biotechnol. 2021, 105, 7651.34568962
N. Ijssennagger, C. Belzer, G. Hooiveld, J. Dekker, S. Mil, Michael Müller, M. Kleerebezem, R. Meer (2015)
Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon
Proceedings of the National Academy of Sciences, 112
T. Wilmanski, N. Rappaport, C. Diener, S. Gibbons, N. Price (2021)
From taxonomy to metabolic output: what factors define gut microbiome health?
Gut Microbes, 13
P. Arvind, E. Papavassiliou, G. Tsioulias, B. Duceman, C. Lovelace, W. Geng, L. Staiano‐Coico, B. Rigas (1994)
Lithocholic acid inhibits the expression of HLA class I genes in colon adenocarcinoma cells. Differential effect on HLA-A, -B and -C loci.
Molecular immunology, 31 8
(2018)
124, 244; b) E. Saus, S. Iraola-Guzmán
Xiaomin Liu, Xin Tong, Yuanqiang Zou, Xiaoqian Lin, Hui Zhao, Liu Tian, Zhuye Jie, Qi Wang, Zhe Zhang, Haorong Lu, L. Xiao, Xu-Wen Qiu, J. Zi, Rong Wang, Xun Xu, Huanming Yang, Jian Wang, Yang Zong, Weibin Liu, Yong Hou, Shida Zhu, Huijue Jia, Tao Zhang (2020)
Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome
Nature Genetics, 54
Yangqian Shi, Lingyu Meng, Chunlian Zhang, Fengmin Zhang, Yong Fang (2021)
Extracellular vesicles of Lacticaseibacillus paracasei PC-H1 induce colorectal cancer cells apoptosis via PDK1/AKT/Bcl-2 signaling pathway.
Microbiological research, 255
Kimberly Krautkramer, Jing Fan, F. Bäckhed (2020)
Gut microbial metabolites as multi-kingdom intermediates
Nature Reviews Microbiology, 19
(2020)
The Authors. Advanced Science published by Wiley-VCH GmbH 2205563
( O. O. Coker , C. Liu , W. K. K. Wu , S. H. Wong , W. Jia , J. J. Y. Sung , J. Yu , Microbiome 2022, 10, 35.35189961)
O. O. Coker , C. Liu , W. K. K. Wu , S. H. Wong , W. Jia , J. J. Y. Sung , J. Yu , Microbiome 2022, 10, 35.35189961
O. O. Coker , C. Liu , W. K. K. Wu , S. H. Wong , W. Jia , J. J. Y. Sung , J. Yu , Microbiome 2022, 10, 35.35189961, O. O. Coker , C. Liu , W. K. K. Wu , S. H. Wong , W. Jia , J. J. Y. Sung , J. Yu , Microbiome 2022, 10, 35.35189961
Inés Mármol, Cristina Sánchez-de-Diego, A. Dieste, E. Cerrada, M. Yoldi (2017)
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
International Journal of Molecular Sciences, 18
( Z. Dai , O. O. Coker , G. Nakatsu , W. K. K. Wu , L. Zhao , Z. Chen , F. K. L. Chan , K. Kristiansen , J. J. Y. Sung , S. H. Wong , J. Yu , Microbiome 2018, 6, 70.29642940)
Z. Dai , O. O. Coker , G. Nakatsu , W. K. K. Wu , L. Zhao , Z. Chen , F. K. L. Chan , K. Kristiansen , J. J. Y. Sung , S. H. Wong , J. Yu , Microbiome 2018, 6, 70.29642940
Z. Dai , O. O. Coker , G. Nakatsu , W. K. K. Wu , L. Zhao , Z. Chen , F. K. L. Chan , K. Kristiansen , J. J. Y. Sung , S. H. Wong , J. Yu , Microbiome 2018, 6, 70.29642940, Z. Dai , O. O. Coker , G. Nakatsu , W. K. K. Wu , L. Zhao , Z. Chen , F. K. L. Chan , K. Kristiansen , J. J. Y. Sung , S. H. Wong , J. Yu , Microbiome 2018, 6, 70.29642940
Nielson Baxter, C. Koumpouras, M. Rogers, M. Ruffin, P. Schloss (2016)
DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model
Microbiome, 4
T. Nguyen, S. Lian, Trong Ung, Yong Xia, J. Han, Y. Jung (2017)
Lithocholic Acid Stimulates IL‐8 Expression in Human Colorectal Cancer Cells Via Activation of Erk1/2 MAPK and Suppression of STAT3 Activity
Journal of Cellular Biochemistry, 118
J. Alexander, I. Wilson, J. Teare, J. Marchesi, J. Nicholson, J. Kinross (2017)
Gut microbiota modulation of chemotherapy efficacy and toxicity
Nature Reviews Gastroenterology &Hepatology, 14
C. Shields, S. Meerbeke, F. Housseau, Hao Wang, D. Huso, R. Casero, H. O’Hagan, C. Sears (2016)
Reduction of Murine Colon Tumorigenesis Driven by Enterotoxigenic Bacteroides fragilis Using Cefoxitin Treatment.
The Journal of infectious diseases, 214 1
Di Cheng, Jihao Xu, Jie-yao Li, Si-yi Wang, Ting-feng Wu, Qi-Kui Chen, Tao Yu (2018)
Butyrate ameliorated‐NLRC3 protects the intestinal barrier in a GPR43‐dependent manner
Experimental Cell Research, 368
M. Pichler, C. Yamada, Bashar Shuoker, Camila Alvarez-Silva, Aina Gotoh, M. Leth, E. Schoof, Toshihiko Katoh, Mikiyasu Sakanaka, T. Katayama, C. Jin, N. Karlsson, Manimozhiyan Arumugam, S. Fushinobu, M. Hachem (2020)
Butyrate producing colonic Clostridiales metabolise human milk oligosaccharides and cross feed on mucin via conserved pathways
Nature Communications, 11
A. García-González, Ashlyn Ritter, Shaleen Shrestha, Erik Andersen, L. Yilmaz, Albertha Walhout (2017)
Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics
Cell, 169
K. Daly, S. Shirazi-Beechey (2006)
Microarray analysis of butyrate regulated genes in colonic epithelial cells.
DNA and cell biology, 25 1
S. Yachida, Sayaka Mizutani, H. Shiroma, Satoshi Shiba, T. Nakajima, T. Sakamoto, Hikaru Watanabe, Keigo Masuda, Y. Nishimoto, Masaru Kubo, F. Hosoda, Hirofumi Rokutan, Minori Matsumoto, H. Takamaru, M. Yamada, T. Matsuda, M. Iwasaki, T. Yamaji, T. Yachida, T. Soga, K. Kurokawa, A. Toyoda, Yoshitoshi Ogura, Tetsuya Hayashi, M. Hatakeyama, H. Nakagama, Yutaka Saito, S. Fukuda, T. Shibata, Takuji Yamada (2019)
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
Nature Medicine, 25
Yuxia Yao, Xiangji Li, Baohong Xu, Lihan Luo, Qingdong Guo, Xingyu Wang, Lan Sun, Zheng Zhang, Peng Li (2022)
Cholecystectomy promotes colon carcinogenesis by activating the Wnt signaling pathway by increasing the deoxycholic acid level
Cell Communication and Signaling : CCS, 20
Yean Loke, M. Chew, Y. Ngeow, Wendy Lim, S. Peh (2020)
Colon Carcinogenesis: The Interplay Between Diet and Gut Microbiota
Frontiers in Cellular and Infection Microbiology, 10
K. Dubin, M. Callahan, Boyu Ren, R. Khanin, A. Viale, Lilan Ling, Daniel No, Asia Gobourne, E. Littmann, C. Huttenhower, E. Pamer, J. Wolchok (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Nature Communications, 7
, , (a) C. E. DeStefano Shields , S. W. Van Meerbeke , F. Housseau , H. Wang , D. L. Huso , R. A. Casero Jr , H. M. O'Hagan , C. L. Sears , J. Infect. Dis. 2016, 214, 122;26908749)
a) C. E. DeStefano Shields , S. W. Van Meerbeke , F. Housseau , H. Wang , D. L. Huso , R. A. Casero Jr , H. M. O'Hagan , C. L. Sears , J. Infect. Dis. 2016, 214, 122;26908749
a) C. E. DeStefano Shields , S. W. Van Meerbeke , F. Housseau , H. Wang , D. L. Huso , R. A. Casero Jr , H. M. O'Hagan , C. L. Sears , J. Infect. Dis. 2016, 214, 122;26908749, a) C. E. DeStefano Shields , S. W. Van Meerbeke , F. Housseau , H. Wang , D. L. Huso , R. A. Casero Jr , H. M. O'Hagan , C. L. Sears , J. Infect. Dis. 2016, 214, 122;26908749
Huan Zhang, Huanji Xu, Chenliang Zhang, Qiu-lin Tang, F. Bi (2021)
Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis
Cell Death Discovery, 7
S. Wong, Jun Yu (2019)
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Nature Reviews Gastroenterology & Hepatology
( M. R. Rubinstein , J. E. Baik , S. M. Lagana , R. P. Han , W. J. Raab , D. Sahoo , P. Dalerba , T. C. Wang , Y. W. Han , EMBO Rep. 2019, 20, 47638.)
M. R. Rubinstein , J. E. Baik , S. M. Lagana , R. P. Han , W. J. Raab , D. Sahoo , P. Dalerba , T. C. Wang , Y. W. Han , EMBO Rep. 2019, 20, 47638.
M. R. Rubinstein , J. E. Baik , S. M. Lagana , R. P. Han , W. J. Raab , D. Sahoo , P. Dalerba , T. C. Wang , Y. W. Han , EMBO Rep. 2019, 20, 47638., M. R. Rubinstein , J. E. Baik , S. M. Lagana , R. P. Han , W. J. Raab , D. Sahoo , P. Dalerba , T. C. Wang , Y. W. Han , EMBO Rep. 2019, 20, 47638.
R. Siegel, K. Miller, Ann Sauer, S. Fedewa, L. Butterly, Joseph Anderson, A. Cercek, Robert Smith, A. Jemal (2020)
Colorectal cancer statistics, 2020
CA: A Cancer Journal for Clinicians, 70
( A. R. Weingarden , B. P. Vaughn , Gut Microbes 2017, 8, 238.28609251)
A. R. Weingarden , B. P. Vaughn , Gut Microbes 2017, 8, 238.28609251
A. R. Weingarden , B. P. Vaughn , Gut Microbes 2017, 8, 238.28609251, A. R. Weingarden , B. P. Vaughn , Gut Microbes 2017, 8, 238.28609251
( F. M. Ruemmele , Ann. Nutr. Metab. 2016, 68, 33.27355913)
F. M. Ruemmele , Ann. Nutr. Metab. 2016, 68, 33.27355913
F. M. Ruemmele , Ann. Nutr. Metab. 2016, 68, 33.27355913, F. M. Ruemmele , Ann. Nutr. Metab. 2016, 68, 33.27355913
( I. Mármol , C. Sánchez‐de‐Diego , A. Pradilla Dieste , E. Cerrada , M. J. Rodriguez Yoldi , Int. J. Mol. Sci. 2017, 18, 197.28106826)
I. Mármol , C. Sánchez‐de‐Diego , A. Pradilla Dieste , E. Cerrada , M. J. Rodriguez Yoldi , Int. J. Mol. Sci. 2017, 18, 197.28106826
I. Mármol , C. Sánchez‐de‐Diego , A. Pradilla Dieste , E. Cerrada , M. J. Rodriguez Yoldi , Int. J. Mol. Sci. 2017, 18, 197.28106826, I. Mármol , C. Sánchez‐de‐Diego , A. Pradilla Dieste , E. Cerrada , M. J. Rodriguez Yoldi , Int. J. Mol. Sci. 2017, 18, 197.28106826
Jun Yu, Q. Feng, S. Wong, Dongya Zhang, Q. Liang, Youwen Qin, Longqing Tang, Hui Zhao, J. Stenvang, Yanling Li, Xiaokai Wang, Xiaoqiang Xu, N. Chen, W. Wu, J. Al-Aama, H. Nielsen, P. Kiilerich, B. Jensen, T. Yau, Zhou Lan, Huijue Jia, Junhua Li, L. Xiao, T. Lam, S. Ng, A. Cheng, V. Wong, F. Chan, Xun Xu, Huanming Yang, L. Madsen, C. Datz, H. Tilg, Jian Wang, N. Brünner, K. Kristiansen, Manimozhiyan Arumugam, J. Sung, Jun Wang (2015)
Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer
Gut, 66
Magdalena Stoeva, Jeewon Garcia-So, N. Justice, J. Myers, Surabhi Tyagi, Madeleine Nemchek, Paul McMurdie, O. Kolterman, J. Eid (2021)
Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease
Gut Microbes, 13
Meng Zhang, Yiwei Lai, V. Krupalnik, Pengcheng Guo, Xiangpeng Guo, Jianguo Zhou, Yan Xu, Zhijun Yu, Longqi Liu, Ao Jiang, Wenjuan Li, M. Abdul, Gang Ma, Na Li, Xiuling Fu, Yuan Lv, Mengling Jiang, M. Tariq, Shahzina Kanwal, Hao Liu, Xueting Xu, Hui Zhang, Yinghua Huang, Lulu Wang, Shuhan Chen, I. Babarinde, Zhiwei Luo, Dongye Wang, Tiantian Zhou, C. Ward, Minghui He, David Ibañez, Yunpan Li, Jiajian Zhou, Jie Yuan, Yayan Feng, Karthik Arumugam, U. Vicino, Xichen Bao, Guangming Wu, A. Schambach, Huating Wang, Hao Sun, F. Gao, Baoming Qin, A. Hutchins, B. Doble, C. Hartmann, M. Cosma, Yan Qin, Guo-Liang Xu, Runsheng Chen, G. Volpe, Liang Chen, J. Hanna, M. Esteban (2020)
β-Catenin safeguards the ground state of mousepluripotency by strengthening the robustness of the transcriptional apparatus
Science Advances, 6
L. Wilkinson (1891)
Immunity
The Indian Medical Gazette, 26
S. Nozari, Y. Faridvand, A. Etesami, M. Beiki, S. Mazrakhondi, J. Abdolalizadeh (2019)
Potential anticancer effects of cell wall protein fractions from Lactobacillus paracasei on human intestinal Caco‐2 cell line
Letters in Applied Microbiology, 69
( L. A. Bolte , A. Vich Vila , F. Imhann , V. Collij , R. Gacesa , V. Peters , C. Wijmenga , A. Kurilshikov , M. J. E. Campmans‐Kuijpers , J. Fu , G. Dijkstra , A. Zhernakova , R. K. Weersma , Gut 2021, 70, 1287.33811041)
L. A. Bolte , A. Vich Vila , F. Imhann , V. Collij , R. Gacesa , V. Peters , C. Wijmenga , A. Kurilshikov , M. J. E. Campmans‐Kuijpers , J. Fu , G. Dijkstra , A. Zhernakova , R. K. Weersma , Gut 2021, 70, 1287.33811041
L. A. Bolte , A. Vich Vila , F. Imhann , V. Collij , R. Gacesa , V. Peters , C. Wijmenga , A. Kurilshikov , M. J. E. Campmans‐Kuijpers , J. Fu , G. Dijkstra , A. Zhernakova , R. K. Weersma , Gut 2021, 70, 1287.33811041, L. A. Bolte , A. Vich Vila , F. Imhann , V. Collij , R. Gacesa , V. Peters , C. Wijmenga , A. Kurilshikov , M. J. E. Campmans‐Kuijpers , J. Fu , G. Dijkstra , A. Zhernakova , R. K. Weersma , Gut 2021, 70, 1287.33811041
( Q. Li , W. Hu , W. X. Liu , L. Y. Zhao , D. Huang , X. D. Liu , H. Chan , Y. Zhang , J. D. Zeng , O. O. Coker , W. Kang , S. S. M. Ng , L. Zhang , S. H. Wong , T. Gin , M. T. V. Chan , J. L. Wu , J. Yu , W. K. K. Wu , Gastroenterology 2021, 160, 1179.32920015)
Q. Li , W. Hu , W. X. Liu , L. Y. Zhao , D. Huang , X. D. Liu , H. Chan , Y. Zhang , J. D. Zeng , O. O. Coker , W. Kang , S. S. M. Ng , L. Zhang , S. H. Wong , T. Gin , M. T. V. Chan , J. L. Wu , J. Yu , W. K. K. Wu , Gastroenterology 2021, 160, 1179.32920015
Q. Li , W. Hu , W. X. Liu , L. Y. Zhao , D. Huang , X. D. Liu , H. Chan , Y. Zhang , J. D. Zeng , O. O. Coker , W. Kang , S. S. M. Ng , L. Zhang , S. H. Wong , T. Gin , M. T. V. Chan , J. L. Wu , J. Yu , W. K. K. Wu , Gastroenterology 2021, 160, 1179.32920015, Q. Li , W. Hu , W. X. Liu , L. Y. Zhao , D. Huang , X. D. Liu , H. Chan , Y. Zhang , J. D. Zeng , O. O. Coker , W. Kang , S. S. M. Ng , L. Zhang , S. H. Wong , T. Gin , M. T. V. Chan , J. L. Wu , J. Yu , W. K. K. Wu , Gastroenterology 2021, 160, 1179.32920015
Vyara Matson, Jessica Fessler, R. Bao, Tara Chongsuwat, Y. Zha, M. Alegre, J. Luke, T. Gajewski (2018)
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
Science, 359
Rachel Gao, C. Shearn, D. Orlicky, Kayla Battista, Erica Alexeev, Ian Cartwright, Jordi Lanis, Rachael Kostelecky, C. Ju, S. Colgan, B. Fennimore (2020)
Bile Acids Modulate Colonic MAdCAM-1 Expression in a Murine Model of Combined Cholestasis and Colitis
Mucosal immunology, 14
Nagendra Singh, Ashish Gurav, Sathish Sivaprakasam, E. Brady, Ravi Padia, Huidong Shi, M. Thangaraju, P. Prasad, S. Manicassamy, D. Munn, J. Lee, S. Offermanns, V. Ganapathy (2014)
Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis.
Immunity, 40 1
(2017)
PLoS Pathog
T. Ryu, Kwangho Kim, Tae-Su Han, Mi-Ok Lee, Jinkwon Lee, Jinhyeon Choi, Kwang Jung, E. Jeong, Dandan An, Cho-Rok Jung, J. Lim, Jaeeun Jung, Kunhyang Park, Moo-Seung Lee, Miyoung Kim, S. Oh, K. Hur, Ryuji Hamamoto, Doo-Sang Park, Dae-Soo Kim, M. Son, Hyun-Soo Cho (2022)
Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer
The ISME Journal, 16
B. Dalile, L. Oudenhove, B. Vervliet, K. Verbeke (2019)
The role of short-chain fatty acids in microbiota–gut–brain communication
Nature Reviews Gastroenterology & Hepatology
Weixin Liu, Xiang Zhang, Hongzhi Xu, Shengmian Li, H. Lau, Qiongyun Chen, B. Zhang, Liuyang Zhao, Huarong Chen, Joseph Sung, Jun Yu (2021)
Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis.
Gastroenterology
( Y. Zhang , Q. Wu , L. Xu , H. Wang , X. Liu , S. Li , T. Hu , Y. Liu , Q. Peng , Z. Chen , X. Wu , J. B. Fan , Clin. Epigenet. 2021, 13, 90.)
Y. Zhang , Q. Wu , L. Xu , H. Wang , X. Liu , S. Li , T. Hu , Y. Liu , Q. Peng , Z. Chen , X. Wu , J. B. Fan , Clin. Epigenet. 2021, 13, 90.
Y. Zhang , Q. Wu , L. Xu , H. Wang , X. Liu , S. Li , T. Hu , Y. Liu , Q. Peng , Z. Chen , X. Wu , J. B. Fan , Clin. Epigenet. 2021, 13, 90., Y. Zhang , Q. Wu , L. Xu , H. Wang , X. Liu , S. Li , T. Hu , Y. Liu , Q. Peng , Z. Chen , X. Wu , J. B. Fan , Clin. Epigenet. 2021, 13, 90.
J. Goc, Mengze Lv, N. Bessman, A. Flamar, S. Sahota, Hiroaki Suzuki, F. Teng, G. Putzel, G. Eberl, D. Withers, Janelle Arthur, Manish Shah, Gregory Sonnenberg (2021)
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Cell, 184
G. Kaiko, Stacy Ryu, Olivia Koues, P. Collins, L. Solnica-Krezel, E. Pearce, Erika Pearce, E. Oltz, T. Stappenbeck (2016)
The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites
Cell, 165
Yaohui Gao, Dexi Bi, Ru-ting Xie, Man Li, Jing Guo, Hu Liu, Xianling Guo, Jue-min Fang, T. Ding, Huiyuan Zhu, Yuan Cao, Meichun Xing, Jiayi Zheng, Qing Xu, Qian Xu, Q. Wei, H. Qin (2021)
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Signal Transduction and Targeted Therapy, 6
J. Yang, Hong Wei, Yunfei Zhou, C. Szeto, Chuangen Li, Yufeng Lin, O. Coker, H. Lau, A. Chan, J. Sung, Jun Yu (2020)
High-Fat Diet Promotes Colorectal Tumorigenesis through Modulating Gut Microbiota and Metabolites.
Gastroenterology
( P. J. Dziubańska‐Kusibab , H. Berger , F. Battistini , B. A. M. Bouwman , A. Iftekhar , R. Katainen , T. Cajuso , N. Crosetto , M. Orozco , L. A. Aaltonen , T. F. Meyer , Nat. Med. 2020, 26, 1063.32483361)
P. J. Dziubańska‐Kusibab , H. Berger , F. Battistini , B. A. M. Bouwman , A. Iftekhar , R. Katainen , T. Cajuso , N. Crosetto , M. Orozco , L. A. Aaltonen , T. F. Meyer , Nat. Med. 2020, 26, 1063.32483361
P. J. Dziubańska‐Kusibab , H. Berger , F. Battistini , B. A. M. Bouwman , A. Iftekhar , R. Katainen , T. Cajuso , N. Crosetto , M. Orozco , L. A. Aaltonen , T. F. Meyer , Nat. Med. 2020, 26, 1063.32483361, P. J. Dziubańska‐Kusibab , H. Berger , F. Battistini , B. A. M. Bouwman , A. Iftekhar , R. Katainen , T. Cajuso , N. Crosetto , M. Orozco , L. A. Aaltonen , T. F. Meyer , Nat. Med. 2020, 26, 1063.32483361
Noriho Iida, A. Dzutsev, C. Stewart, Loretta Smith, N. Bouladoux, R. Weingarten, D. Molina, R. Salcedo, T. Back, Sarah Cramer, Ren-Ming Dai, Hiu Kiu, M. Cardone, S. Naik, A. Patri, E. Wang, F. Marincola, F. Marincola, K. Frank, Y. Belkaid, G. Trinchieri, R. Goldszmid (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Science, 342
Wenjing Yang, Tianming Yu, Xiangsheng Huang, A. Bilotta, Leiqi Xu, Y. Lu, Jiaren Sun, F. Pan, Jia Zhou, Wenbo Zhang, Suxia Yao, Craig Maynard, Nagendra Singh, Sara Dann, Zhanju Liu, Y. Cong (2020)
Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity
Nature Communications, 11
( S. R. Sinha , Y. Haileselassie , L. P. Nguyen , C. Tropini , M. Wang , L. S. Becker , D. Sim , K. Jarr , E. T. Spear , G. Singh , H. Namkoong , K. Bittinger , M. A. Fischbach , J. L. Sonnenburg , A. Habtezion , Cell Host Microbe 2020, 27, 659.32101703)
S. R. Sinha , Y. Haileselassie , L. P. Nguyen , C. Tropini , M. Wang , L. S. Becker , D. Sim , K. Jarr , E. T. Spear , G. Singh , H. Namkoong , K. Bittinger , M. A. Fischbach , J. L. Sonnenburg , A. Habtezion , Cell Host Microbe 2020, 27, 659.32101703
S. R. Sinha , Y. Haileselassie , L. P. Nguyen , C. Tropini , M. Wang , L. S. Becker , D. Sim , K. Jarr , E. T. Spear , G. Singh , H. Namkoong , K. Bittinger , M. A. Fischbach , J. L. Sonnenburg , A. Habtezion , Cell Host Microbe 2020, 27, 659.32101703, S. R. Sinha , Y. Haileselassie , L. P. Nguyen , C. Tropini , M. Wang , L. S. Becker , D. Sim , K. Jarr , E. T. Spear , G. Singh , H. Namkoong , K. Bittinger , M. A. Fischbach , J. L. Sonnenburg , A. Habtezion , Cell Host Microbe 2020, 27, 659.32101703
( H. N. Bell , R. J. Rebernick , J. Goyert , R. Singhal , M. Kuljanin , S. A. Kerk , W. Huang , N. K. Das , A. Andren , S. Solanki , S. L. Miller , P. K. Todd , E. R. Fearon , C. A. Lyssiotis , S. P. Gygi , J. D. Mancias , Y. M. Shah , Cancer Cell 2021, 40, 185.34951957)
H. N. Bell , R. J. Rebernick , J. Goyert , R. Singhal , M. Kuljanin , S. A. Kerk , W. Huang , N. K. Das , A. Andren , S. Solanki , S. L. Miller , P. K. Todd , E. R. Fearon , C. A. Lyssiotis , S. P. Gygi , J. D. Mancias , Y. M. Shah , Cancer Cell 2021, 40, 185.34951957
H. N. Bell , R. J. Rebernick , J. Goyert , R. Singhal , M. Kuljanin , S. A. Kerk , W. Huang , N. K. Das , A. Andren , S. Solanki , S. L. Miller , P. K. Todd , E. R. Fearon , C. A. Lyssiotis , S. P. Gygi , J. D. Mancias , Y. M. Shah , Cancer Cell 2021, 40, 185.34951957, H. N. Bell , R. J. Rebernick , J. Goyert , R. Singhal , M. Kuljanin , S. A. Kerk , W. Huang , N. K. Das , A. Andren , S. Solanki , S. L. Miller , P. K. Todd , E. R. Fearon , C. A. Lyssiotis , S. P. Gygi , J. D. Mancias , Y. M. Shah , Cancer Cell 2021, 40, 185.34951957
( J. U. Peled , S. M. Devlin , A. Staffas , M. Lumish , R. Khanin , E. R. Littmann , L. Ling , S. Kosuri , M. Maloy , J. B. Slingerland , K. F. Ahr , K. A. Porosnicu Rodriguez , Y. Shono , A. E. Slingerland , M. D. Docampo , A. D. Sung , D. Weber , A. M. Alousi , B. Gyurkocza , D. M. Ponce , J. N. Barker , M. A. Perales , S. A. Giralt , Y. Taur , E. G. Pamer , R. R. Jenq , M. R. M. van den Brink , J. Clin. Oncol. 2017, 35, 1650.28296584)
J. U. Peled , S. M. Devlin , A. Staffas , M. Lumish , R. Khanin , E. R. Littmann , L. Ling , S. Kosuri , M. Maloy , J. B. Slingerland , K. F. Ahr , K. A. Porosnicu Rodriguez , Y. Shono , A. E. Slingerland , M. D. Docampo , A. D. Sung , D. Weber , A. M. Alousi , B. Gyurkocza , D. M. Ponce , J. N. Barker , M. A. Perales , S. A. Giralt , Y. Taur , E. G. Pamer , R. R. Jenq , M. R. M. van den Brink , J. Clin. Oncol. 2017, 35, 1650.28296584
J. U. Peled , S. M. Devlin , A. Staffas , M. Lumish , R. Khanin , E. R. Littmann , L. Ling , S. Kosuri , M. Maloy , J. B. Slingerland , K. F. Ahr , K. A. Porosnicu Rodriguez , Y. Shono , A. E. Slingerland , M. D. Docampo , A. D. Sung , D. Weber , A. M. Alousi , B. Gyurkocza , D. M. Ponce , J. N. Barker , M. A. Perales , S. A. Giralt , Y. Taur , E. G. Pamer , R. R. Jenq , M. R. M. van den Brink , J. Clin. Oncol. 2017, 35, 1650.28296584, J. U. Peled , S. M. Devlin , A. Staffas , M. Lumish , R. Khanin , E. R. Littmann , L. Ling , S. Kosuri , M. Maloy , J. B. Slingerland , K. F. Ahr , K. A. Porosnicu Rodriguez , Y. Shono , A. E. Slingerland , M. D. Docampo , A. D. Sung , D. Weber , A. M. Alousi , B. Gyurkocza , D. M. Ponce , J. N. Barker , M. A. Perales , S. A. Giralt , Y. Taur , E. G. Pamer , R. R. Jenq , M. R. M. van den Brink , J. Clin. Oncol. 2017, 35, 1650.28296584
M. Baretti, E. Karunasena, M. Zahurak, R. Walker, Yang Zhao, T. Pisanic, Tza-Huei Wang, T. Greten, A. Duffy, E. Gootjes, G. Meijer, Henk Verheul, N. Ahuja, J. Herman, N. Azad (2021)
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype
Clinical and Translational Science, 14
( H. Zhang , H. Xu , C. Zhang , Q. Tang , F. Bi , Cell Death Discovery 2021, 7, 207.34365464)
H. Zhang , H. Xu , C. Zhang , Q. Tang , F. Bi , Cell Death Discovery 2021, 7, 207.34365464
H. Zhang , H. Xu , C. Zhang , Q. Tang , F. Bi , Cell Death Discovery 2021, 7, 207.34365464, H. Zhang , H. Xu , C. Zhang , Q. Tang , F. Bi , Cell Death Discovery 2021, 7, 207.34365464
J. Yang, Jun Yu (2018)
The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get
Protein & Cell, 9
N. Lyu, Youen Lin, Y. Kong, Zhenfeng Zhang, Longzhong Liu, Lie Zheng, Luwen Mu, Jian-peng Wang, Xishan Li, T. Pan, Qiankun Xie, Yaru Liu, A. Lin, Peihong Wu, Ming Zhao (2017)
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma
Gut, 67
Shaobo Mo, Peiyuan Tang, W. Luo, Long Zhang, Yaqi Li, Xiang Hu, Xiao-ji Ma, Yikuan Chen, Yichao Bao, Xingfeng He, G. Fu, Xiaoya Xu, X. Rao, Xiaomeng Li, Ruoyu Guan, Shengzhi Chen, Yun Deng, T. Lv, P. Mu, Q. Zheng, Simin Wang, Fangqi Liu, Yiwei Li, W. Sheng, D. Huang, Chen Hu, Jianjun Gao, Zhen Zhang, S. Cai, H. Clevers, J. Peng, Guoqiang Hua (2022)
Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy
Advanced Science, 9
( J. E. Wilkinson , E. A. Franzosa , C. Everett , C. Li , F. B. Hu , D. F. Wirth , M. Song , A. T. Chan , E. Rimm , W. S. Garrett , C. Huttenhower , Nat. Med. 2021, 27, 766.33820996)
J. E. Wilkinson , E. A. Franzosa , C. Everett , C. Li , F. B. Hu , D. F. Wirth , M. Song , A. T. Chan , E. Rimm , W. S. Garrett , C. Huttenhower , Nat. Med. 2021, 27, 766.33820996
J. E. Wilkinson , E. A. Franzosa , C. Everett , C. Li , F. B. Hu , D. F. Wirth , M. Song , A. T. Chan , E. Rimm , W. S. Garrett , C. Huttenhower , Nat. Med. 2021, 27, 766.33820996, J. E. Wilkinson , E. A. Franzosa , C. Everett , C. Li , F. B. Hu , D. F. Wirth , M. Song , A. T. Chan , E. Rimm , W. S. Garrett , C. Huttenhower , Nat. Med. 2021, 27, 766.33820996
Janelle Arthur, E. Peréz-Chanona, Marcus Mühlbauer, Sarah Tomkovich, Joshua Uronis, Ting-Jia Fan, B. Campbell, T. Abujamel, B. Dogan, A. Rogers, J. Rhodes, A. Stintzi, K. Simpson, J. Hansen, T. Keku, A. Fodor, C. Jobin (2012)
Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
Science, 338
J. Taylor, Xinsheng Gao, Juan Xu, M. Holder, J. Petrosino, Ritesh Kumar, Wen Liu, M. Höök, C. Mackenzie, A. Hillhouse, Wesley Brashear, M. Nunez, Yi Xu (2021)
A type VII secretion system of Streptococcus gallolyticus subsp. gallolyticus contributes to gut colonization and the development of colon tumors
PLoS Pathogens, 17
S. Viaud, F. Saccheri, G. Mignot, T. Yamazaki, Romain Daillère, D. Hannani, D. Enot, C. Pfirschke, Camilla Engblom, M. Pittet, A. Schlitzer, F. Ginhoux, L. Apetoh, E. Chachaty, P. Woerther, G. Eberl, M. Bérard, C. Ecobichon, D. Clermont, C. Bizet, V. Gaboriau-Routhiau, N. Cerf‐Bensussan, P. Opolon, Nadia Yessaad, É. Vivier, B. Ryffel, C. Elson, J. Doré, G. Kroemer, P. Lepage, I. Boneca, F. Ghiringhelli, L. Zitvogel (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Science, 342
Jason Ridlon, J. Bajaj (2015)
The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics
Acta Pharmaceutica Sinica. B, 5
W. Russell, L. Hoyles, H. Flint, M. Dumas (2013)
Colonic bacterial metabolites and human health.
Current opinion in microbiology, 16 3
S. Wong, Liuyang Zhao, Xiang Zhang, Geicho Nakatsu, Juqiang Han, Weiqi Xu, Xuequan Xiao, Thomas Kwong, H. Tsoi, William Wu, B. Zeng, F. Chan, J. Sung, Hong Wei, Jun Yu (2017)
Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice.
Gastroenterology, 153 6
B. Peters, Christine Dominianni, J. Shapiro, T. Church, Jing Wu, G. Miller, Elizabeth Yuen, H. Freiman, I. Lustbader, James Salik, Charles Friedlander, R. Hayes, Jiyoung Ahn (2016)
The gut microbiota in conventional and serrated precursors of colorectal cancer
Microbiome, 4
A. Koh, F. Vadder, P. Kovatcheva-Datchary, F. Bäckhed (2016)
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Cell, 165
( P. Arvind , E. D. Papavassiliou , G. J. Tsioulias , B. W. Duceman , C. I. Lovelace , W. Geng , L. Staiano‐Coico , B. Rigas , Mol. Immunol. 1994, 31, 607.8196671)
P. Arvind , E. D. Papavassiliou , G. J. Tsioulias , B. W. Duceman , C. I. Lovelace , W. Geng , L. Staiano‐Coico , B. Rigas , Mol. Immunol. 1994, 31, 607.8196671
P. Arvind , E. D. Papavassiliou , G. J. Tsioulias , B. W. Duceman , C. I. Lovelace , W. Geng , L. Staiano‐Coico , B. Rigas , Mol. Immunol. 1994, 31, 607.8196671, P. Arvind , E. D. Papavassiliou , G. J. Tsioulias , B. W. Duceman , C. I. Lovelace , W. Geng , L. Staiano‐Coico , B. Rigas , Mol. Immunol. 1994, 31, 607.8196671
G. Zeller, J. Tap, A. Voigt, S. Sunagawa, Jens Kultima, P. Costea, A. Amiot, J. Böhm, F. Brunetti, N. Habermann, R. Hercog, M. Koch, A. Luciani, D. Mende, M. Schneider, P. Schrotz-King, C. Tournigand, J. Nhieu, Takuji Yamada, J. Zimmermann, V. Beneš, M. Kloor, C. Ulrich, M. Doeberitz, I. Sobhani, P. Bork
Molecular Systems Biology Peer Review Process File Potential of Fecal Microbiota for Early Stage Detection of Colorectal Cancer Transaction Report
Haiyang Liu, Junfeng Du, Shanshan Chao, Shuoguo Li, Huiyun Cai, Hongjie Zhang, Gang Chen, Pingsheng Liu, Pengcheng Bu (2022)
Fusobacterium nucleatum Promotes Colorectal Cancer Cell to Acquire Stem Cell‐Like Features by Manipulating Lipid Droplet‐Mediated Numb Degradation
Advanced Science, 9
( M. M. Leonard , F. Valitutti , H. Karathia , M. Pujolassos , V. Kenyon , B. Fanelli , J. Troisi , P. Subramanian , S. Camhi , A. Colucci , G. Serena , S. Cucchiara , C. M. Trovato , B. Malamisura , R. Francavilla , L. Elli , N. A. Hasan , A. R. Zomorrodi , R. Colwell , A. Fasano , Proc. Natl. Acad. Sci. USA 2021, 118.)
M. M. Leonard , F. Valitutti , H. Karathia , M. Pujolassos , V. Kenyon , B. Fanelli , J. Troisi , P. Subramanian , S. Camhi , A. Colucci , G. Serena , S. Cucchiara , C. M. Trovato , B. Malamisura , R. Francavilla , L. Elli , N. A. Hasan , A. R. Zomorrodi , R. Colwell , A. Fasano , Proc. Natl. Acad. Sci. USA 2021, 118.
M. M. Leonard , F. Valitutti , H. Karathia , M. Pujolassos , V. Kenyon , B. Fanelli , J. Troisi , P. Subramanian , S. Camhi , A. Colucci , G. Serena , S. Cucchiara , C. M. Trovato , B. Malamisura , R. Francavilla , L. Elli , N. A. Hasan , A. R. Zomorrodi , R. Colwell , A. Fasano , Proc. Natl. Acad. Sci. USA 2021, 118., M. M. Leonard , F. Valitutti , H. Karathia , M. Pujolassos , V. Kenyon , B. Fanelli , J. Troisi , P. Subramanian , S. Camhi , A. Colucci , G. Serena , S. Cucchiara , C. M. Trovato , B. Malamisura , R. Francavilla , L. Elli , N. A. Hasan , A. R. Zomorrodi , R. Colwell , A. Fasano , Proc. Natl. Acad. Sci. USA 2021, 118.
A. Janney, F. Powrie, E. Mann (2020)
Host–microbiota maladaptation in colorectal cancer
Nature, 585
A. Bhatt, M. Redinbo, S. Bultman (2017)
The role of the microbiome in cancer development and therapy
CA: A Cancer Journal for Clinicians, 67
C. Murphy, M. Barrett, P. Pellanda, S. Killeen, M. Mccourt, E. Andrews, M. Riordain, F. Shanahan, P. O’Toole (2021)
Mapping the colorectal tumor microbiota
Gut Microbes, 13
( R. L. Siegel , K. D. Miller , A. Goding Sauer , S. A. Fedewa , L. F. Butterly , J. C. Anderson , A. Cercek , R. A. Smith , A. Jemal , Ca‐Cancer J. Clin. 2020, 70, 145.32133645)
R. L. Siegel , K. D. Miller , A. Goding Sauer , S. A. Fedewa , L. F. Butterly , J. C. Anderson , A. Cercek , R. A. Smith , A. Jemal , Ca‐Cancer J. Clin. 2020, 70, 145.32133645
R. L. Siegel , K. D. Miller , A. Goding Sauer , S. A. Fedewa , L. F. Butterly , J. C. Anderson , A. Cercek , R. A. Smith , A. Jemal , Ca‐Cancer J. Clin. 2020, 70, 145.32133645, R. L. Siegel , K. D. Miller , A. Goding Sauer , S. A. Fedewa , L. F. Butterly , J. C. Anderson , A. Cercek , R. A. Smith , A. Jemal , Ca‐Cancer J. Clin. 2020, 70, 145.32133645

Publisher: Wiley
Copyright: © 2023 Wiley‐VCH GmbH
eISSN: 2198-3844
DOI: 10.1002/advs.202205563
Publisher site: See Article on Publisher Site

Abstract

IntroductionColorectal cancer (CRC) is the third most common and fatal cancer with 71 160 estimated new cases and 24 080 new deaths in the USA in 2023.[1] CRC has heterogeneous genomic, epigenomic, and transcriptomic transformations and undergoes complex processes that lead to tumorigenesis.[2] Genetic predisposition is an important factor in CRC progression accounting for 12–35% of all cases. According to this, CRC can be classified as Lynch syndrome, familial adenomatous polyposis, or Peutz‐Jeghers syndrome.[3] Additionally, emerging evidence indicates that internal and external environmental factors are involved in the development of CRC.[4] The heritability of CRC remains unclear in most patients, while sporadic CRC cases are mostly abided by the “adenoma–carcinoma sequence”; CRC evolves from colorectal polypoid adenomas and progresses into malignant tumors over several years, thus, suggesting the occurrence of complicated mutation procedures[5] and illustrating the non‐negligible importance of environmental factors in its development and progression.[6]The microenvironment of the human body is composed of a highly integrated microbiota, including bacteria, fungi, viruses, archaea, and parasites. Notably, the microbiota mainly consists of bacteria, particularly, Firmicutes, Bacteroidetes, and Actinobacteria.[7] The colorectum has the largest population of bacteria, ≈3 × 1013 cells,[8] and crosstalk between microorganisms and the colorectal epithelium is a key factor influencing basic physiological activities, including energy harvest, metabolic regulation, homeostatic preservation, and immune reactions.[9] Dysbiosis‐related inflammation and carcinogen formation are two of the primary reasons for microbiota‐related carcinogenesis.[10] Alterations of gut microbiota have been observed in precancerous adenomas during early cancer stages.[11] Moreover, microorganisms, especially bacteria, are pivotal in the evolution of several diseases including CRC.[12] Ratios of these microorganisms vary based on the anatomical site and between eastern and western countries,[13] and these differences may be associated with disease development.[14]Metabolites produced by gut microbiota, including bile acids (BAs) and short‐chain fatty acids (SCFAs), are essential components involved in the crosstalk between microorganisms and the host and play either protective or harmful roles in the development of CRC.[15] The effects of these metabolites on inflammation and cancer development and progression warrant further investigation.[16] Studies on the interaction between gut microbiota and CRC have been conducted and hence should be systematically summarized. Moreover, other gut microbiota components, such as viruses and fungi, the recently discovered probiotics from gut microbiota that related to CRC, the intratumoral microbiota in CRC, the pattern of gut microbiota in early‐onset CRC patients, and the metabolites produced by the microbiota have also been reviewed, but to a lesser extent. In this review, we summarize and discuss the latest reports on the relationship between gut microbiota and metabolites in CRC and the prospects of treating CRC through the targeting of these metabolites.Association between Gut Microbiota and CRCLandscape of CRC MicrobiotaThe gut microbiota of healthy individuals is less diverse than that of patients with CRC, which show a global compositional shift.[17] Specific bacteria, including Fusobacterium nucleatum, Escherichia coli, Bacteroides fragilis, and Streptococcus gallolyticus, were linked to CRC in various association and mechanistic studies.[18] Despite geographical variations in gut microbiota, a microbial core of seven enriched bacteria (B. fragilis, F. nucleatum, Porphyromonas asaccharolytica, Parvimonas micra, Prevotella intermedia, Alistipes finegoldii, and Thermanaerovibrio acidaminovorans) has been confirmed in CRC through meta‐analysis of 526 fecal samples from shotgun metagenome datasets.[19] Therefore, microbiota can be used as CRC biomarkers through the detection and quantification of the alterations in the relative abundances of these bacteria.Gut microbiota composition varies between anatomical locations.[20] As was previously reported, operational taxonomic unit level of gut microbiota composition changed in distal but not proximal CRC cases, while mucosal bacterial biofilms affects tumor formation in proximal CRC cases but not distal ones, suggesting different roles of gut microbiota in different anatomical subsites of CRC.[21] One reason could be that bacteria showed more accumulation in the distal colon when there are changes in the local environment including surgery and infection;[22] it was also found that bacterial oncogenes were more abundant in the stools of distal CRC patients compared to proximal CRC patients.[23] However, a greater abundance of F. nucleatum was found in proximal CRC cases, whose metabolism can induce carcinogens and inflammation in the tumor microenvironment and increase mutation rate.[24] These phenomena suggest that the subsite location of CRC tumor may be associated with site‐specific bacteria, and some bacteria play differential roles in proximal and distal CRCs, which should be further examined in the future.Other than bacteria, the gut microbiota also includes viruses and fungi whose roles in the development of CRC have been studied. One study indicated substantial changes in the abundance of enteroviruses and 22 other viral taxa (including cytomegalovirus) in patients with CRC,[25] but other studies have reported conflicting data.[26] Meanwhile, another study highlighted the changes in phage characteristics in CRC and indicated that the cancer‐related virome is primarily formed by temperate bacteriophages.[27] Despite limited studies, an enhanced abundance of Malassezia has been identified in patients with CRC.[28] These studies suggest that transkingdom microbial interactions may be essential in CRC oncogenesis.Interaction between Gut Microbiota and CRCSubsequent studies have shown that the gut microbiota which includes E. coli, Enterococcus, Bacteroides, and Clostridium can contribute to CRC by enhancing abnormal crypt foci induced by 1,2‐dimethylhydrazine.[29] Interestingly, mice transplanted with gut microbiota from patients with CRC had more intestinal polyps than those receiving microbiota from healthy controls.[30] Comparative metagenomic or metataxonomic approaches have indisputably proven that patients with CRC have an imbalanced taxonomic structure in comparison to healthy individuals, with an upregulation and downregulation in the abundance of pro‐oncogenic (e.g., Bacteroides, Escherichia, Fusobacterium, and Porphyromonas) and potentially protective (e.g., Roseburia) bacteria, respectively.[31] These data highlight the essential role of the microbial communities on carcinogenesis.Undeniably, the formation of the human gut microbiota is continuously progressing, but the functional components of this microbiota are not well understood. This could be attributed to the complex composition of the gut microbiota and the impact of the external environment on the microbes.These factors result in unpredictable crosstalk between the host and microbes.[32] Host–microbial interactions in CRC were first identified in 1975, when it was shown that the incidence of colon tumors caused by dimethylhydrazine, a carcinogen, was significantly lower in germ‐free rats than in rats with an intestinal microbiome.[4] Notably, the influence of the gut microbiota on the development of CRC includes communication with the host immune system through pattern recognition receptor signaling, inflammasomes, and cytokines; the production of inflammation, which is a special type of immune reaction; and the secretion of metabolites, including BAs and SCFAs.[33] Mechanistically, inflammatory and immune reactions caused by the interplay between the CRC‐promoting bacteria and the host are among the most common mechanisms in CRC development[34] (Figure 1). These bacterial species stimulate chemokine production by CRC cells including chemokine (C‐C motif) ligand 5 and chemokine (C‐X‐C motif) ligands 9 and 17, thereby activating immune responses which can lead to accumulation of T cells (e.g., cytotoxic T lymphocytes, T helper type 1 (Th1), and interleukin (IL)‐17‐producing Th cells) in tumor tissues[35] and the modulation of inflammatory responses in the colon. The latter occurs through cytokine secretion, specifically of IL‐17A, IL‐22, and IL‐23A, which promote tissue inflammation.[30] Moreover, pattern recognition receptors are involved in the crosstalk between the immune system and the microbiota as they can recognize microbial antigens and activate a number of signaling pathways, including the nucleotide‐binding oligomerization domain‐like receptor,[36] retinoic acid‐inducible gene I‐like receptor,[37] toll‐like receptor,[38] and absent in melanoma 2‐like receptor[39] pathways, to activate an immune response. Furthermore, production of metabolites that induce CRC development is another essential mechanism. However, the detailed mechanism of host–microbial interaction in CRC is still unknown, and further confirmatory research is needed before it can be leveraged for beneficial therapeutic effects.1FigureThe role of the gut microbiota in CRC progression through immune, inflammatory, and metabolic reactions. Several bacterial species in the gut could induce the host to produce chemokines including chemokine (C‐C motif) ligand 5 (CCL5), chemokine (C‐X‐C motif) ligands 9 (CXCL9), and CXCL17. Tumor cells accumulate T cells that promote inflammation and leads to progression of CRC. Microbial antigens produced by the gut microbiota could activate signaling through various receptors including nucleotide‐binding oligomerization‐like receptor (NLR), retinoic acid‐inducible gene I‐like receptor (RLR), toll‐like receptor (TLR), and absent in melanoma 2‐like receptor (AIMR), that stimulate the immune response.Herein, we discuss the major bacterial species of the microbiota and summarize the protective or harmful roles they may play in CRC formation, development, and/or metastasis (Table 1).1TableMechanisms of action of CRC‐associated gut bacterial speciesOrganismGram stainingEffect in CRCExpression pattern in CRCMechanismRole in tumor formation, development, and metastasisInteraction with other gut microbiotaFusobacterium nucleatumNegativePromoteEnhancedProliferation of CRC cellsDNA damage and carcinogenesis through oxidative stressMutation in the Apc tumor suppressor geneIncrease of tumor‐promoting cytokines through NF‐κB activationSecretion of FadA adhesion protein that activating Wnt/β‐catenin signalingInhibit T cell activation and NK cell‐meditated killing of tumor cellsImmune surveillance suppressionPromote CRC cell to acquire stem cell‐like featuresFormationDevelopmentMetastasis–Escherichia coliNegativePromoteEnhancedInflammatory reactionsDNA damageSecretion of virulence factors to activate COX‐2, etc.Promote cell‐cycle arrestInduce apoptosis of CRC cellsDisrupt the gut vascular barrierFormationMetastasisPromoting procarcinogenic bacteria including Bacteroides fragilisBacteroides fragilisNegativePromoteEnhancedHigher in proximal colonInteraction with IL‐17Activation of NF‐κBAccumulation of regulatory T cells to enhance inflammatory responseIncreasing paracellular permeabilityActivation of β‐catenin signaling pathwayProliferation of CRC cellsDNA damage through polyamine metabolismInducing bacterial dysbiosis by promoting procarcinogenic bacteriaDisturbance of the host immune apparatus and gut barrierPromotion of mucin degradationDevelopmentPromoting procarcinogenic bacteria including Escherichia coliStreptococcus gallolyticusPositivePromoteEnhancedActivation of NF‐κB and IL‐8Inflammatory reactionProliferation of CRC cells through β‐catenin signaling but not inflammationFormation–Clostridium butyricumPositiveInhibitDecreasedProduction of SCFAs including butyrate and acetateDecrease of secondary BAs secretionInhibiting proliferation of CRC cellsInducing apoptosis in CRC cellsInhibition of Wnt/β‐catenin signaling pathwayModulation of gut microbiotaActivation of GPRs including GPR43 and GPR109ADevelopmentModulating gut microbiotaStreptococcus thermophilusPositiveInhibitDecreasedBanning the invasion of Escherichia coliProduction of β‐Galactosidase to enhance abundance of probioticsActivation of oxidative phosphorylationInhibition of Hippo signaling pathwayDevelopmentBanning the invasion of Escherichia coliEnhance abundance of probiotics including Bifidobacterium and LactobacillusLacticaseibacillus paracaseiPositiveInhibitDecreasedInhibiting proliferation of CRC cellsInducing apoptosis of CRC cellsProducing LpEVs as intercellular communication moleculesLactobacillus paracasei DTA81 diminish liver oxidative stress and decrease proliferating cell nuclear antigenDevelopment–Ruminococcus gnavusPositiveInhibitDecreasedDegrade lysoglycerophospholipidPromote tumor immune surveillance function of CD8+T cellFormationDevelopmentCommensal growing with Blautia productaCRC: colorectal cancer; NF‐κB: nuclear factor‐kappa B; NK: natural killer; COX‐2: cyclooxygenase 2; IL‐: interleukin; GPR: G‐protein coupled receptor; LpEVs: Lacticaseibacillus paracasei‐derived extracellular vesicles.CRC‐Promoting Bacterial SpeciesEnrichment of tumor‐promoting bacterial species is an important mechanism employed by gut microbiota during CRC development. Along with polyketide synthase positive (pks+) E. coli, enterotoxigenic B. fragilis, and S. gallolyticus, F. nucleatum isolates are major protumorigenic bacteria. F. nucleatum is a gram‐negative oral commensal anaerobe implicated in a wide spectrum of disorders, such as cardiovascular diseases, rheumatoid arthritis, inflammatory bowel disease, and CRC.[40] Patients with these disorders show higher levels of F. nucleatum compared to healthy individuals;[41] importantly, a progressive trend for an increased abundance of F. nucleatum in CRC, from highly dysplastic adenomas through to late cancer stages, has been observed.[5] F. nucleatum can activate the formation and development of CRC through proliferation of cancer cells but not noncancerous cell lines.[42] Infection of CRC cells with F. nucleatum increases tumor cell proliferation, invasive activity, and ability to form xenograft tumors in Apcmin/+ mice.[43] The abundance of F. nucleatum in CRC was associated with an increase of tumor‐promoting cytokines, including IL‐17A and tumor necrosis factor‐α (TNF‐α), through the sensitization of the nuclear factor‐kappa B (NF‐κB) signaling pathway.[44] Additionally, F. nucleatum has been shown to promote CRC metastasis by upregulating long noncoding RNA Keratin7‐antisense (KRT7‐AS) and Keratin7 (KRT7) through activation of NF‐κB.[45] F. nucleatum also causes CRC cells to acquire stem cell‐like features through manipulating lipid droplet‐mediated Numb degradation.[46] The FadA adhesion protein secreted by F. nucleatum binds to E‐cadherin, and enhances the level of inflammatory and cancer genes, through activating the Wnt/β‐catenin signaling in intestinal epithelial cells.[42,47]E. coli is a gram‐negative anaerobic bacterium mainly found in the intestines. Though generally not pathogenic, some virulent strains of E. coli which colonize the human gut are nosogenic and can lead to diseases via multiple mechanisms.[48] Greater abundance of E. coli was observed in mucosal samples from patients with CRC.[49] Colibactin, a genotoxic polyketide‐peptide produced by polyketide synthase positive (pks+) E. coli,[50] causes double‐stranded DNA damage through the activation of the DNA damage signaling and cell‐cycle arrest pathways[51] and induction of tumor formation.[52] E. coli also secretes other virulence factors, such as cycle‐inhibiting factor, cytotoxic necrotizing factor and cyclooxygenase 2 (COX‐2), and cytolethal distending toxin, which can induce cell‐cycle arrest, DNA damage, and apoptosis.[53] Moreover, E. coli was also found to promote CRC metastasis through disrupting the gut vascular barrier, and induce the formation of a premetastatic niche.[54]B. fragilis toxin (BFT), a secreted metalloproteinase enterotoxin, is linked to early carcinogenesis. BFT is associated with the occurrence of adenomas and serrated polyps in the human colon,[11a] promotion of Th17‐mediated colitis in a mouse model,[55] and distal CRC in Apcmin+/− mice through interaction with IL‐17 and subsequent activation of the NF‐κB signaling pathway.[56] In addition, colonization by BFT+ B. fragilis can promote accumulation of regulatory T cells, thereby inducing IL‐17‐mediated procarcinogenic inflammatory responses.[57] In colon epithelial cells, BFT promotes the cleavage of E‐cadherin, increasing paracellular permeability and activating the β‐catenin signaling pathway leading to enhanced cell proliferation.[58] Moreover, BFT activates DNA damage through polyamine catabolism in CRC cells.[59] Interestingly, BFT+ B. fragilis can also induce bacterial dysbiosis locally by promoting the growth of other procarcinogenic bacteria, disturbing the host immune apparatus[57] and the gut barrier,[58] and inducing mucin degradation.[60]S. gallolyticus infection‐related endocarditis and bacteremia can enhance the risk of CRC,[61] and exposure to S. gallolyticus antigens is closely correlated with increased CRC incidence.[62] In xenograft and azoxymethane/dextran sodium sulfate (AOM/DSS) mouse models exposed to S. gallolyticus, the tumor burden increased, and the dysplasia grade worsened.[63] Nevertheless, the underlying mechanisms involved in S. gallolyticus‐mediated CRC progression may be associated with high levels of NF‐κB and IL‐8 mRNA, inflammatory reactions, and β‐catenin,[63a] although further investigations are warranted.A meta‐analysis has revealed seven bacteria commonly enriched in CRC,[19] including P. asaccharolytica, P. micra, P. intermedia, A. finegoldii, and T. acidaminovorans. These bacterial species may have harmful roles in cancer promotion, yet their roles in CRC progression have not been adequately studied to date.CRC‐Protecting Bacterial SpeciesIn addition to these core bacteria, several CRC‐depleted bacteria have been named and were negatively linked to mutualistic networks of enriched bacteria.[19] The depleted bacteria included probiotic bacteria, such as Clostridium butyricum and Streptococcus thermophilus, which are potentially beneficial in CRC prevention through production of substances, such as butyrate, and antagonistic action against the pathobionts.[64] Ruminococcus gnavus and Blautia producta are commensal bacteria that were found to degrade lysoglycerophospholipid in the microenvironment of the intestinal tissue and promote tumor immune surveillance function of CD8+T cells, thus inhibiting the occurrence and development of colon cancer.[65] Research on CRC‐protecting microbiota is still limited, despite its high translational potential in prevention and treatment of CRC.Clostridium ButyricumC. butyricum, a gram‐positive anaerobic bacterium that produces butyrate, exists in various natural environments, including soil, milk products, and some vegetables. C. butyricum is also one of the common human gut microbiota species that is found in ≈10% to 20% of adults and is one of the original colonizers found in human infants.[66] As a symbiont in the human digestive system, C. butyricum ferments fibrous foods in the gut to aid digestion, thus, producing SCFAs, including butyrate and acetate,[67] which are protective in CRC. In addition, C. butyricum inhibits proliferation and induces apoptosis in CRC cells, through interacting with the Wnt/β‐catenin signaling pathway and modulating the composition of the gut microbiota. This decreases the secretion of secondary BAs closely related to cancer development, enhances the secretion of SCFAs, and activates G‐protein coupled receptors (GPRs) including GPR43 and GPR109A that suppress tumor progression.[68]Streptococcus ThermophilusS. thermophilus is a gram‐positive fermentative anaerobic bacterium which can be isolated from fermented milk products, such as yogurt. It protects the gut epithelium through preventing invasive E. coli, thereby relieving acute diarrhea in infants, and small‐intestinal methotrexate‐induced mucositis in rat models.[69] Gavage of S. thermophilus inhibited tumor formation in both Apcmin/+ and azoxymethane‐injected mice. Moreover, production of β‐galactosidase by S. thermophilus enhances the abundance of probiotics, such as Bifidobacterium and Lactobacillus. Furthermore, the galactose produced by S. thermophilus was shown to modulate oxidative phosphorylation and the Hippo signaling pathway, which lead to tumor‐suppressive effects.[70]Lacticaseibacillus ParacaseiL. paracasei is a gram‐positive bacterium with probiotic properties in CRC. It enhances apoptosis and inhibits proliferation of tumor cells by regulating the Bcl‐2 family proteins, producing reactive oxygen species (ROS) and cell wall protein, enhancing calreticulin translocation, and modifying the cell cycle.[71] L. paracasei‐derived extracellular vesicles act as intercellular communication molecules. They are taken up by CRC cells, where they inhibit the proliferation, migration, invasion, and promote apoptosis.[72] Additionally, L. paracasei DTA81 prevents the development of CRC at an early stage by diminishing liver oxidative stress (OS) and decreasing the secretion of proliferating cell nuclear antigen.[73]Other Microbiota TypesViromeAlterations have been reported in the fecal virome (phages included) in patients with CRC.[25,27] The bacterial composition of the gut microbiota could be changed through phage regulation including pathogenic bacteria development and subsequent biofilm formation. An increase in the abundance of several phages was found in the feces of patients with CRC. Through analysis of 317 metagenomic samples gathered from China (Hong Kong), Austria, and Japan, enrichment of five bacteriophages was identified, namely, Peptacetobacter hiranonis Phage, F. nucleatum animalis 7_1 Phage, F. nucleatum polymorphum Phage, F. nucleatum animalis 4_8 Phage, and P. micra Phage.[74] SpSL1 is the phage that being more abundant in early‐stage CRC, and infects Streptococcus species.[25] HK544, Punalikevirus, Lambdalikevirus, and Mulikevirus can reduce the abundance of E. coli in patients with CRC and lead to dysbiosis.[25] However, the causal relationship between the phage and bacteria remains unclear, and further studies on the underlying mechanisms are essential to identify potential therapeutic targets.FungiFungi are major components of the gut microbiota whose dysbiosis affects human health through induction of inflammatory and immune reactions.[75] Fungal diversity is diminished in patients with CRC in comparison to healthy individuals, which is more evident in the early stage the disease.[76] Dysbiosis in patients with CRC and colon polyps could be attributed to the downregulation of beneficial yeasts and upregulation of pathological fungi, including Trichosporon and Malassezia genera. Immune reaction is currently considered to be the major paths employed by fungi during CRC development. For instance, Candida albicans can activate the interaction between macrophages and innate lymphoid cells, increase expression of IL‐22, and promote CRC.[77] Dysbiosis of gut fungi also affects the function of CARD9, thereby decreasing the activation of inflammasomes and maturation of IL‐18 and enhancing expansion of myeloid‐derived suppressor cells. Consequently, this increases susceptibility to CRC.[75] Owing to the limited studies and sample sizes, the spectrum of fungi in CRC remains unclear, although fungal dysbiosis has important roles in tumor development.Intratumoral Microbiota in CRCThe advent of metagenomic sequencing highlights the tumor microbiota as an integral part of the microenvironment affecting tumor progression. Moreover, the abundance of Fusobacterium increased in liver metastatic CRCs but not primary liver cancers,[78] and intratumoral E. coli damaged the gut vascular barrier and promoted metastasis,[54] indicating the importance of tumor microbiota. The intratumoral microbiota is heterogeneous and progressively changes as CRC progresses from adenoma to carcinoma.[79] The mechanisms underlying these changes are unclear. One study evaluating CRC and adenoma samples found an enrichment of Fusobacterium, Bacteroides, Parvimonas, and Prevotella without a reduction in other bacteria.[79] Yet another study, which examined 294 matched tumor and tumor‐adjacent biopsies, reported an increase in the abundance of Fusobacterium, Streptococcus, and Proteobacteria in tumors, whereas Firmicutes abundance decreased.[80] Interestingly, the intratumoral microbiota also changes based on the anatomical subsite; ascending and descending colon cancer samples showed significant microbial alterations.[81] Importantly, the microbiota in a single tumor is evenly distributed and not limited to some regions.[82]F. nucleatum is among the most common bacterial species in patients with CRC and can be detected in their biopsies. Its DNA is generally found in tumor cells.[83] Moreover, increased levels of mucosa‐associated and internalized E. coli were observed in tumors, and higher bacterial levels were observed in patients with stage III/IV cancer than in those with stage I cancer, suggesting a possible association between bacterial abundance and poor prognosis.[54] Data on intratumoral microbiota in CRC are currently limited, but a list of available literature sources has been summarized in Table 2. Future research on the microbial community of tumors may further reveal the host–bacterial interactions in CRC.2TableSummary of recent studies on intratumoral microbiota in CRCGut microbiotaAuthorYearDisease typeSample typeSample sizeIncreaseDecreaseBurns 2015CRCSurgery tissue88CandidatusPortieraProvidenciaFusobacteriumBacteroidesRikenellaceaeLachnospiraceaeRuminococcaceaeFlemer2017CRCColorectal polypSurgery tissueBiopsies tissue136Bacteroidetes Cluster2Firmicutes Cluster2PathogenPrevotellaBacteroidetes Cluster1Firmicutes Cluster1Bullman2017CRCFresh‐frozen tissue88Fusobacterium nucleatumFusobacterium necrophorumBacteroides fragilisBacteroides thetaiotaomicronNoneShah2018CRCBiopsies tissue294FusobacteriumStreptococcusParvimonasFaecalibacteriumRuminococcaceaeNielsen2019CRCColorectal adenomaFFPE tissue299PrevotellaNoneLee2021CRC (MSI‐H)Surgery tissue153Fusobacterium nucleatumNoneKordahi2021Colorectal polypsBiopsies tissue240TAP: BacteroidetesSSP: ProteobacteriaFirmicutesLiu2021CRCColorectal adenomaBiopsies tissue436FusobacteriumBacteroidesParvimonasPrevotellaNoneCRC: colorectal cancer; MSI‐H: microsatellite instability high; TAP: tubular adenomatous polyps; SSP: sessile serrated polyps; FFPE: formalin‐fixed and paraffin‐embedded.Gut Microbiota Metabolites and Their Effects on CRCMetabolites are essential components in the interaction (crosstalk) between the gut microbiota and the human body.[6] Microorganisms in the colon produce metabolites after the uptake of certain substances,[84] which then act as signaling elements and substrates in metabolic reactions[85] and are closely related to cancer development, including CRC.[86] The composition of gut microbiota metabolites includes volatile small molecules, lipids, proteins and peptides, sugars, secondary bile products or terpenes, biogenic amines, oligosaccharides, glycolipids, organic acids, and amino acids.[53] Various metabolites possess different properties depending on the regulation pathways involved; some have health‐promoting and antineoplastic abilities, while others have proinflammatory and carcinogenic properties.[87] Additionally, these metabolites are potentially beneficial in clinical and translational research, particularly, in the detection of cancers such as CRC and prediction of treatment effects.[88] Moreover, they may be more easily applicable than microbial taxa because they affect microbial functions and host–microbiota metabolic crosstalk.[85] In the following sections, we summarized some major gut microbiota metabolites and their promoting (Figure 2) and inhibiting (Figure 3) effects on CRC (Table 3).2FigurePromoting effects of gut microbiota metabolites on CRC. Metabolites including several bile acids (e.g., DCA and LCA), and trimethylamine n‐oxide (TMAO) promote CRC development by increasing cancer cell proliferation, increasing DNA damage, enhancing tumor invasion and metastasis, reducing cell–cell adhesion, and promoting genomic instability.3FigureProtective roles of gut microbiota metabolites against CRC. Metabolites including bile acids such as ursodeoxycholic acid (UDCA), SCFAs such as butyrate, and amino acids play a protective role by assembling the tight junction, inhibiting inflammation, promoting cancer cell apoptosis, and protecting colon epithelial barriers, to inhibit growth of CRC.3TableGut microbiota‐associated metabolites in CRC and their mechanisms of actionClass of metabolitesMetaboliteProducersPotential mechanismBAsDCAClostridium hiranonis,Clostridium hylemonae,Clostridium sordelli,Clostridium scindensInflammation, angiogenic formation, DNA damage, and DNA repair inhibitionLCAClostridium hiranonis, Clostridium hylemonae,Clostridium sordelli,Clostridium scindensApoptosis, cell proliferation, oxidative DNA damage, inflammatory reactionsUDCAParabacteroides distasonisAntiapoptotic, anti‐inflammatory, and antioxidant effectSCFAsAcetateBacteroides. Hydrogenotrophica, M ethanobrevibacter smithii, R uminococcus gnavus–ButyrateRoseburia intestinalis, Butyrivibriocrossotus, Faecalibacterium cf. prausnitziiImmunity, inflammation, differentiation, apoptosis, phagocytosis, and efferocytosisFormateF. nucleatumAhR signaling, cancer stemness, inflammationTMAOTMAOEnterobacteriaceaeInflammation, altering protein folding, oxidative stress, and DNA damageTryptophanIndoleEscherichia coli, Bacteroides thetaiotaomicron, Bacteroides ovatus, C. limosumSuppress inflammation, fix abdominal wall structures, AHR ligendsIAABacteroides ovatus, Bacteroides fragilis, Escherichia coliSuppress inflammation, fix abdominal wall structures, AHR ligendsSerineS‐adenosylmethionineSaccharomyces cerevisiae, Pichia pastoris, Candida utilis, and Escherichia coliUpregulates cell adhesion gene expression and promotes cell migration and metastasisVirulence factorsFadAFusobacterium nucleatummediates adhesion and invasion of epithelial and endothelial cellsFap2Fusobacterium nucleatumImmunity, binds to Gal‐GalNAcBAs: bile acids; DCA: deoxycholic acid; LCA: lithocholic acid; UDCA: ursodeoxycholic acid; SCFAs: short‐chain fatty acids; TMAO: trimethylamine n‐oxide; IAA: indoleacetic acid.Bile AcidsBA metabolism is associated with gut microbiota and exerts both beneficial and harmful effects on the host.[89] Primary BAs, including cholic acid (CA) and chenodeoxycholic acid (CDCA), are produced using cholesterol in the liver, conjugated to glycine or taurine, and excreted into the duodenum to facilitate fat digestion. They are biotransformed and activate the gut microbiota by reshaping the gut microbiota composition.[10b] On the one hand, BAs can alter membrane lipid composition, and increased BA concentrations can solubilize membranes and dissociate integral membrane proteins.[90] On the other hand, BAs could also shape the composition of the gut microbiota by indirect effects through BA receptors, especially the farnesoid X receptor (FXR). In healthy participants, the FXR agonist obeticholic acid (OCA) inhibited the synthesis of endogenous BAs and significantly increased the abundances of S. thermophilus, Lactobacillus casei, and Bifidobacterium breve, suggesting that FXR activation alters the small intestinal microbiota in response to changes in endogenous BA concentrations.[91] Subsequently, the BAs were reabsorbed in the distal ileum for enterohepatic circulation. BAs that enter the colon undergo complex biotransformation through interaction with gut microbiota, and are converted to secondary BAs,[87] which are linked to tumor progression. Notably, accumulating evidence has demonstrated an association between BA metabolism and CRC.[92] For example, CA and CDCA were found to regulate NF‐κB and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathways to promote CRC.[93] In addition, in N‐methyl‐N′nitro‐N‐nitrosoguanidine‐treated mice infusion of CA and CDCA caused a higher incidence of neoplasia in normal versus germ‐free mice, which highlights the key role of microbiota conversion of BAs in CRC progression.[94]Bile salt hydrolases catalyze the hydrolysis of the conjugated primary BAs and have been purified from bacteria of the gut microbiota, including B. fragilis, Bacteroides vulgatus, Clostridium perfringens, Listeria monocytogenes, Lactobacillus, and Bifidobacterium.[87] Dehydroxylation is also essential for secondary BA formation, and is catalyzed by intestinal bacterial enzymes.[95]Both primary and secondary BAs are involved in the regulation of lipid activity and glucose metabolism, which is enabled by BA‐responsive receptors, including FXR, pregnane X receptor (PXR), constitutive androstane receptor, vitamin D receptor (VDR), and G protein‐coupled bile acid receptor 1 (TGR5).[96] BA could activate these receptors and play an essential role not only in regulating lipid absorption and energy homeostasis, but also in initiating various pathologies, including CRC.[97] The related BA‐responsive receptors and associated signaling pathways of the major BAs in CRC are summarized in Table 4.4TableMajor bile acids in CRC and their related bile acid‐responsive receptors and associated signaling pathwaysBAsBA‐responsive receptorsAssociated signaling pathwaysCANot specifiedNF‐κB signaling, MAPK signalingCDCATGR5NF‐κB signaling, JAK2/STAT3 signalingDCAFXR, PXRNF‐κB signaling, EGFR/MAPK signaling, Wnt/β‐catenin signaling, ERK signalingLCAVDRNF‐κB signaling, Wnt/β‐catenin signalingUDCATGR5YAP signaling, EGFR/ERK signalingCA: cholic acid; CDCA: chenodeoxycholic acid; DCA: deoxycholic acid; LCA: lithocholic acid; UDCA: ursodeoxycholic acid; FXR: farnesoid X receptor; PXR: pregnane X receptor; VDR: vitamin D receptor; TGR5: G protein‐coupled bile acid receptor 1; NF‐κB: nuclear factor‐kappa B; MAPK: mitogen‐activated protein kinase; JAK2: Janus kinase 2; STAT3: signal transducer and activator of transcription 3; EGFR: epidermal growth factor receptor; ERK: extracellular regulated kinase; YAP: yes‐associated protein.Deoxycholic Acid (DCA)DCA, one of the main secondary BAs produced by Clostridium, is a tumor promoter in CRC.[98] Clinical studies found a relationship between serum DCA levels and colonic mucosal proliferation,[99] and more importantly, an increase in DCA levels in the sera and feces from patients with CRC.[89] The role of DCA in CRC progression is attributed its regulatory effects on cellular signaling cascades and its membrane perturbing effects. DCA has detergent properties that can result in membrane perturbations, leading to prostaglandin and ROS production from arachidonic acid via the activation of COX‐2 and lipooxygenase. This results in inflammation, angiogenic formation, DNA damage, and DNA repair inhibition, which could be reversed through apoptotic promoting effect of PXR through DCA resistance.[100] Additionally, the epidermal growth factor receptor and β‐catenin signaling pathway are activated in response to reduced expression of FXR,[101] and β‐catenin stabilized COX‐2 mRNA to form a positive feedback loop.[102] DCA was also found to specifically reduced adhesion of HET‐1A cells to vitronectin and reduced cell–surface expression of integrin‐αν via effects on endocytic recycling processes.[103] Moreover, DCA regulates p53 through proteasome‐mediated degradation by stimulating the extracellular signal‐related kinase (ERK) signaling pathway, thereby enhancing tumor promotion in CRC.[104]Lithocholic Acid (LCA)LCA, mainly produced by Clostridium, is a secondary BA that acts as an endogenous CRC promoter, similar to DCA.[99] It produces ROS in the gastrointestinal tract, leading to destruction of the epithelial layer through decreased apoptosis, enhanced cell proliferation, oxidative DNA damage, inflammatory reactions, and NF‐κB signaling pathway activation.[89] Additionally, LCA modulates the muscarinic 3 receptor and Wnt/β‐catenin signaling in colonic epithelial cells, promoting cancer stemness that play a role in the development of CRC.[105] Loss of the human leukocyte antigen was observed in colon adenocarcinoma cells after LCA treatment, and this may be an immune surveillance escape mechanism.[106] Furthermore, LCA treatment induced increased the expression of matrix metalloproteinase (MMP) genes, including MMP‐1, MMP‐2, and MMP‐7, and stimulated urokinase plasminogen activator receptor, which induced tumor invasion and metastasis and promoted a malignant epithelial phenotype.[107] IL‐8 expression was also enhanced when stimulated with LCA, thus, activating the ERK1/2/mitogen‐activated protein kinase (MAPK) signaling pathway, suppressing the activity of STAT3, and stimulating CRC angiogenesis.[108] However, LCA was also determined to be CRC‐protective in a context‐dependent manner with the VDR. LCA was found to bind and activate VDR, inducing expression of CYP3A in vivo, which functions to detoxify BAs in the liver and intestine, thereby providing protection against CRC.[109]Ursodeoxycholic Acid (UDCA)UDCA is a secondary BA and the 7β‐hydroxy isomer of CDCA produced by Parabacteroides distasonis, and used in clinical settings due to its therapeutic effects in cholesterol gallstone diseases and other digestive diseases, including biliary cirrhosis, sclerosing cholangitis, and recurrent pancreatitis.[98] However, the effect of UDCA on CRC remains debatable.UDCA exerts its therapeutic effects by upregulating the hydrophilicity of the biliary pool and downregulating the potency of harmful secondary BAs, including DCA and LCA which can lower inflammatory reactions on the colonic mucosa, through modulation of epidermal growth factor receptor/ERK signaling pathways.[110] UDCA can also inhibit the activation of COX‐2 by DCA, thereby controlling inflammatory reactions.[100a] In addition, UDCA was found to protect against malignant progression of CRC through TGR5–yes‐associated protein (YAP) axis.[111]By contrast, other studies have claimed that UDCA can be converted into toxic LCA by microorganisms and lead to CRC development and progression. The authors argued that Clostridium can convert UDCA to LCA and impact the 7α‐dehydroxylation of CA and CDCA.[112] Moreover, the protective effects of UDCA against colorectal adenomatous polyps were investigated, and UDCA had no significant overall effect on cancer risk reduction.[112] Further studies on UDCA are warranted to determine its effect and underlying mechanisms in CRC.SCFAsSCFAs are metabolites found in the digestive system, which are produced from microbial fermentation of fiber by anaerobic gut microbiota, including Firmicutes (Clostridium and Lactobacillus), Bacteroides (Bifidobacterium), Actinobacteria (Propionibacterium), Proteobacteria, and Verrucomicrobia.[113] SCFAs are easily absorbed and can supply energy to colon cells.[114] Butyrate, propionate, and acetate are the three main SCFAs in the intestines; butyrate is primarily produced by Firmicutes,[115] propionate by Firmicutes, Bacteroides, Acetobacterium, and Clostridium aceticum, and acetate by Propionibacterium species.[116] Importantly, SCFAs are a key component of glycolysis that play important roles in host and cell homeostasis,[117] act as protective molecules in CRC development, and change as the gut microbiota changes during tumor progression;[11b] therefore, SCFAs are closely associated with CRC development.ButyrateButyrate is produced by anaerobic bacteria (such as Roseburia intestinalis, Butyrivibriocrossotus, Faecalibacterium cf. prausnitzii) in the colon,[118] provides energy for colorectal epithelial cells,[119] and inhibits inflammation and tumor formation.[120] Expression of a butyrate transporter protein, which could maximize the transport and metabolism of butyrate induced by rapid beta‐oxidation to generate cellular fuel,[121] was reduced in tumors of patients with CRC.[122] Notably, epithelial barrier dysfunction is a major contributing factor to the development and progression of CRC because it triggers inflammation by activating macrophages that produce inflammatory cytokines.[123] Butyrate can help to maintain epithelial tight junctions through activation of adenosine monophosphate‐activated protein kinase[124] and protect the function of the colon epithelial barrier through induction of mucin 2 secretion,[125] which may occur in a GPR43‐dependent manner.[126] Moreover, butyrate can affect the internal nervous system and regulate neuronal excitability; thus, colon motility and extracorporeal contraction reactions are increased, which prevents CRC development.[127]Butyrate also accumulates and functions as a histone deacetylase (HDAC) inhibitor to accelerate histone acetylation and participate in the apoptosis and proliferation of CRC cells.[128] Additionally, butyrate impedes the angiogenesis, metastasis, and survival of CRC cells through the neuropilin‐1/vascular endothelial growth factor pathway by inhibiting Sp1 transactivation;[129] it can reduce cell proliferation, clone formation, and migration by promoting secretion of endocan through the ERK2/MAPK pathway;[130] butyrate inducing apoptosis in CRC cells by inhibiting the Wnt/β‐catenin signaling[131] and facilitates anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity.[132] In summary, butyrate acts as a vital gut microbiome metabolite and protects against the progression of CRC.Other SCFAsAcetate and propionate are SCFAs fermented from soluble fibers, which have protective effects against CRC. As the final product of fermentation, acetate can be condensed to butyrate in the human colon by bacteria, such as Roseburia spp., F. prausnitzii, and Coprococcus sp. through the action of butyryl‐CoA:acetate CoA‐transferase,[133] thereby contributing to the syntrophy of the gut microbiome and inhibiting CRC progression. Propionate is an HDAC inhibitor which inhibits malignant transformation and induces the apoptosis of precancerous colonic cells, despite its poor effectiveness (in comparison to butyrate) and reduced abundance in CRC.[134] Finally, formate secreted by F. nucleatum, can drives CRC tumor invasion by triggering Aryl hydrocarbon receptor signaling, while increasing cancer stemness.[135] Formate can be considered a gut‐derived oncometabolite relevant for CRC progression.Trimethylamine n‐oxide (TMAO)TMAO is a small organic compound, mainly produced by Enterobacteriaceae, whose concentration in blood increases after ingestion of dietary l‐carnitine and phosphatidylcholine. TMAO is a marker of cardiovascular risk associated with CRC. A prospective cohort study of 835 CRC cases and 835 matched controls found a positive correlation between plasma TMAO levels and CRC risk for the first time. The study showed that subjects with high plasma TMAO levels had a 3.4‐fold higher risk of CRC than subjects with low plasma TMAO levels.[136] In 2017, a study found that serum TMAO levels in patients with CRC was significantly higher than in healthy control subjects. In addition, the study reported that patients with higher serum TMAO levels have lower survival rates than those with lower serum TMAO levels, thus, serum TMAO is a possible prognostic marker for CRC.[137] Although these studies suggest a direct or indirect role for TMAO in CRC, others have shown no correlation between serum TMAO levels and CRC risk. A study conducted on 677 CRC patients and 677 healthy controls reported no significant correlation between serum TMAO levels and the incidence of CRC.[138] Since TMAO levels vary by ethnicity, diet, and region, larger clinical trials are needed to validate the TMAO–CRC correlation, and whether elevated TMAO levels are a cause or a consequence of cancer. Recent studies have postulated a possible association between TMAO levels and CRC, but there is no valid mechanistic approach to its role in carcinogenesis. As studied previously, TMAO may interact in several processes that could impact CRC, such as inflammation, protein folding, oxidative stress, and DNA damage.[139] Excess TMAO leads to sustained and uncontrolled ROS production, which causes inflammation. Inflammation can damage DNA, cause mutations or induce genomic instability, and ultimately leading to the development of CRC.[139]Amino AcidsWhen compared to healthy controls, 17 metabolites were significantly altered in CRC patients.[140] Among them, 10 metabolites are amino acids, specifically l‐alanine, glycine, l‐proline, l‐aspartate, l‐valine, l‐leucine, l‐serine, l‐phenylalanine, l‐α‐aminobutyric acid, and norvaline. Furthermore, differences in the pathways associated with branched‐chain amino acid (BCAA) metabolism in the stages leading to CRC were also observed. Compared to healthy control, the first 4 enriched pathways in CRC are 1) amyl‐tRNA biosynthesis, 2) valine, leucine, and isoleucine biosynthesis, 3) phenylalanine metabolism, and 4) phenylalanine, tyrosine, and tryptophan biosynthesis, suggesting that amino acids metabolic pathways other than individual amino acids in the colorectum are altered in the early the stages leading to CRC.[140]The metabolism of amino acids provides the host with biologically active metabolites through gut microbiota. The amino acid tryptophan is catabolized to a series of indole derivatives (e.g., indole‐3‐acetic acid, indole‐3‐sulfate, indole‐3‐propionic acid, and indole‐3‐aldehyde), which are ligand receptors for aromatic hydrocarbons, such as the Aryl hydrocarbon receptor. Activation of innate lymphocytes and aromatic hydrocarbons in gut‐resident T cells increases IL‐22 production, which helps to prevent colonic inflammation (colitis) and inflammatory bowel disease, which can lead to precancerous lesions.[141] In addition, in vivo, tryptophan metabolites not only suppress inflammation, but also fix abdominal wall structures and in association with beneficial bacteria in the gut, may slow the progression of CRC.[142] Tryptophan metabolism plays an important role in inhibiting the growth of CRC, although the underlying mechanism remains nebulous.Serine metabolism plays a crucial role in the proliferation and survival of tumor cells. Phosphoglycerate dehydrogenase (PHGDH), a key enzyme in serine biosynthesis, can undergo monoubiquitination and increase activity in CRC cells, thereby increasing levels of serine, glycine, and S‐adenosylmethionine (SAM), which in turn upregulates cell adhesion gene expression and promotes cell migration and CRC metastasis.[143]Other MetabolitesIn addition to the above, metabolites originating from dietary phytochemicals also play important roles in CRC. Most of the dietary phytochemicals are transformed into other metabolites by the gut microbiota in the colon through hydrogenation, dehydroxylation, and demethylation.[144] These metabolites have altered bioactivity, and some phenolic metabolites, such as the stilbene resveratrol and dehydroxylated phenolic acids, have anti‐inflammatory properties, thus, reducing the secretion of inflammatory cytokines, such as TNF‐α, COX‐2, and NF‐κB.[145] Moreover, a few phenolic compounds produced by the gut microbiota have antimicrobial effects and alter the composition of gut microbiota by suppressing pathogens such as C. perfringens, and promoting probiotics such as Lactobacilli spp.,[146] thereby producing knock‐on effects on gut microbiota metabolism.[16a] Besides, some virulence factors, such as Fusobacterium adhesin A (FadA) and fibroblast activation protein 2 (Fap2), are induced by gut microbiota and contribute to carcinogenesis. FadA, secreted by F. nucleatum, is a highly conserved virulence factor in C. perfringens that mediates adhesion and invasion of epithelial and endothelial cells.[47] The binding of FadA to E‐cadherin activates the β‐catenin signaling pathway, which in turn increases NF‐κB, Wnt7b, and the cyclin D1 and Myc oncogenes.[42] Fap2 is a galactose‐sensitive hemagglutinin and adhesin that may play a role in the virulence of C. perfringens.[147] The binding of Fap2 to the T‐cell immune receptor with immunoglobulin G inhibits the activity of natural killer cells against tumor cells, leading to the development of CRC.[148] Abed et al. showed that fusobacterial Fap2 could act as a lectin, binding to d‐galactose‐β‐(1–3)‐N‐acetyl‐d‐galactosamine, which is overexpressed in CRC.[149] Investigations on fecal metabolites associated with mouse models of colon tumorigenesis with varying mutational loads revealed that Lactobacillus reuteri and its metabolite, reuterin, are downregulated in mouse and human CRC. Reuterin may alter the redox balance and reduce proliferation and survival of colon cancer cells or induce selective protein oxidation and inhibit ribosomal biogenesis and protein translation to protect against CRC.[150]Several gut microbiota‐derived metabolites contribute to CRC development and progression. Thus, a better understanding of the gut microbiota pathways involved in the biosynthesis of CRC‐related metabolites would greatly aid in intestinal health management, especially CRC prevention. It is important to identify the causal role between gut microbiota‐derived metabolites and CRC.Role of Diet on the Gut Microbiota–Host InteractionsAs discussed above, the gut microbiota may influence the pathophysiology of host disease through several pathways, including the secretion of metabolites.[33] In addition, a direct correlation between diet and the type and amount of gut bacteria has been reported.[151] The impact of diet on gut microbiota–host interactions is increasingly recognized and explored (Table 5). The Western diet is characterized by high levels of protein, sugar, saturated fat, refined grains, alcohol, salt, high‐fructose corn syrup, and low levels of fiber.[152] It has been found to induce microbial dysbiosis, increasing the abundance of Fusobacterium spp., E. coli, and Enterobacter spp. and decreasing the abundance of Faecalibacterium prausnitzii, Roseburia hominis, and Bifidobacterium spp., thus leading to inflammatory responses in the host,[153] which increases the risk of CRC. A plant‐based diet has been found to increase the abundance of Bifidobacterium spp. and Lactobaccilus spp. and decrease the abundance of B. fragilis and C. perfringens, thereby reducing inflammatory responses.[154] Foxtail millet consumption has been shown to increase the abundance of Bifidobacterium spp. and Bacteroidales_S‐24‐7, thereby attenuating colonic inflammation and reducing colitis‐associated CRC in mouse models.[155] Research into the effect of diet on CRC‐associated gut microbiota–host interactions is still lacking. Given that diet is the most important factor influencing the dynamics of the gut microbiota, comprehensive studies of gut microbiota–host interactions shaped by diet have the potential to provide insights into the mechanisms underlying CRC.5TableDiet‐correlated gut microbiota–host interactionsDietGut microbiotaHost interactionIncreaseDecreaseWestern dietFusobacterium spp.Escherichia coliEnterobacter spp.Faecalibacterium prausnitziiRoseburia hominisBifidobacterium spp.ProinflammatoryPlant‐based dietBifidobacterium spp.Lactobaccilus spp.Bacteroides fragilisClostridium perfringensAnti‐inflammatoryFoxtail millet consumptionBifidobacterium spp.Bacteroidales_S‐24‐7∖Anti‐inflammatoryPotential Roles of Gut Microbiota and Its Metabolites in CRC Diagnosis and TreatmentOwing to the dysbiosis of gut microbiota, several species are involved in CRC diagnosis and treatment, which could be used as therapeutic targets. Herein, we summarized the applications of gut microbiota in screening, prognosis, and treatment of CRC (Figure 4).4FigureThe role of gut microbiota in CRC diagnosis and treatment. Detection of fecal bacteria including F. nucleatum, serum antibodies against F. nucleatum and gut microbiota metabolites including BAs and SCFAs could play roles in CRC screening. Fecal bacteria including two species of Bacteroides, Lachnospiraceae, Clostridiales, and Clostridium could be used to detect adenomas. F. nucleatum can be used in prognostic predictions for CRC patients. Treatment methods including chemotherapy, immunotherapy, and radiotherapy could disturb microbial community, while the composition of the gut microbiota could, in turn, affect the treatments. Methods including supplementation with probiotics, prebiotics and their metabolites, and fecal microbiota transplantation (FMT) could modify gut microbiota composition in order to treat CRC.Role of Gut Microbiota in CRC DiagnosisDue to the emerging clinical demand of CRC screening and treatment, which remarkably improves CRC prognosis,[156] research and development on accurate and noninvasive diagnostic methods are of necessity. In addition to traditional (endoscopy) and nascent (fecal immunochemical test (FIT) and circulating tumor DNA) diagnostic methods,[157] fecal microbial markers are a promising and desirable diagnostic tool as they seem accurate, economical, and noninvasive.[6]CRC ScreeningEarly detection of CRC through screening has been widely accepted as a main path in CRC prevention and treatment, and it significantly improves the overall survival rate of patients.[158] Fecal samples are most ideal for screening because of the noninvasive collection method. FIT has been applied in clinical settings in recent years, but its sensitivity for CRC is limited.[159] FIT using fecal DNA has >90% sensitivity in CRC detection, but <50% sensitivity in detecting advanced colorectal adenomas.[160]Fecal microbial markers are being considered to screen patients for CRC with enhanced sensitivity and accuracy. Based on microbiota‐based screening, several bacterial species with alterations in abundance were selected and compared to FIT and a fecal occult blood test.[161] Among the selected bacteria, addition of F. nucleatum screening enhanced the accuracy and sensitivity of FIT,[161b,162] which reached a sensitivity and specificity of 84.6% and 92.3%, respectively, when combined with Bifidobacterium[163] and a sensitivity and specificity of 84.6% and 63.1%, respectively, when combined with colibactin‐producing bacteria.[164] In addition, serum antibodies against F. nucleatum were also useful in CRC detection.[165] Importantly, detection of adenomas is also a key factor in CRC prevention. Combination of the abundance of five bacterial species and other clinical parameters reached an AUC of 0.90, indicating the potential value of fecal microbial markers in colorectal adenoma detection.[166] Interestingly, an increased abundance of F. nucleatum was also detected in the fecal samples of patients with adenomas, and this can be evaluated in further studies.[161b]Additionally, gut microbiota metabolites have the potential in screening for CRC. Divergence of BAs and SCFAs were determined in fecal extracts.[167] Higher levels of acetate, valeric acid, isobutyric acid, and isovaleric acid, and lower levels of butyrate, linoleic acid, glycerol, oleic acid, and trans‐oleic acid were detected in patients with CRC than in healthy individuals.[167] However, further large‐scale clinical studies should be conducted to investigate the feasibility of CRC screening using fecal microbial markers, gut microbiota, and its metabolites.Prediction of CRC PrognosisFecal microbial markers are correlated to the clinical outcomes of CRC and are useful in predicting CRC prognosis.[25] F. nucleatum is a key factor in prognostication; its abundance in CRC tumors is negatively correlated with patients’ survival.[168] Importantly, further research on the value of bacterial markers in CRC prognostication must be conducted, with a wider range of microorganisms and limited interference factors.Role of Gut Microbiota in CRC TreatmentChemotherapy and immunotherapy have dramatically improved the survival of patients, but the side effects and sequelae have become increasingly significant. These therapies disturb the gut microbiota leading to dysbiosis which can be reversed after treatment.[169] More importantly, the gut microbiota can enhance treatment efficacy and reduce adverse effects.[170]ChemotherapyChemotherapy disturbs the microbial community, leading to a reduction in microbial diversity and changes in the abundance of several bacteria.[171] For example, treatment with 5‐fluorouracil (5‐FU) can result in the enrichment of Proteobacteria, and decrease of Firmicutes and Actinobacteria, resulting in a reduction of inflammatory reactions through interaction with the NF‐κB signaling pathway and production of SCFAs.[172] Conversely, the gut microbiota can also affect chemotherapy within a mechanistic framework: translocation, immunomodulation, metabolism, enzymatic degradation, and reduced diversity and ecological variation (TIMER).[169] The curative effects of many widely applied agents, including 5‐FU,[172] gemcitabine,[173] oxaliplatin,[174] and cyclophosphamide,[175] are regulated by gut microbiota using the TIMER mechanism. In vivo studies have proven that a lack of gut microorganisms can diminish the therapeutic effects of drugs on tumor‐infiltrating myeloid‐derived cells and lead to ROS production and cytotoxicity.[174] Notably, F. nucleatum has been shown to enhance the resistance of colonized tumors to the therapeutic effects of 5‐FU and oxaliplatin through the activation of cell autophagy.[40] Therefore, chemotherapy can be augmented by therapeutic agents targeting F. nucleatum to improve treatment outcomes, and detection of this bacterium may predict the potency of chemotherapy, thus, it should be considered in the future.ImmunotherapyInhibitory signals of T cell activation can be reversed by immune checkpoint inhibitors (ICIs) to enable tumor‐reactive T cells to induce significant antitumor responses.[176] This type of immunotherapy has not been widely applied in clinical settings but has attracted great attention as a promising therapeutic pathway in CRC treatment,[177] especially in patients with CRC who have high levels of microsatellite instability and/or DNA mismatch repair‐deficient metastasis.[178] Interestingly, immunotherapy alters the composition of the gut microbiota,[179] which has a role in the immune responses generated by immunotherapy.[180] The gut microbiota regulates a few pivotal ICIs, including the programmed cell death 1 (PD‐1)/PD‐1 ligand 1[181] and cytotoxic T lymphocyte‐associated antigen 4 axes.[182] Several bacteria, including B. fragilis,[182a] Akkermansia muciniphila,[181a] Alistipes shahii,[174] Bifidobacterium spp.,[181b,d] Faecalibacterium spp.,[183] and Eubacterium limosum,[184] are advantageous to immunotherapy. Bacterial supplements of Lactobacillus, Ruminococcus, and Alistipes can enhance the therapeutic response to ICIs,[174] and bacteria, such as Akkermansia muciniphila, accumulate in immunotherapy responders.[185] However, some of the side effects of immunotherapy are correlated with the gut microbiota,[182a] and resistance to immunotherapy is associated with several bacteria, including Bacteroidetes.[186] Therefore, additional treatment targeting these bacteria might be conducive to the therapeutic efficacy of immunotherapy toward cancers, including CRC.[174,187]Probiotics and PrebioticsWith the increasing awareness of the importance of gut microbiota in tumorigenesis and cancer treatment outcomes, restoring intestinal microbiota homeostasis has become a potential CRC prevention and treatment measure. Probiotics and prebiotics are emerging biotherapeutics, which modify the gut microbiota, thus, benefiting the host.[188]Probiotics are microorganisms which benefit the human body if taken in moderation.[188] Lactobacillus and Bifidobacterium are the most studied probiotics in CRC treatment.[189] As the concept of probiotics evolved over the past few decades, it is now understood that the effects of probiotics are not only microbiota‐mediated, but also host‐mediated through the induction of physiological and metabolic changes. Probiotic administration corrects microbial dysbiosis and maintains the intestinal microbial balance by occupying host tissues, preventing colonization by pathogenic bacteria, exerting immunomodulatory effects, and enhancing gut barrier function.[190] Evidence has indicated that probiotics could diminish tumor incidence and act as a preventive treatment for CRC. For instance, Lactobacillus plantarum decreased tumor development by increasing the innate immune response through a set of reactions, including dendritic cell maturation which led to the polarization of Th1 responses, migration of CD8+ and natural killer cells, reduction of tumor growth, and prolongation of survival of mice with CRC.[191] Furthermore, clinical trials have indicated that a lower incidence of moderate and higher atypia‐graded tumors were found in patients receiving a preparation of Lactobacillus casei than in patients not receiving this probiotic.[192]Prebiotics are substrates which are selectively utilized by host microorganisms that confer health benefits.[188] At present, prebiotics are predominantly carbohydrate‐based, but other substances, such as polyphenols and polyunsaturated fatty acids, may also play a prebiotic role.[188] Prebiotics exert their beneficial health effects in the intestines mainly by stimulating the growth and selective fermentation of probiotics, interacting with pathogens and preventing colonization, playing an anti‐inflammatory role, exerting selective cytotoxicity on tumor cells, inhibiting the apoptosis of normal epithelial cells, and enhancing IgA secretion that protects the intestinal epithelium.[190] Butyrate treatment promotes epithelial cell proliferation, polyp formation, and ultimately leads to tumor progression in Apcmin/+; Msh2−/− mice.[193] Though the strength of evidence for prebiotic interventions lags behind that for probiotics, prebiotics may improve the abundance of four symbiotic microbes, which can be opportunistic pathogens in patients with CRC.[194]Although the results of animal experiments are highly encouraging, the quantity and quality of clinal trials related to this field remains limited. It has been extremely challenging to conduct randomized clinical trials with large sample sizes, proper randomization, analysis, and validation to obtain sufficient evidence to support the benefit of prebiotic treatment in CRC.Other Microbiota‐Related Therapeutic ApproachesOther microbiota‐related therapeutic approaches which may be effective against CRC are also being considered. These include antibiotics and fecal microbiota transplantation (FMT). Antibiotic treatment may kill intestinal microbiota and reverse harmful dysbiosis primarily through the elimination of carcinogenic B. fragilis, mucin degradation, inflammation, and DNA methylation.[195] Metronidazole treatment reduced cancer cell proliferation and shrunk tumor volume in mice bearing a colon cancer xenograft.[78] Another study also reported that an antibiotic cocktail composed of ampicillin, neomycin, metronidazole, and vancomycin depleted the gut microbiota and attenuated colon tumor formation in mice fed a high‐fat diet.[196] However, the role of antibiotic treatment in cancer management is controversial as a register‐based study showed a robust association between antibiotic treatment and an increased risk of proximal CRC.[197]FMT from healthy donors to individuals with cancer restores microbial homeostasis, which may be helpful for improving various gastrointestinal diseases, including irritable bowel syndrome, Clostridium difficile infection, and CRC.[198] FMT also increases microbial diversity without disruption of the microbial gut ecology in contrast to antibiotic treatment, and its long‐term implantation allows it to be designed as a single‐dose regimen, thus, adding therapeutic benefits to probiotics and prebiotics, whose effects are short‐term.[199] A recent study reported that FMT from wild mice to laboratory mice improved host fitness and resistance against AOM/DSS‐induced colorectal tumorigenesis.[200] The practical application of FMT in patients with CRC awaits trial results on its effect (in combination with cancer immunotherapy or chemotherapy), which are in progress.[201] Other novel approaches could include bacteriocins[202] or bacteriophages[203] to modify the gut microbiota. More studies are imperative to evaluate the clinical application potential of these engineered products in CRC.Conclusions and OutlookDifferences in the composition and abundance of the gut microbiota in patients with CRC patients and interaction between the gut microbiota and CRC have been reported. The gut microbiota and its metabolites interact closely with host epithelial cells and have a crucial role in CRC. As research elucidates the role played by intestinal flora during carcinogenesis, it offers unprecedented opportunities to explore applications in CRC diagnosis, treatment, and prognosis, although many obstacles remain.Some questions are still to be answered by future research. Evidence such as the increased abundance of F. nucleatum, E. coli, or B. fragilis in CRC provides an opportunity for these organisms to be targeted as biomarkers in conjunction with conventional diagnostics. However, due to the diversity of sequencing methods, it is difficult to reach a consensus on the composition of the gut microbiota. Therapeutic approaches targeting the microbiome are gaining attention in clinical applications, yet their implementation remains challenging due to the numerous effects of the gut microbiota on host biology, many of which are currently unknown. More importantly, it should be of great concern that lifestyle, drugs, genetics, and other factors could have a significant impact on the remodeling of the gut microbiota. However, these influencing factors have been ignored and not corrected in many cancer studies, thus confounding the real facts and leading to potentially mistaken conclusions. Care should be taken to control for confounding factors in order to find the key bacteria and mechanisms that really influence the pathogenesis of cancers, including CRC, when analyzing the complex and diverse sequencing data of large sample size. For the metabolites, there is still a lack of evidence on the source of the metabolites detected in feces or serum, and there is still a debate on whether they are secreted by the gut microbiota or the host, or whether they are ingested from the diet. Clarification of metabolite sources will facilitate research into subsequent treatment modalities for CRC.Exploring the significance of clinical transformation is an important direction for future microbial research. There could be three major potential applications of gut microbiota in CRC, including noninvasive diagnostic tools, restoration of microbial dysbiosis or probiotic supplementation for CRC prevention, or modulation of gut microbes to enhance therapeutic responses. Bacteria‐based therapy could be achieved by selective elimination of oncogenic microbes, fecal transplantation of antitumor species, and altering the composition of the microbiota through oral probiotic supplementation or targeted phage therapy. However, large‐scale clinical trials based on rigorous animal studies are needed to further establish their efficacy and safety in the clinic. Thus, such applications still remain a long way from routine use.To proclaim the expected clinical potential of the gut microbiota in CRC, researchers must decipher whether specific strains or the collective capabilities of some microbiota, influence the development of disease. Further studies are needed to help fully determine the pathogenic role of the gut microbiota in carcinogenesis and its response to treatment, and to address the challenges that impede the achievement of personalized medicine, by focusing on specific individuals including early‐onset patients. With the vigorous development in this rapidly developing field, gut microbiota will become a crucial part of future diagnosis, cancer prevention, and treatment measures.AcknowledgementsThe authors acknowledge Dr. Jucheng Bai from Peking University Third Hospital for the modification of figures. This research was supported in part by the National Key Research and Development Program of China (2018YFA0800700), the National Natural Science Foundation of China (Nos. 82130022, 31925021, 81972702, 91959110, 82273104, and 62173005), Peking University Clinical Scientist Training Program Project (BMU2023PYJH021), and the National Health and Family Planning Commission Foundation of China (Grant No. 2020YB57).Conflict of InterestThe authors declare no conflict of interest.Author ContributionsR.Q., Y.Z., and Y.M. contributed equally to the work. All authors have contributed to the article and approved its publication. R.Q., Y.Z., Y.M., X.Z., and L.S.: designing, writing, and figure preparation. L.S., C.J., Z.Z., and W.F.: designing, funding acquisition, reviewing, and editing.R. L. Siegel, K. D. Miller, N. S. Wagle, A. Jemal, Ca‐Cancer J. Clin. 2023, 73, 17.a) S. Bian, Y. Hou, X. Zhou, X. Li, J. Yong, Y. Wang, W. Wang, J. Yan, B. Hu, H. Guo, J. Wang, S. Gao, Y. Mao, J. Dong, P. Zhu, D. Xiu, L. Yan, L. Wen, J. Qiao, F. Tang, W. Fu, Science 2018, 362, 1060;b) S. Mo, P. Tang, W. Luo, L. Zhang, Y. Li, X. Hu, X. Ma, Y. Chen, Y. Bao, X. He, G. Fu, X. Xu, X. Rao, X. Li, R. Guan, S. Chen, Y. Deng, T. Lv, P. Mu, Q. Zheng, S. Wang, F. Liu, Y. Li, W. Sheng, D. Huang, C. Hu, J. Gao, Z. Zhang, S. Cai, H. Clevers, et al., Adv. Sci. 2022, 9, 2204097.E. S. Oh, A. Petronis, Nat. Rev. Genet. 2021, 22, 533.A. Janney, F. Powrie, E. H. Mann, Nature 2020, 585, 509.S. Yachida, S. Mizutani, H. Shiroma, S. Shiba, T. Nakajima, T. Sakamoto, H. Watanabe, K. Masuda, Y. Nishimoto, M. Kubo, F. Hosoda, H. Rokutan, M. Matsumoto, H. Takamaru, M. Yamada, T. Matsuda, M. Iwasaki, T. Yamaji, T. Yachida, T. Soga, K. Kurokawa, A. Toyoda, Y. Ogura, T. Hayashi, M. Hatakeyama, H. Nakagama, Y. Saito, S. Fukuda, T. Shibata, T. Yamada, Nat. Med. 2019, 25, 968.S. H. Wong, J. Yu, Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 690.M. Schmitt, F. R. Greten, Nat. Rev. Immunol. 2021, 21, 653.X. Liu, X. Tong, Y. Zou, X. Lin, H. Zhao, L. Tian, Z. Jie, Q. Wang, Z. Zhang, H. Lu, L. Xiao, X. Qiu, J. Zi, R. Wang, X. Xu, H. Yang, J. Wang, Y. Zong, W. Liu, Y. Hou, S. Zhu, H. Jia, T. Zhang, Nat. Genet. 2022, 54, 52.S. Heilbronner, B. Krismer, H. Brötz‐Oesterhelt, A. Peschel, Nat. Rev. Microbiol. 2021, 19, 726.a) J. Li, W. Hou, S. Lin, L. Wang, C. Pan, F. Wu, J. Liu, Adv. Sci. 2022, 9, 2104006;b) J. Cai, L. Sun, F. J. Gonzalez, Cell Host Microbe 2022, 30, 289.a) S. Rezasoltani, H. Asadzadeh Aghdaei, H. Dabiri, A. Akhavan Sepahi, M. H. Modarressi, E. Nazemalhosseini Mojarad, Microb. Pathog. 2018, 124, 244;b) E. Saus, S. Iraola‐Guzmán, J. R. Willis, A. Brunet‐Vega, T. Gabaldón, Mol. Aspects Med. 2019, 69, 93.a) J. M. Brown, S. L. Hazen, Nat. Rev. Microbiol. 2018, 16, 171;b) L. Ge, J. Qi, B. Shao, Z. Ruan, Y. Ren, S. Sui, X. Wu, X. Sun, S. Liu, S. Li, C. Xu, W. Song, Gut Microbes 2022, 14, 2013764;c) M. D. Gershon, K. G. Margolis, J. Clin. Invest. 2021, 131, 143768.R. Qu, Y. Ma, L. Tao, X. Bao, X. Zhou, B. Wang, F. Li, S. Lu, L. Tuo, S. Zhan, Z. Zhang, W. Fu, Chin. J. Cancer Res. 2021, 33, 500,A. P. Bhatt, M. R. Redinbo, S. J. Bultman, Ca‐Cancer J. Clin. 2017, 67, 326.G. D. Sepich‐Poore, L. Zitvogel, R. Straussman, J. Hasty, J. A. Wargo, R. Knight, Science 2021, 371, 4552.a) Z. E. Stine, Z. T. Schug, J. M. Salvino, C. V. Dang, Nat. Rev. Drug Discovery 2021, 21, 141;b) F. Kong, C. Fang, Y. Zhang, L. Duan, D. Du, G. Xu, X. Li, H. Li, Y. Yin, H. Xu, K. Zhang, Adv. Sci. 2022, 9, 2105523.Y. S. Chen, J. Li, R. Menon, A. Jayaraman, K. Lee, Y. Huang, W. M. Dashwood, K. Zhang, D. Sun, R. H. Dashwood, Gut Microbes 2021, 13, 1972756.J. E. Wilkinson, E. A. Franzosa, C. Everett, C. Li, F. B. Hu, D. F. Wirth, M. Song, A. T. Chan, E. Rimm, W. S. Garrett, C. Huttenhower, Nat. Med. 2021, 27, 766.Z. Dai, O. O. Coker, G. Nakatsu, W. K. K. Wu, L. Zhao, Z. Chen, F. K. L. Chan, K. Kristiansen, J. J. Y. Sung, S. H. Wong, J. Yu, Microbiome 2018, 6, 70.Y. He, W. Wu, H. M. Zheng, P. Li, D. McDonald, H. F. Sheng, M. X. Chen, Z. H. Chen, G. Y. Ji, Z. D. Zheng, P. Mujagond, X. J. Chen, Z. H. Rong, P. Chen, L. Y. Lyu, X. Wang, C. B. Wu, N. Yu, Y. J. Xu, J. Yin, J. Raes, R. Knight, W. J. Ma, H. W. Zhou, Nat. Med. 2018, 24, 1532.B. A. Peters, C. Dominianni, J. A. Shapiro, T. R. Church, J. Wu, G. Miller, E. Yuen, H. Freiman, I. Lustbader, J. Salik, C. Friedlander, R. B. Hayes, J. Ahn, Microbiome 2016, 4, 69.B. Flemer, D. B. Lynch, J. M. Brown, I. B. Jeffery, F. J. Ryan, M. J. Claesson, M. O'Riordain, F. Shanahan, P. W. O'Toole, Gut 2017, 66, 633.Q. Feng, S. Liang, H. Jia, A. Stadlmayr, L. Tang, Z. Lan, D. Zhang, H. Xia, X. Xu, Z. Jie, L. Su, X. Li, X. Li, J. Li, L. Xiao, U. Huber‐Schönauer, D. Niederseer, X. Xu, J. Y. Al‐Aama, H. Yang, J. Wang, K. Kristiansen, M. Arumugam, H. Tilg, C. Datz, J. Wang, Nat. Commun. 2015, 6, 6528.A. D. Kostic, E. Chun, L. Robertson, J. N. Glickman, C. A. Gallini, M. Michaud, T. E. Clancy, D. C. Chung, P. Lochhead, G. L. Hold, E. M. El‐Omar, D. Brenner, C. S. Fuchs, M. Meyerson, W. S. Garrett, Cell Host Microbe 2013, 14, 207.G. Nakatsu, H. Zhou, W. K. K. Wu, S. H. Wong, O. O. Coker, Z. Dai, X. Li, C. H. Szeto, N. Sugimura, T. Y. Lam, A. C. Yu, X. Wang, Z. Chen, M. C. Wong, S. C. Ng, M. T. V. Chan, P. K. S. Chan, F. K. L. Chan, J. J. Sung, J. Yu, Gastroenterology 2018, 155, 529.S. Ogino, A. T. Chan, C. S. Fuchs, E. Giovannucci, Gut 2011, 60, 397.G. D. Hannigan, M. B. Duhaime, M. T. t. Ruffin, C. C. Koumpouras, P. D. Schloss, mBio 2018, 9, 02248.O. O. Coker, G. Nakatsu, R. Z. Dai, W. K. K. Wu, S. H. Wong, S. C. Ng, F. K. L. Chan, J. J. Y. Sung, J. Yu, Gut 2019, 68, 654.M. Xue, H. Liang, X. Ji, Z. Zhou, Y. Liu, T. Sun, L. Zhang, J. Nutr. Biochem. 2020, 82, 108396.S. H. Wong, L. Zhao, X. Zhang, G. Nakatsu, J. Han, W. Xu, X. Xiao, T. N. Y. Kwong, H. Tsoi, W. K. K. Wu, B. Zeng, F. K. L. Chan, J. J. Y. Sung, H. Wei, J. Yu, Gastroenterology 2017, 153, 1621.a) J. Yu, Q. Feng, S. H. Wong, D. Zhang, Q. Y. Liang, Y. Qin, L. Tang, H. Zhao, J. Stenvang, Y. Li, X. Wang, X. Xu, N. Chen, W. K. Wu, J. Al‐Aama, H. J. Nielsen, P. Kiilerich, B. A. Jensen, T. O. Yau, Z. Lan, H. Jia, J. Li, L. Xiao, T. Y. Lam, S. C. Ng, A. S. Cheng, V. W. Wong, F. K. Chan, X. Xu, H. Yang, et al., Gut 2017, 66, 70;b) Y. Gao, D. Bi, R. Xie, M. Li, J. Guo, H. Liu, X. Guo, J. Fang, T. Ding, H. Zhu, Y. Cao, M. Xing, J. Zheng, Q. Xu, Q. Xu, Q. Wei, H. Qin, Signal Transduction Targeted Ther. 2021, 6, 398;c) Y. Wu, N. Jiao, R. Zhu, Y. Zhang, D. Wu, A. J. Wang, S. Fang, L. Tao, Y. Li, S. Cheng, X. He, P. Lan, C. Tian, N. N. Liu, L. Zhu, Nat. Commun. 2021, 12, 3063.Q. Liang, J. Chiu, Y. Chen, Y. Huang, A. Higashimori, J. Fang, H. Brim, H. Ashktorab, S. C. Ng, S. S. M. Ng, S. Zheng, F. K. L. Chan, J. J. Y. Sung, J. Yu, Clin. Cancer Res. 2017, 23, 2061.H. Tilg, T. E. Adolph, R. R. Gerner, A. R. Moschen, Cancer Cell 2018, 33, 954.a) J. Goc, M. Lv, N. J. Bessman, A. L. Flamar, S. Sahota, H. Suzuki, F. Teng, G. G. Putzel, G. Eberl, D. R. Withers, J. C. Arthur, M. A. Shah, G. F. Sonnenberg, Cell 2021, 184, 5015;b) P. Liu, C. Gao, H. Chen, C. T. Vong, X. Wu, X. Tang, S. Wang, Y. Wang, Acta Pharm. Sin. B 2021, 11, 2798;c) S. Beyaz, C. Chung, H. Mou, K. E. Bauer‐Rowe, M. E. Xifaras, I. Ergin, L. Dohnalova, M. Biton, K. Shekhar, O. Eskiocak, K. Papciak, K. Ozler, M. Almeqdadi, B. Yueh, M. Fein, D. Annamalai, E. Valle‐Encinas, A. Erdemir, K. Dogum, V. Shah, A. Alici‐Garipcan, H. V. Meyer, D. M. Özata, E. Elinav, A. Kucukural, P. Kumar, J. P. McAleer, J. G. Fox, C. A. Thaiss, A. Regev, et al., Cell Stem Cell 2021, 28, 1922.E. Cremonesi, V. Governa, J. F. G. Garzon, V. Mele, F. Amicarella, M. G. Muraro, E. Trella, V. Galati‐Fournier, D. Oertli, S. R. Däster, R. A. Droeser, B. Weixler, M. Bolli, R. Rosso, U. Nitsche, N. Khanna, A. Egli, S. Keck, J. Slotta‐Huspenina, L. M. Terracciano, P. Zajac, G. C. Spagnoli, S. Eppenberger‐Castori, K. P. Janssen, L. Borsig, G. Iezzi, Gut 2018, 67, 1984.T. Secher, S. Normand, M. Chamaillard, Gut Microbes 2013, 4, 353.H. Zhu, W. Y. Xu, Z. Hu, H. Zhang, Y. Shen, S. Lu, C. Wei, Z. G. Wang, J. Exp. Clin. Cancer Res. 2017, 36, 2.R. Kesselring, J. Glaesner, A. Hiergeist, E. Naschberger, H. Neumann, S. M. Brunner, A. K. Wege, C. Seebauer, G. Köhl, S. Merkl, R. S. Croner, C. Hackl, M. Stürzl, M. F. Neurath, A. Gessner, H. J. Schlitt, E. K. Geissler, S. Fichtner‐Feigl, Cancer Cell 2016, 29, 684.S. M. Man, Q. Zhu, L. Zhu, Z. Liu, R. Karki, A. Malik, D. Sharma, L. Li, R. K. Malireddi, P. Gurung, G. Neale, S. R. Olsen, R. A. Carter, D. J. McGoldrick, G. Wu, D. Finkelstein, P. Vogel, R. J. Gilbertson, T. D. Kanneganti, Cell 2015, 162, 45.T. Yu, F. Guo, Y. Yu, T. Sun, D. Ma, J. Han, Y. Qian, I. Kryczek, D. Sun, N. Nagarsheth, Y. Chen, H. Chen, J. Hong, W. Zou, J. Y. Fang, Cell 2017, 170, 548.C. A. Brennan, S. L. Clay, S. L. Lavoie, S. Bae, J. K. Lang, D. Fonseca‐Pereira, K. G. Rosinski, N. Ou, J. N. Glickman, W. S. Garrett, Gut Microbes 2021, 13, 1987780.M. R. Rubinstein, X. Wang, W. Liu, Y. Hao, G. Cai, Y. W. Han, Cell Host Microbe 2013, 14, 195.Y. Yang, W. Weng, J. Peng, L. Hong, L. Yang, Y. Toiyama, R. Gao, M. Liu, M. Yin, C. Pan, H. Li, B. Guo, Q. Zhu, Q. Wei, M. P. Moyer, P. Wang, S. Cai, A. Goel, H. Qin, Y. Ma, Gastroenterology 2017, 152, 851.X. Ye, R. Wang, R. Bhattacharya, D. R. Boulbes, F. Fan, L. Xia, H. Adoni, N. J. Ajami, M. C. Wong, D. P. Smith, J. F. Petrosino, S. Venable, W. Qiao, V. Baladandayuthapani, D. Maru, L. M. Ellis, Cancer Prev. Res. 2017, 10, 398.S. Chen, T. Su, Y. Zhang, A. Lee, J. He, Q. Ge, L. Wang, J. Si, W. Zhuo, L. Wang, Gut Microbes 2020, 11, 511.H. Liu, J. Du, S. Chao, S. Li, H. Cai, H. Zhang, G. Chen, P. Liu, P. Bu, Adv. Sci. 2022, 9, 2105222.M. R. Rubinstein, J. E. Baik, S. M. Lagana, R. P. Han, W. J. Raab, D. Sahoo, P. Dalerba, T. C. Wang, Y. W. Han, EMBO Rep. 2019, 20, 47638.C. Palmela, C. Chevarin, Z. Xu, J. Torres, G. Sevrin, R. Hirten, N. Barnich, S. C. Ng, J. F. Colombel, Gut 2018, 67, 574.I. Sobhani, H. Rotkopf, K. Khazaie, Gut Microbes 2020, 12, 1800898.K. A. Lee, M. K. Luong, H. Shaw, P. Nathan, V. Bataille, T. D. Spector, Br. J. Cancer 2021, 125, 1197.P. J. Dziubańska‐Kusibab, H. Berger, F. Battistini, B. A. M. Bouwman, A. Iftekhar, R. Katainen, T. Cajuso, N. Crosetto, M. Orozco, L. A. Aaltonen, T. F. Meyer, Nat. Med. 2020, 26, 1063.a) J. C. Arthur, E. Perez‐Chanona, M. Mühlbauer, S. Tomkovich, J. M. Uronis, T. J. Fan, B. J. Campbell, T. Abujamel, B. Dogan, A. B. Rogers, J. M. Rhodes, A. Stintzi, K. W. Simpson, J. J. Hansen, T. O. Keku, A. A. Fodor, C. Jobin, Science 2012, 338, 120;b) S. Tomkovich, Y. Yang, K. Winglee, J. Gauthier, M. Mühlbauer, X. Sun, M. Mohamadzadeh, X. Liu, P. Martin, G. P. Wang, E. Oswald, A. A. Fodor, C. Jobin, Cancer Res. 2017, 77, 2620.N. Dalal, R. Jalandra, N. Bayal, A. K. Yadav, Harshulika, M. Sharma, G. K. Makharia, P. Kumar, R. Singh, P. R. Solanki, A. Kumar, J. Cancer Res. Clin. Oncol. 2021, 147, 3141.A. Bertocchi, S. Carloni, P. S. Ravenda, G. Bertalot, I. Spadoni, A. Lo Cascio, S. Gandini, M. Lizier, D. Braga, F. Asnicar, N. Segata, C. Klaver, P. Brescia, E. Rossi, A. Anselmo, S. Guglietta, A. Maroli, P. Spaggiari, N. Tarazona, A. Cervantes, S. Marsoni, L. Lazzari, M. G. Jodice, C. Luise, M. Erreni, S. Pece, P. P. Di Fiore, G. Viale, A. Spinelli, C. Pozzi, et al., Cancer Cell 2021, 39, 708.S. Wu, K. J. Rhee, E. Albesiano, S. Rabizadeh, X. Wu, H. R. Yen, D. L. Huso, F. L. Brancati, E. Wick, F. McAllister, F. Housseau, D. M. Pardoll, C. L. Sears, Nat. Med. 2009, 15, 1016.L. Chung, E. Thiele Orberg, A. L. Geis, J. L. Chan, K. Fu, C. E. DeStefano Shields, C. M. Dejea, P. Fathi, J. Chen, B. B. Finard, A. J. Tam, F. McAllister, H. Fan, X. Wu, S. Ganguly, A. Lebid, P. Metz, S. W. Van Meerbeke, D. L. Huso, E. C. Wick, D. M. Pardoll, F. Wan, S. Wu, C. L. Sears, F. Housseau, Cell Host Microbe 2018, 23, 203.A. L. Geis, H. Fan, X. Wu, S. Wu, D. L. Huso, J. L. Wolfe, C. L. Sears, D. M. Pardoll, F. Housseau, Cancer Discovery 2015, 5, 1098.L. DeDecker, B. Coppedge, J. Avelar‐Barragan, W. Karnes, K. Whiteson, Gut Microbes 2021, 13, 1854641.A. C. Goodwin, C. E. Destefano Shields, S. Wu, D. L. Huso, X. Wu, T. R. Murray‐Stewart, A. Hacker‐Prietz, S. Rabizadeh, P. M. Woster, C. L. Sears, R. A. Casero Jr, Proc. Natl. Acad. Sci. USA 2011, 108, 15354.J. Allen, S. Hao, C. L. Sears, W. Timp, Infect. Immun. 2019, 87.a) J. C. Taylor, X. Gao, J. Xu, M. Holder, J. Petrosino, R. Kumar, W. Liu, M. Höök, C. Mackenzie, A. Hillhouse, W. Brashear, M. P. Nunez, Y. Xu, PLoS Pathog. 2021, 17, 1009182;b) L. Aymeric, F. Donnadieu, C. Mulet, L. du Merle, G. Nigro, A. Saffarian, M. Bérard, C. Poyart, S. Robine, B. Regnault, P. Trieu‐Cuot, P. J. Sansonetti, S. Dramsi, Proc. Natl. Acad. Sci. USA 2018, 115, E283.J. Butt, B. Romero‐Hernández, B. Pérez‐Gómez, M. Willhauck‐Fleckenstein, D. Holzinger, V. Martin, V. Moreno, C. Linares, T. Dierssen‐Sotos, A. Barricarte, A. Tardón, J. M. Altzibar, E. Moreno‐Osset, F. Franco, R. O. Requena, J. M. Huerta, A. Michel, T. Waterboer, G. Castaño‐Vinyals, M. Kogevinas, M. Pollán, A. Boleij, S. de Sanjosé, R. Del Campo, H. Tjalsma, N. Aragonés, M. Pawlita, Int. J. Cancer 2016, 138, 1670.a) R. Kumar, J. L. Herold, D. Schady, J. Davis, S. Kopetz, M. Martinez‐Moczygemba, B. E. Murray, F. Han, Y. Li, E. Callaway, R. S. Chapkin, W. M. Dashwood, R. H. Dashwood, T. Berry, C. Mackenzie, Y. Xu, PLoS Pathog. 2017, 13, 1006440;b) Y. Zhang, Y. Weng, H. Gan, X. Zhao, F. Zhi, Biochem. Biophys. Res. Commun. 2018, 506, 907.Q. Guo, J. Z. Goldenberg, C. Humphrey, R. El Dib, B. C. Johnston, Cochrane Database Syst. Rev. 2019, 4, 004827.X. Zhang, D. Yu, D. Wu, X. Gao, F. Shao, M. Zhao, J. Wang, J. Ma, W. Wang, X. Qin, Y. Chen, P. Xia, S. Wang, Cell Host Microbe 2023, 31, 418.M. K. Stoeva, J. Garcia‐So, N. Justice, J. Myers, S. Tyagi, M. Nemchek, P. J. McMurdie, O. Kolterman, J. Eid, Gut Microbes 2021, 13, 1.A. Koh, F. De Vadder, P. Kovatcheva‐Datchary, F. Bäckhed, Cell 2016, 165, 1332.D. Chen, D. Jin, S. Huang, J. Wu, M. Xu, T. Liu, W. Dong, X. Liu, S. Wang, W. Zhong, Y. Liu, R. Jiang, M. Piao, B. Wang, H. Cao, Cancer Lett 2020, 469, 456.M. M. Leonard, F. Valitutti, H. Karathia, M. Pujolassos, V. Kenyon, B. Fanelli, J. Troisi, P. Subramanian, S. Camhi, A. Colucci, G. Serena, S. Cucchiara, C. M. Trovato, B. Malamisura, R. Francavilla, L. Elli, N. A. Hasan, A. R. Zomorrodi, R. Colwell, A. Fasano, Proc. Natl. Acad. Sci. USA 2021, 118.Q. Li, W. Hu, W. X. Liu, L. Y. Zhao, D. Huang, X. D. Liu, H. Chan, Y. Zhang, J. D. Zeng, O. O. Coker, W. Kang, S. S. M. Ng, L. Zhang, S. H. Wong, T. Gin, M. T. V. Chan, J. L. Wu, J. Yu, W. K. K. Wu, Gastroenterology 2021, 160, 1179.a) P. Hu, W. Song, Y. Shan, M. Du, M. Huang, C. Song, L. Zhang, Food Funct. 2015, 6, 2257;b) P. Chondrou, A. Karapetsas, D. E. Kiousi, D. Tsela, A. Tiptiri‐Kourpeti, I. Anestopoulos, I. Kotsianidis, E. Bezirtzoglou, A. Pappa, A. Galanis, Benefic. Microbes 2018, 9, 975;c) S. Nozari, Y. Faridvand, A. Etesami, M. Ahmad Khan Beiki, S. A. Miresmaeili Mazrakhondi, J. Abdolalizadeh, Lett. Appl. Microbiol. 2019, 69, 148.Y. Shi, L. Meng, C. Zhang, F. Zhang, Y. Fang, Microbiol. Res. 2021, 255, 126921.V. da Silva Duarte, B. C. Dos Santos Cruz, A. Tarrah, R. Sousa Dias, L. de Paula Dias Moreira, W. J. F. Lemos Junior, L. C. Fidélis Silva, G. Rocha Santana, L. Licursi de Oliveira, M. D. C. Gouveia Peluzio, H. C. Mantovani, V. Corich, A. Giacomini, S. O. de Paula, Microorganisms 2020, 8.S. Shen, D. Huo, C. Ma, S. Jiang, J. Zhang, Microbiol. Spectrum 2021, 9, 0009021.a) A. Malik, D. Sharma, R. K. S. Malireddi, C. S. Guy, T. C. Chang, S. R. Olsen, G. Neale, P. Vogel, T. D. Kanneganti, Immunity 2018, 49, 515;b) T. Wang, C. Fan, A. Yao, X. Xu, G. Zheng, Y. You, C. Jiang, X. Zhao, Y. Hou, M. C. Hung, X. Lin, Immunity 2018, 49, 504.R. Gao, C. Kong, H. Li, L. Huang, X. Qu, N. Qin, H. Qin, Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 2457.Y. Zhu, T. Shi, X. Lu, Z. Xu, J. Qu, Z. Zhang, G. Shi, S. Shen, Y. Hou, Y. Chen, T. Wang, EMBO J. 2021, 40, 105320.S. Bullman, C. S. Pedamallu, E. Sicinska, T. E. Clancy, X. Zhang, D. Cai, D. Neuberg, K. Huang, F. Guevara, T. Nelson, O. Chipashvili, T. Hagan, M. Walker, A. Ramachandran, B. Diosdado, G. Serna, N. Mulet, S. Landolfi, Y. C. S. Ramon, R. Fasani, A. J. Aguirre, K. Ng, E. Élez, S. Ogino, J. Tabernero, C. S. Fuchs, W. C. Hahn, P. Nuciforo, M. Meyerson, Science 2017, 358, 1443.W. Liu, X. Zhang, H. Xu, S. Li, H. C. Lau, Q. Chen, B. Zhang, L. Zhao, H. Chen, J. J. Sung, J. Yu, Gastroenterology 2021, 160, 2395.M. S. Shah, T. DeSantis, J. M. Yamal, T. Weir, E. P. Ryan, J. L. Cope, E. B. Hollister, PLoS One 2018, 13, 0207002.H. Omar Al‐Hassi, O. Ng, M. Brookes, Gut 2018, 67, 3952.C. L. Murphy, M. Barrett, P. Pellanda, S. Killeen, M. McCourt, E. Andrews, M O’ Riordain, F. Shanahan, P. O'Toole, Gut Microbes 2021, 13, 1.J. Yu, Y. Chen, X. Fu, X. Zhou, Y. Peng, L. Shi, T. Chen, Y. Wu, Int. J. Cancer 2016, 139, 1318.D. Dodd, M. H. Spitzer, W. Van Treuren, B. D. Merrill, A. J. Hryckowian, S. K. Higginbottom, A. Le, T. M. Cowan, G. P. Nolan, M. A. Fischbach, J. L. Sonnenburg, Nature 2017, 551, 648.K. A. Krautkramer, J. Fan, F. Bäckhed, Nat. Rev. Microbiol. 2021, 19, 77.S. J. O'Keefe, Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 691.W. Jia, G. Xie, W. Jia, Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 111.a) T. Korem, D. Zeevi, N. Zmora, O. Weissbrod, N. Bar, M. Lotan‐Pompan, T. Avnit‐Sagi, N. Kosower, G. Malka, M. Rein, J. Suez, B. Z. Goldberg, A. Weinberger, A. A. Levy, E. Elinav, E. Segal, Cell Metab. 2017, 25, 1243;b) D. Zeevi, T. Korem, N. Zmora, D. Israeli, D. Rothschild, A. Weinberger, O. Ben‐Yacov, D. Lador, T. Avnit‐Sagi, M. Lotan‐Pompan, J. Suez, J. A. Mahdi, E. Matot, G. Malka, N. Kosower, M. Rein, G. Zilberman‐Schapira, L. Dohnalová, M. Pevsner‐Fischer, R. Bikovsky, Z. Halpern, E. Elinav, E. Segal, Cell 2015, 163, 1079.S. R. Sinha, Y. Haileselassie, L. P. Nguyen, C. Tropini, M. Wang, L. S. Becker, D. Sim, K. Jarr, E. T. Spear, G. Singh, H. Namkoong, K. Bittinger, M. A. Fischbach, J. L. Sonnenburg, A. Habtezion, Cell Host Microbe 2020, 27, 659.a) M. P. Taranto, G. Perez‐Martinez, G. Font de Valdez, Res. Microbiol. 2006, 157, 720;b) R. Coleman, P. J. Lowe, D. Billington, Biochim. Biophys. Acta 1980, 599, 294.E. S. Friedman, Y. Li, T. D. Shen, J. Jiang, L. Chau, L. Adorini, F. Babakhani, J. Edwards, D. Shapiro, C. Zhao, R. M. Carr, K. Bittinger, H. Li, G. D. Wu, Gastroenterology 2018, 155, 1741.S. Ocvirk, S. J. D. O'Keefe, Semin. Cancer Biol. 2020, 73, 347.B. Guan, J. Tong, H. Hao, Z. Yang, K. Chen, H. Xu, A. Wang, Acta Pharm. Sin. B 2022, 12, 2129.J. M. Ridlon, P. G. Wolf, H. R. Gaskins, Gut Microbes 2016, 7, 201.S. C. Harris, S. Devendran, C. Méndez‐García, S. M. Mythen, C. L. Wright, C. J. Fields, A. G. Hernandez, I. Cann, P. B. Hylemon, J. M. Ridlon, Gut Microbes 2018, 9, 523.a) L. Sun, J. Cai, F. J. Gonzalez, Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 335;b) T. Fu, S. Coulter, E. Yoshihara, T. G. Oh, S. Fang, F. Cayabyab, Q. Zhu, T. Zhang, M. Leblanc, S. Liu, M. He, W. Waizenegger, E. Gasser, B. Schnabl, A. R. Atkins, R. T. Yu, R. Knight, C. Liddle, M. Downes, R. M. Evans, Cell 2019, 176, 1098.a) M. Song, A. T. Chan, J. Sun, Gastroenterology 2020, 158, 322;b) T. Kühn, M. Stepien, M. López‐Nogueroles, A. Damms‐Machado, D. Sookthai, T. Johnson, M. Roca, A. Hüsing, S. G. Maldonado, A. J. Cross, N. Murphy, H. Freisling, S. Rinaldi, A. Scalbert, V. Fedirko, G. Severi, M. C. Boutron‐Ruault, F. R. Mancini, S. A. Sowah, H. Boeing, P. Jakszyn, M. J. Sánchez, S. Merino, S. Colorado‐Yohar, A. Barricarte, K. T. Khaw, J. A. Schmidt, A. Perez‐Cornago, A. Trichopoulou, A. Karakatsani, et al., J. Natl. Cancer Inst. 2020, 112, 516.J. M. Ridlon, J. S. Bajaj, Acta Pharm. Sin. B 2015, 5, 99.D. Dermadi, S. Valo, S. Ollila, R. Soliymani, N. Sipari, M. Pussila, L. Sarantaus, J. Linden, M. Baumann, M. Nyström, Cancer Res. 2017, 77, 3352.a) L. Sun, J. Cai, F. J. Gonzalez, Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 335;b) J. Zhou, M. Liu, Y. Zhai, W. Xie, Mol. Endocrinol. 2008, 22, 868.a) J. Ma, Y. Hong, N. Zheng, G. Xie, Y. Lyu, Y. Gu, C. Xi, L. Chen, G. Wu, Y. Li, X. Tao, J. Zhong, Z. Huang, W. Wu, L. Yuan, M. Lin, X. Lu, W. Zhang, W. Jia, L. Sheng, H. Li, Gut Microbes 2020, 11, 1450;b) Y. Yao, X. Li, B. Xu, L. Luo, Q. Guo, X. Wang, L. Sun, Z. Zhang, P. Li, Cell Commun. Signaling 2022, 20, 71.M. Zhang, Y. Lai, V. Krupalnik, P. Guo, X. Guo, J. Zhou, Y. Xu, Z. Yu, L. Liu, A. Jiang, W. Li, M. M. Abdul, G. Ma, N. Li, X. Fu, Y. Lv, M. Jiang, M. Tariq, S. Kanwal, H. Liu, X. Xu, H. Zhang, Y. Huang, L. Wang, S. Chen, I. A. Babarinde, Z. Luo, D. Wang, T. Zhou, C. Ward, et al., Sci. Adv. 2020, 6, 1593.R. Y. Gao, C. T. Shearn, D. J. Orlicky, K. D. Battista, E. E. Alexeev, I. M. Cartwright, J. M. Lanis, R. E. Kostelecky, C. Ju, S. P. Colgan, B. P. Fennimore, Mucosal. Immunol. 2021, 14, 479.Y. L. Loke, M. T. Chew, Y. F. Ngeow, W. W. D. Lim, S. C. Peh, Front. Cell. Infect. Microbiol. 2020, 10, 603086.L. Farhana, P. Nangia‐Makker, E. Arbit, K. Shango, S. Sarkar, H. Mahmud, T. Hadden, Y. Yu, A. P. Majumdar, Stem Cell Res. Ther. 2016, 7, 181.P. Arvind, E. D. Papavassiliou, G. J. Tsioulias, B. W. Duceman, C. I. Lovelace, W. Geng, L. Staiano‐Coico, B. Rigas, Mol. Immunol. 1994, 31, 607.T. Rossi, D. Vergara, F. Fanini, M. Maffia, S. Bravaccini, F. Pirini, Int. J. Mol. Sci. 2020, 21, 5786.T. T. Nguyen, S. Lian, T. T. Ung, Y. Xia, J. Y. Han, Y. D. Jung, J. Cell. Biochem. 2017, 118, 2958.M. Makishima, T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, D. J. Mangelsdorf, Science 2002, 296, 1313.J. M. Ridlon, S. C. Harris, S. Bhowmik, D. J. Kang, P. B. Hylemon, Gut Microbes 2016, 7, 22.H. Zhang, H. Xu, C. Zhang, Q. Tang, F. Bi, Cell Death Discovery 2021, 7, 207.M. T. Sorbara, E. G. Pamer, Nat. Rev. Microbiol. 2022, 20, 365.K. Makki, E. C. Deehan, J. Walter, F. Bäckhed, Cell Host Microbe 2018, 23, 705.a) A. Rauf, A. A. Khalil, U. U. Rahman, A. Khalid, S. Naz, M. A. Shariati, M. Rebezov, E. Z. Urtecho, R. de Albuquerque, S. Anwar, A. Alamri, R. K. Saini, K. R. R. Rengasamy, Crit. Rev. Food Sci. Nutr. 2021, 62, 6034;b) S. A. Smith, S. A. Ogawa, L. Chau, K. A. Whelan, K. E. Hamilton, J. Chen, L. Tan, E. Z. Chen, S. Keilbaugh, F. Fogt, M. Bewtra, J. Braun, R. J. Xavier, C. B. Clish, B. Slaff, A. M. Weljie, F. D. Bushman, J. D. Lewis, H. Li, S. R. Master, M. J. Bennett, H. Nakagawa, G. D. Wu, J. Clin. Invest. 2021, 131, 133371.M. J. Pichler, C. Yamada, B. Shuoker, C. Alvarez‐Silva, A. Gotoh, M. L. Leth, E. Schoof, T. Katoh, M. Sakanaka, T. Katayama, C. Jin, N. G. Karlsson, M. Arumugam, S. Fushinobu, M. Abou Hachem, Nat. Commun. 2020, 11, 3285.a) C. Bücher, J. Burtscher, K. J. Domig, Compr. Rev. Food Sci. Food Saf. 2021, 20, 4299;b) B. Dalile, L. Van Oudenhove, B. Vervliet, K. Verbeke, Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 461.W. Yang, T. Yu, X. Huang, A. J. Bilotta, L. Xu, Y. Lu, J. Sun, F. Pan, J. Zhou, W. Zhang, S. Yao, C. L. Maynard, N. Singh, S. M. Dann, Z. Liu, Y. Cong, Nat. Commun. 2020, 11, 4457.G. E. Kaiko, S. H. Ryu, O. I. Koues, P. L. Collins, L. Solnica‐Krezel, E. J. Pearce, E. L. Pearce, E. M. Oltz, T. S. Stappenbeck, Cell 2016, 165, 1708.K. Daly, S. P. Shirazi‐Beechey, DNA Cell Biol. 2006, 25, 49.N. Singh, A. Gurav, S. Sivaprakasam, E. Brady, R. Padia, H. Shi, M. Thangaraju, P. D. Prasad, S. Manicassamy, D. H. Munn, J. R. Lee, S. Offermanns, V. Ganapathy, Immunity 2014, 40, 128.D. Kirat, S. Kato, Exp. Physiol. 2006, 91, 835.J. Yang, J. Yu, Protein Cell 2018, 9, 474.K. Gronke, P. P. Hernández, J. Zimmermann, C. S. N. Klose, M. Kofoed‐Branzk, F. Guendel, M. Witkowski, C. Tizian, L. Amann, F. Schumacher, H. Glatt, A. Triantafyllopoulou, A. Diefenbach, Nature 2019, 566, 249.J. Chen, L. Vitetta, Proc. Natl. Acad. Sci. USA 2021, 118.E. R. Cobo, V. Kissoon‐Singh, F. Moreau, R. Holani, K. Chadee, Infect. Immun. 2017, 85.D. Cheng, J. H. Xu, J. Y. Li, S. Y. Wang, T. F. Wu, Q. K. Chen, T. Yu, Exp. Cell Res. 2018, 368, 101.B. Waclawiková, A. Codutti, K. Alim, S. El Aidy, Gut Microbes 2022, 14, 1997296.a) D. R. Donohoe, D. Holley, L. B. Collins, S. A. Montgomery, A. C. Whitmore, A. Hillhouse, K. P. Curry, S. W. Renner, A. Greenwalt, E. P. Ryan, V. Godfrey, M. T. Heise, D. S. Threadgill, A. Han, J. A. Swenberg, D. W. Threadgill, S. J. Bultman, Cancer Discovery 2014, 4, 1387;b) D. R. Donohoe, L. B. Collins, A. Wali, R. Bigler, W. Sun, S. J. Bultman, Mol. Cell 2012, 48, 612.D. C. Yu, J. S. Waby, H. Chirakkal, C. A. Staton, B. M. Corfe, Mol Cancer 2010, 9, 276.L. Zuo, M. Lu, Q. Zhou, W. Wei, Y. Wang, Food Chem. Toxicol. 2013, 62, 892.X. Wu, Y. Wu, L. He, L. Wu, X. Wang, Z. Liu, J Cancer 2018, 9, 2510.Y. He, L. Fu, Y. Li, W. Wang, M. Gong, J. Zhang, X. Dong, J. Huang, Q. Wang, C. R. Mackay, Y. X. Fu, Y. Chen, X. Guo, Cell Metab. 2021, 33, 988.M. Depner, D. H. Taft, P. V. Kirjavainen, K. M. Kalanetra, A. M. Karvonen, S. Peschel, E. Schmausser‐Hechfellner, C. Roduit, R. Frei, R. Lauener, A. Divaret‐Chauveau, J. C. Dalphin, J. Riedler, M. Roponen, M. Kabesch, H. Renz, J. Pekkanen, F. M. Farquharson, P. Louis, D. A. Mills, E. von Mutius, M. J. Ege, Nat. Med. 2020, 26, 1766.T. Y. Ryu, K. Kim, T. S. Han, M. O. Lee, J. Lee, J. Choi, K. B. Jung, E. J. Jeong, D. M. An, C. R. Jung, J. H. Lim, J. Jung, K. Park, M. S. Lee, M. Y. Kim, S. J. Oh, K. Hur, R. Hamamoto, D. S. Park, D. S. Kim, M. Y. Son, H. S. Cho, ISME J. 2022, 16, 1205.D. Ternes, M. Tsenkova, V. I. Pozdeev, M. Meyers, E. Koncina, S. Atatri, M. Schmitz, J. Karta, M. Schmoetten, A. Heinken, F. Rodriguez, C. Delbrouck, A. Gaigneaux, A. Ginolhac, T. T. D. Nguyen, L. Grandmougin, A. Frachet‐Bour, C. Martin‐Gallausiaux, M. Pacheco, L. Neuberger‐Castillo, P. Miranda, N. Zuegel, J. Y. Ferrand, M. Gantenbein, T. Sauter, D. J. Slade, I. Thiele, J. Meiser, S. Haan, P. Wilmes, et al., Nat. Metab. 2022, 4, 458.S. Bae, C. M. Ulrich, M. L. Neuhouser, O. Malysheva, L. B. Bailey, L. Xiao, E. C. Brown, K. L. Cushing‐Haugen, Y. Zheng, T. Y. Cheng, J. W. Miller, R. Green, D. S. Lane, S. A. Beresford, M. A. Caudill, Cancer Res. 2014, 74, 7442.X. Liu, H. Liu, C. Yuan, Y. Zhang, W. Wang, S. Hu, L. Liu, Y. Wang, Biomarkers Med. 2017, 11, 443.K. A. Guertin, X. S. Li, B. I. Graubard, D. Albanes, S. J. Weinstein, J. J. Goedert, Z. Wang, S. L. Hazen, R. Sinha, Cancer Epidemiol., Biomarkers Prev. 2017, 26, 945.R. Jalandra, N. Dalal, A. K. Yadav, D. Verma, M. Sharma, R. Singh, A. Khosla, A. Kumar, P. R. Solanki, Appl. Microbiol. Biotechnol. 2021, 105, 7651.O. O. Coker, C. Liu, W. K. K. Wu, S. H. Wong, W. Jia, J. J. Y. Sung, J. Yu, Microbiome 2022, 10, 35.M. Beaumont, A. M. Neyrinck, M. Olivares, J. Rodriguez, A. de Rocca Serra, M. Roumain, L. B. Bindels, P. D. Cani, P. Evenepoel, G. G. Muccioli, J. B. Demoulin, N. M. Delzenne, FASEB J. 2018, 32, 6681.N. Venkateswaran, M. C. Lafita‐Navarro, Y. H. Hao, J. A. Kilgore, L. Perez‐Castro, J. Braverman, N. Borenstein‐Auerbach, M. Kim, N. P. Lesner, P. Mishra, T. Brabletz, J. W. Shay, R. J. DeBerardinis, N. S. Williams, O. H. Yilmaz, M. Conacci‐Sorrell, Genes Dev. 2019, 33, 1236.Y. Zhang, H. Yu, J. Zhang, H. Gao, S. Wang, S. Li, P. Wei, J. Liang, G. Yu, X. Wang, X. Li, D. Li, W. Yang, J. Clin. Invest. 2021, 131, 146187.W. R. Russell, L. Hoyles, H. J. Flint, M. E. Dumas, Curr. Opin. Microbiol. 2013, 16, 246.T. Wilmanski, N. Rappaport, C. Diener, S. M. Gibbons, N. D. Price, Gut Microbes 2021, 13, 1.L. Wang, M. Gao, G. Kang, H. Huang, Front. Nutr. 2021, 8, 798038.K. Ganesan, S. Guo, S. Fayyaz, G. Zhang, B. Xu, Cancers 2019, 11, 1285.C. Gur, Y. Ibrahim, B. Isaacson, R. Yamin, J. Abed, M. Gamliel, J. Enk, Y. Bar‐On, N. Stanietsky‐Kaynan, S. Coppenhagen‐Glazer, N. Shussman, G. Almogy, A. Cuapio, E. Hofer, D. Mevorach, A. Tabib, R. Ortenberg, G. Markel, K. Miklić, S. Jonjic, C. A. Brennan, W. S. Garrett, G. Bachrach, O. Mandelboim, Immunity 2015, 42, 344.J. Abed, J. E. Emgård, G. Zamir, M. Faroja, G. Almogy, A. Grenov, A. Sol, R. Naor, E. Pikarsky, K. A. Atlan, A. Mellul, S. Chaushu, A. L. Manson, A. M. Earl, N. Ou, C. A. Brennan, W. S. Garrett, G. Bachrach, Cell Host Microbe 2016, 20, 215.H. N. Bell, R. J. Rebernick, J. Goyert, R. Singhal, M. Kuljanin, S. A. Kerk, W. Huang, N. K. Das, A. Andren, S. Solanki, S. L. Miller, P. K. Todd, E. R. Fearon, C. A. Lyssiotis, S. P. Gygi, J. D. Mancias, Y. M. Shah, Cancer Cell 2021, 40, 185.Z. T. Shakour, N. G. Shehab, A. S. Gomaa, L. A. Wessjohann, M. A. Farag, Biotechnol. Adv. 2022, 54, 107784.A. Christ, M. Lauterbach, E. Latz, Immunity 2019, 51, 794.F. M. Ruemmele, Ann. Nutr. Metab. 2016, 68, 33.L. A. Bolte, A. Vich Vila, F. Imhann, V. Collij, R. Gacesa, V. Peters, C. Wijmenga, A. Kurilshikov, M. J. E. Campmans‐Kuijpers, J. Fu, G. Dijkstra, A. Zhernakova, R. K. Weersma, Gut 2021, 70, 1287.B. Zhang, Y. Xu, S. Liu, H. Lv, Y. Hu, Y. Wang, Z. Li, J. Wang, X. Ji, H. Ma, X. Wang, S. Wang, Nutrients 2020, 12, 2367.B. Lauby‐Secretan, N. Vilahur, F. Bianchini, N. Guha, K. Straif, N. Engl. J. Med. 2018, 378, 1734.J. Li, X. Zhou, X. Liu, J. Ren, J. Wang, W. Wang, Y. Zheng, X. Shi, T. Sun, Z. Li, A. Kang, F. Tang, L. Wen, W. Fu, Clin. Chem. 2019, 65, 916.R. L. Siegel, K. D. Miller, A. Goding Sauer, S. A. Fedewa, L. F. Butterly, J. C. Anderson, A. Cercek, R. A. Smith, A. Jemal, Ca‐Cancer J. Clin. 2020, 70, 145.Y. Zhang, Q. Wu, L. Xu, H. Wang, X. Liu, S. Li, T. Hu, Y. Liu, Q. Peng, Z. Chen, X. Wu, J. B. Fan, Clin. Epigenet. 2021, 13, 90.J. M. Carethers, Annu. Rev. Med. 2020, 71, 59.a) N. T. Baxter, M. T. Ruffin, M. A. Rogers, P. D. Schloss, Genome Med. 2016, 8, 37;b) S. H. Wong, T. N. Y. Kwong, T. C. Chow, A. K. C. Luk, R. Z. W. Dai, G. Nakatsu, T. Y. T. Lam, L. Zhang, J. C. Y. Wu, F. K. L. Chan, S. S. M. Ng, M. C. S. Wong, S. C. Ng, W. K. K. Wu, J. Yu, J. J. Y. Sung, Gut 2017, 66, 1441;c) N. T. Baxter, C. C. Koumpouras, M. A. Rogers, M. T. t. Ruffin, P. D. Schloss, Microbiome 2016, 4, 59.G. Zeller, J. Tap, A. Y. Voigt, S. Sunagawa, J. R. Kultima, P. I. Costea, A. Amiot, J. Böhm, F. Brunetti, N. Habermann, R. Hercog, M. Koch, A. Luciani, D. R. Mende, M. A. Schneider, P. Schrotz‐King, C. Tournigand, J. Tran Van Nhieu, T. Yamada, J. Zimmermann, V. Benes, M. Kloor, C. M. Ulrich, M. von Knebel Doeberitz, I. Sobhani, P. Bork, Mol. Syst. Biol. 2014, 10, 766.S. Guo, L. Li, B. Xu, M. Li, Q. Zeng, H. Xiao, Y. Xue, Y. Wu, Y. Wang, W. Liu, G. Zhang, Clin. Chem. 2018, 64, 1327.V. Eklöf, A. Löfgren‐Burström, C. Zingmark, S. Edin, P. Larsson, P. Karling, O. Alexeyev, J. Rutegård, M. L. Wikberg, R. Palmqvist, Int. J. Cancer 2017, 141, 2528.M. Mutignani, R. Penagini, G. Gargari, S. Guglielmetti, M. Cintolo, A. Airoldi, P. Leone, P. Carnevali, C. Ciafardini, G. Petrocelli, F. Mascaretti, B. Oreggia, L. Dioscoridi, F. Cavalcoli, M. Primignani, F. Pugliese, P. Bertuccio, P. Soru, C. Magistro, G. Ferrari, M. C. Speciani, G. Bonato, M. Bini, P. Cantù, F. Caprioli, M. Vangeli, E. Forti, S. Mazza, G. Tosetti, R. Bonzi, et al., Cancers 2021, 13, 6363.J. P. Zackular, M. A. Rogers, M. T. Ruffin, P. D. Schloss, Cancer Prev. Res. 2014, 7, 1112.X. Wang, J. Wang, B. Rao, L. Deng, Exp. Ther. Med. 2017, 13, 2848.K. Mima, R. Nishihara, Z. R. Qian, Y. Cao, Y. Sukawa, J. A. Nowak, J. Yang, R. Dou, Y. Masugi, M. Song, A. D. Kostic, M. Giannakis, S. Bullman, D. A. Milner, H. Baba, E. L. Giovannucci, L. A. Garraway, G. J. Freeman, G. Dranoff, W. S. Garrett, C. Huttenhower, M. Meyerson, J. A. Meyerhardt, A. T. Chan, C. S. Fuchs, S. Ogino, Gut 2016, 65, 1973.J. L. Alexander, I. D. Wilson, J. Teare, J. R. Marchesi, J. K. Nicholson, J. M. Kinross, Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356.L. Zitvogel, Y. Ma, D. Raoult, G. Kroemer, T. F. Gajewski, Science 2018, 359, 1366.A. E. Frankel, L. A. Coughlin, J. Kim, T. W. Froehlich, Y. Xie, E. P. Frenkel, A. Y. Koh, Neoplasia 2017, 19, 848.A. P. García‐González, A. D. Ritter, S. Shrestha, E. C. Andersen, L. S. Yilmaz, A. J. M. Walhout, Cell 2017, 169, 431.M. Baretti, E. Karunasena, M. Zahurak, R. Walker, Y. Zhao, T. R. Pisanic 2nd, T. H. Wang, T. F. Greten, A. G. Duffy, E. Gootjes, G. Meijer, H. M. W. Verheul, N. Ahuja, J. G. Herman, N. S. Azad, Clin. Transl. Sci. 2021, 14, 954.N. Iida, A. Dzutsev, C. A. Stewart, L. Smith, N. Bouladoux, R. A. Weingarten, D. A. Molina, R. Salcedo, T. Back, S. Cramer, R. M. Dai, H. Kiu, M. Cardone, S. Naik, A. K. Patri, E. Wang, F. M. Marincola, K. M. Frank, Y. Belkaid, G. Trinchieri, R. S. Goldszmid, Science 2013, 342, 967.a) S. Viaud, F. Saccheri, G. Mignot, T. Yamazaki, R. Daillère, D. Hannani, D. P. Enot, C. Pfirschke, C. Engblom, M. J. Pittet, A. Schlitzer, F. Ginhoux, L. Apetoh, E. Chachaty, P. L. Woerther, G. Eberl, M. Bérard, C. Ecobichon, D. Clermont, C. Bizet, V. Gaboriau‐Routhiau, N. Cerf‐Bensussan, P. Opolon, N. Yessaad, E. Vivier, B. Ryffel, C. O. Elson, J. Doré, G. Kroemer, P. Lepage, et al., Science 2013, 342, 971;b) R. Daillère, M. Vétizou, N. Waldschmitt, T. Yamazaki, C. Isnard, V. Poirier‐Colame, C. P. M. Duong, C. Flament, P. Lepage, M. P. Roberti, B. Routy, N. Jacquelot, L. Apetoh, S. Becharef, S. Rusakiewicz, P. Langella, H. Sokol, G. Kroemer, D. Enot, A. Roux, A. Eggermont, E. Tartour, L. Johannes, P. L. Woerther, E. Chachaty, J. C. Soria, E. Golden, S. Formenti, M. Plebanski, M. Madondo, et al., Immunity 2016, 45, 931.S. C. Wei, C. R. Duffy, J. P. Allison, Cancer Discovery 2018, 8, 1069.K. Ganesh, Z. K. Stadler, A. Cercek, R. B. Mendelsohn, J. Shia, N. H. Segal, L. A. Diaz Jr., Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361.a) M. J. Overman, R. McDermott, J. L. Leach, S. Lonardi, H. J. Lenz, M. A. Morse, J. Desai, A. Hill, M. Axelson, R. A. Moss, M. V. Goldberg, Z. A. Cao, J. M. Ledeine, G. A. Maglinte, S. Kopetz, T. André, Lancet Oncol. 2017, 18, 1182;b) M. J. Overman, S. Lonardi, K. Y. M. Wong, H. J. Lenz, F. Gelsomino, M. Aglietta, M. A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, M. Svrcek, R. A. Moss, J. M. Ledeine, Z. A. Cao, S. Kamble, S. Kopetz, T. André, J. Clin. Oncol. 2018, 36, 773.J. Schluter, J. U. Peled, B. P. Taylor, K. A. Markey, M. Smith, Y. Taur, R. Niehus, A. Staffas, A. Dai, E. Fontana, L. A. Amoretti, R. J. Wright, S. Morjaria, M. Fenelus, M. S. Pessin, N. J. Chao, M. Lew, L. Bohannon, A. Bush, A. D. Sung, T. M. Hohl, M. A. Perales, M. R. M. van den Brink, J. B. Xavier, Nature 2020, 588, 303.L. Derosa, M. D. Hellmann, M. Spaziano, D. Halpenny, M. Fidelle, H. Rizvi, N. Long, A. J. Plodkowski, K. C. Arbour, J. E. Chaft, J. A. Rouche, L. Zitvogel, G. Zalcman, L. Albiges, B. Escudier, B. Routy, Ann. Oncol. 2018, 29, 1437.a) B. Routy, E. Le Chatelier, L. Derosa, C. P. M. Duong, M. T. Alou, R. Daillère, A. Fluckiger, M. Messaoudene, C. Rauber, M. P. Roberti, M. Fidelle, C. Flament, V. Poirier‐Colame, P. Opolon, C. Klein, K. Iribarren, L. Mondragón, N. Jacquelot, B. Qu, G. Ferrere, C. Clémenson, L. Mezquita, J. R. Masip, C. Naltet, S. Brosseau, C. Kaderbhai, C. Richard, H. Rizvi, F. Levenez, N. Galleron, et al., Science 2018, 359, 91;b) A. Sivan, L. Corrales, N. Hubert, J. B. Williams, K. Aquino‐Michaels, Z. M. Earley, F. W. Benyamin, Y. M. Lei, B. Jabri, M. L. Alegre, E. B. Chang, T. F. Gajewski, Science 2015, 350, 1084;c) V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews, T. V. Karpinets, P. A. Prieto, D. Vicente, K. Hoffman, S. C. Wei, A. P. Cogdill, L. Zhao, C. W. Hudgens, D. S. Hutchinson, T. Manzo, M. Petaccia de Macedo, T. Cotechini, T. Kumar, W. S. Chen, S. M. Reddy, R. Szczepaniak Sloane, J. Galloway‐Pena, H. Jiang, P. L. Chen, E. J. Shpall, K. Rezvani, A. M. Alousi, R. F. Chemaly, S. Shelburne, L. M. Vence, et al., Science 2018, 359, 97;d) V. Matson, J. Fessler, R. Bao, T. Chongsuwat, Y. Zha, M. L. Alegre, J. J. Luke, T. F. Gajewski, Science 2018, 359, 104.a) M. Vétizou, J. M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. P. Roberti, C. P. Duong, V. Poirier‐Colame, A. Roux, S. Becharef, S. Formenti, E. Golden, S. Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquelot, D. P. Enot, M. Bérard, J. Nigou, P. Opolon, A. Eggermont, P. L. Woerther, E. Chachaty, N. Chaput, et al., Science 2015, 350, 1079;b) J. M. Pitt, M. Vétizou, R. Daillère, M. P. Roberti, T. Yamazaki, B. Routy, P. Lepage, I. G. Boneca, M. Chamaillard, G. Kroemer, L. Zitvogel, Immunity 2016, 44, 1255.N. Chaput, P. Lepage, C. Coutzac, E. Soularue, K. Le Roux, C. Monot, L. Boselli, E. Routier, L. Cassard, M. Collins, T. Vaysse, L. Marthey, A. Eggermont, V. Asvatourian, E. Lanoy, C. Mateus, C. Robert, F. Carbonnel, Ann. Oncol. 2017, 28, 1368.J. U. Peled, S. M. Devlin, A. Staffas, M. Lumish, R. Khanin, E. R. Littmann, L. Ling, S. Kosuri, M. Maloy, J. B. Slingerland, K. F. Ahr, K. A. Porosnicu Rodriguez, Y. Shono, A. E. Slingerland, M. D. Docampo, A. D. Sung, D. Weber, A. M. Alousi, B. Gyurkocza, D. M. Ponce, J. N. Barker, M. A. Perales, S. A. Giralt, Y. Taur, E. G. Pamer, R. R. Jenq, M. R. M. van den Brink, J. Clin. Oncol. 2017, 35, 1650.R. Z. Gharaibeh, C. Jobin, Gut 2019, 68, 385.K. Dubin, M. K. Callahan, B. Ren, R. Khanin, A. Viale, L. Ling, D. No, A. Gobourne, E. Littmann, C. Huttenhower, E. G. Pamer, J. D. Wolchok, Nat. Commun. 2016, 7, 10391.T. Tanoue, S. Morita, D. R. Plichta, A. N. Skelly, W. Suda, Y. Sugiura, S. Narushima, H. Vlamakis, I. Motoo, K. Sugita, A. Shiota, K. Takeshita, K. Yasuma‐Mitobe, D. Riethmacher, T. Kaisho, J. M. Norman, D. Mucida, M. Suematsu, T. Yaguchi, V. Bucci, T. Inoue, Y. Kawakami, B. Olle, B. Roberts, M. Hattori, R. J. Xavier, K. Atarashi, K. Honda, Nature 2019, 565, 600.G. R. Gibson, R. Hutkins, M. E. Sanders, S. L. Prescott, R. A. Reimer, S. J. Salminen, K. Scott, C. Stanton, K. S. Swanson, P. D. Cani, K. Verbeke, G. Reid, Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 491.I. Mármol, C. Sánchez‐de‐Diego, A. Pradilla Dieste, E. Cerrada, M. J. Rodriguez Yoldi, Int. J. Mol. Sci. 2017, 18, 197.W. Fong, Q. Li, J. Yu, Oncogene 2020, 39, 4925.J. Hu, C. Wang, L. Ye, W. Yang, H. Huang, F. Meng, S. Shi, Z. Ding, J. Biosci. 2015, 40, 269.L. Zaharuddin, N. M. Mokhtar, K. N. Muhammad Nawawi, R. A. Raja Ali, BMC Gastroenterol. 2019, 19, 131.A. Belcheva, T. Irrazabal, S. J. Robertson, C. Streutker, H. Maughan, S. Rubino, E. H. Moriyama, J. K. Copeland, A. Surendra, S. Kumar, B. Green, K. Geddes, R. C. Pezo, W. W. Navarre, M. Milosevic, B. C. Wilson, S. E. Girardin, T. M. S. Wolever, W. Edelmann, D. S. Guttman, D. J. Philpott, A. Martin, Cell 2014, 158, 288.X. Xie, Y. He, H. Li, D. Yu, L. Na, T. Sun, D. Zhang, X. Shi, Y. Xia, T. Jiang, S. Rong, S. Yang, X. Ma, G. Xu, Nutrition 2019, 61, 132.a) C. E. DeStefano Shields, S. W. Van Meerbeke, F. Housseau, H. Wang, D. L. Huso, R. A. Casero Jr, H. M. O'Hagan, C. L. Sears, J. Infect. Dis. 2016, 214, 122;b) N. Ijssennagger, C. Belzer, G. J. Hooiveld, J. Dekker, S. W. van Mil, M. Müller, M. Kleerebezem, R. van der Meer, Proc. Natl. Acad. Sci. USA 2015, 112, 10038;c) N. Hattori, T. Niwa, T. Ishida, K. Kobayashi, T. Imai, A. Mori, K. Kimura, T. Mori, Y. Asami, T. Ushijima, Cancer Sci. 2019, 110, 147.J. Yang, H. Wei, Y. Zhou, C. H. Szeto, C. Li, Y. Lin, O. O. Coker, H. C. H. Lau, A. W. H. Chan, J. J. Y. Sung, J. Yu, Gastroenterology 2021, 162, 135.S. S. M. Lu, Z. Mohammed, C. Häggström, R. Myte, E. Lindquist, Å. Gylfe, B. Van Guelpen, S. Harlid, J Natl Cancer Inst 2021, 114, 38.R. E. Ooijevaar, E. M. Terveer, H. W. Verspaget, E. J. Kuijper, J. J. Keller, Annu. Rev. Med. 2019, 70, 335.A. R. Weingarden, B. P. Vaughn, Gut Microbes 2017, 8, 238.S. P. Rosshart, B. G. Vassallo, D. Angeletti, D. S. Hutchinson, A. P. Morgan, K. Takeda, H. D. Hickman, J. A. McCulloch, J. H. Badger, N. J. Ajami, G. Trinchieri, F. Pardo‐Manuel de Villena, J. W. Yewdell, B. Rehermann, Cell 2017, 171, 1015.G. R. D'Haens, C. Jobin, Gastroenterology 2019, 157, 624.S. Kommineni, D. J. Bretl, V. Lam, R. Chakraborty, M. Hayward, P. Simpson, Y. Cao, P. Bousounis, C. J. Kristich, N. H. Salzman, Nature 2015, 526, 719.K. Kingwell, Nat. Rev. Drug Discovery 2015, 14, 515.

Journal

Advanced Science – Wiley

Published: Aug 1, 2023

Keywords: colorectal cancer; gut microbiota; intratumoral microbiota; metabolite; probiotic bacteria; tumorigenesis

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

References (288)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies